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Abstract 
FACTORS AFFECTING NEUROPSYCHOLOGICAL TESTING IN 
THE ELDERLY AND THE USE OF A NEWLY DEVELOPED 
VIRTUAL REALITY TEST 
Elizabeth Rachel Walters 
Key Words: neuropsychology, Alzheimer’s disease, cognition, aging, virtual 
reality 
Neuropsychological testing is one method used in the diagnosis of Alzheimer’s 
disease and other cognitive disorders. However, the testing process may be 
affected by subtle external factors which if not controlled for may have the ability 
to affect the scores obtained.  The primary aim of this thesis was to investigate 
the effects of some of these external factors, namely caffeine, non-oily fish 
consumption and time of day. A secondary aim was to evaluate the use of a 
novel virtual assessment as a possible tool for the early detection of AD. 
Healthy elderly participants over the age of sixty with no existing cognitive 
impairment or neurological condition were recruited to take part. For each 
external factor investigated participants were required to undertake a cognitive 
assessment.  The results demonstrated that subtle external factors present 
during a typical testing session have the ability to significantly affect the scores 
obtained.  Scores on one part of the virtual test correlated with existing tests 
used for the early detection of cognitive impairment and were significantly lower 
in participants classified as mildly impaired.  With further modification this test 
has the potential to be used as an early detection tool. The results have 
implications for the interpretation of neuropsychological test scores which may 
be considered when classifying participants, determining treatment 
interventions, selecting participants for research and making a diagnosis.  
These findings have important considerations for psychological and cognitive 
research that investigates human brain function.  
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Chapter 1 
Thesis overview 
 
1.1 Introduction and aims 
Neuropsychological testing is a research tool used to measure cognitive ability, 
detect cognitive impairments and diagnose neurological dysfunction (Chapman 
et al., 2010).  Numerous cognitive assessments are available which differ in the 
domain they assess, the age range they are used for, the level of difficulty and 
administration time.  Research has shown that performance on some 
assessments can be affected by demographic variables such as the 
participant’s age and education level (Fields et al., 2011; Jacova et al., 2007; 
Zamrini et al., 2004; Dubois et al., 2007).  There are a number of factors, albeit 
subtle, which still need to be investigated in order to determine their effects on 
neuropsychological test performance.  This is important if an accurate score is 
to be obtained.  These subtle factors, which are prevalent during a typical 
neuropsychological testing session, may affect performance, skew results and 
have significant consequences for the interpretation of data.   
This thesis explores some of these factors, caffeine and time of day and also 
investigates the effects of a dietary factor, fish consumption, to determine any 
influence of this on neuropsychological performance in the healthy elderly.  The 
findings are discussed in the context of Alzheimer’s disease (AD) and Mild 
Cognitive Impairment (MCI). Although these factors were investigated in the 
health elderly, and established AD patients were not recruited, the results 
obtained may have implications and considerations for the early diagnosis of 
AD. The thesis also evaluates a newly developed virtual reality based 
assessment of spatial route learning.  The test may have the potential to be 
used as a tool for the early detection of cognitive impairment in the future.  
Each experimental chapter describes the factor investigated and includes an 
introduction, methods section (including details of materials and procedure), 
results and discussion.  The general discussion chapter then summarises the 
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main empirical findings, ideas for future work and the implications for the fields 
of experimental psychology and cognitive neuroscience.  
 
1.2 Overview of thesis structure 
The thesis is comprised of nine chapters and the following section gives a brief 
overview of each: 
Chapter two gives an in depth overview of AD and MCI and specifically 
includes information on the incidence, diagnosis, symptoms, neuropathology, 
neurochemistry, treatments and prognosis. 
Chapter three discusses early diagnosis of AD and why there is a prominent 
focus by research teams to try to detect and initiate treatment earlier in the 
disease’s trajectory.  The chapter evaluates the positives and negatives to this 
approach, the tools available to researchers and clinicians to implement this 
and also discusses the available treatment options and lifestyle changes which 
could be suggested if an earlier diagnosis was to occur. This chapter also 
evaluates the effects an early diagnosis may have on the individual and their 
families. 
Chapter four discusses neuropsychological testing. Neuropsychological 
assessments which will form the cognitive batteries delivered to participants in 
this thesis are discussed including the cognitive domain the test assesses and a 
description of how the test is administered and scored.  
Chapter five is the first experimental chapter which investigates the effect of 
prior caffeine consumption on neuropsychological testing.  Caffeine is famously 
consumed by the general population (Nawrot et al., 2003; Carrier et al., 2009) 
and is likely to be prevalent in a person during a usual testing session.  
Chapter six, the second experimental chapter, investigates a dietary factor, 
monthly non-oily fish consumption, in order to investigate any influence of non-
oily fish on neuropsychological test performance in the elderly via the use of a 
four week food diary and a cognitive assessment battery.  
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Chapter seven, the third experimental chapter, investigates the effect of Time 
of Day (TOD), another factor often uncontrolled for in a typical testing session.  
The chapter also investigates whether the administration of caffeine, which is 
commonly used to prevent feelings of tiredness (Carrier et al., 2009), influences 
TOD effects on cognitive test scores in the elderly.  
Chapter eight evaluates a newly designed virtual reality based assessment of 
spatial route learning created in collaboration with the University of Bradford 
School of Computing, Informatics and Media as a possible tool for the early 
detection of cognitive impairment associated with AD and MCI.  
Chapter nine is the discussion chapter which summarises the main findings of 
the thesis and the implications these have for the field of cognitive 
neuropsychology and other disciplines.  The chapter also provides details of 
possible further work before concluding the thesis. 
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Chapter 2 
Alzheimer’s disease and Mild Cognitive Impairment 
 
2.1 Introduction 
The purpose of this chapter is to introduce the reader to Alzheimer’s disease 
(AD) and Mild Cognitive Impairment (MCI).  Knowledge of these two conditions 
is necessary as the thesis progresses as findings are discussed in the context 
of AD and MCI. The chapter begins with some background information on AD 
including the symptomology, diagnosis, key neurological and pathological 
features, risk factors and treatments.  The second half of the chapter discusses 
MCI which is considered to be a prodromal stage of AD (Markwick et al., 2012). 
 
2.2 Background and history 
AD was first described in 1906 by Alois Alzheimer (Meinert et al., 2009) and is a 
chronic, complex neurodegenerative disease (Brousseau et al., 2007).  The 
exact cause of the disease is unknown but it is believed to be due to a 
combination of genetic and environmental factors (Cole et al., 2009; Cummings 
and Cole, 2002).  AD is currently the most common form of dementia and 
affects 25% of those over the age of 85 (Carrera et al., 2012).  In 2010 the 
Alzheimer’s World Report specified that there were an estimated 36 million 
people worldwide suffering from the disease.  This figure is expected to double 
within the next twenty years placing a larger responsibility on the global 
economy and health care resources.  
It is sometimes difficult to discriminate between normal aging and pathological 
abnormalities such as AD (Hedden and Gabrieli, 2004; Petersen, 2011; Albert 
et al., 2011; Forlenza et al., 2010; Petersen, 2009). This remains a pressing 
issue as disease diagnosis often occurs at too late a stage when structural 
damage to the brain has already reached too great an extent for interventions 
and treatments to be maximally beneficial (Pantel et al., 2004).   There is an 
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urgent need to try to detect the disease as early as possible before initial signs 
of cognitive symptoms present.  This is discussed in detail in chapter three, 
‘Early Diagnosis’. 
AD has been categorised into two main types, early onset AD and late onset (or 
sporadic) AD (Alzheimer’s Association, 2013).  Early onset cases usually show 
symptomatic presentation between the ages of 30-60 years and account for 
approximately 1-6% of all AD cases (Bekris et al., 2010). Sixty percent of early 
onset patients have a strong familial history of the disease (Bird, 2008) and 
certain genes have been implicated in the disease’s heritability.  Late onset AD 
accounts for 90% of all AD cases. Although late onset AD can show some 
evidence of a family history, the only significant gene implicated in this form of 
the disease so far is the Apolipoprotein gene (APOE) (Roses et al., 1995; Albert 
et al., 2011).  The genetic implications for both sporadic and early onset AD 
types are discussed in section 2.8.2 ‘Genetics’.  
 
2.3 Symptoms and prognosis 
The primary symptom of AD is memory loss which becomes gradually worse 
over time (Bird, 2008). The degree of memory impairment is exaggerated 
relative to normal age related loss which is common in the elderly and can 
complicate the diagnosis if the patient has always been forgetful.  Other 
symptoms such as confusion, getting lost and personality change vary between 
individual patients, however, the disease is progressive with an amnestic core 
(Dubois et al., 2007).  An initial episodic memory impairment is present in 86-
94% of patients (Dubois et al., 2007).  Symptoms gradually worsen over time 
and a diagnosis at the time of symptomatic onset is sub optimal as underlying 
pathological changes occur decades beforehand (Forlenza et al., 2010).   
Warning signs of early AD, as recommended by the Alzheimer’s Association 
annual report (2013) can include the following: 
 Memory loss which begins to disrupt normal everyday life 
 Difficulties completing familiar tasks 
 Confusion, often with time and place, for example, not knowing what day 
of the week it is, or forgetting how to return home from the local town 
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 Decreased spatial awareness or wandering behaviour 
 The misplacement of objects and belongings 
 Poor judgement, for example, placing trust in strangers 
 Difficulty planning or organising simple tasks 
 Changes in mood or personality 
 Withdrawal from social activities or work 
 
As the disease is progressive patients are usually bracketed into mild, moderate 
or severe AD (Alzheimer’s Association, 2012).  The rate of decline is dependent 
on a multitude of other factors such as family history, presence of co-morbid 
conditions, particularly stroke and other vascular diseases (Mielke et al., 2011), 
age at time of diagnosis (Rountree et al., 2013), APOE status (Mielke et al., 
2011) and many more (Alzheimer’s Association, 2013). Risk factors for AD are 
discussed in more detail in section 2.8.1 ‘Risk Factors’.  Patients with advanced 
AD require help with basic activities of daily living (ADL) such as bathing, 
clothing and eating.  In the end stages of the disease the patient often loses 
mobility, the ability to communicate and fails to recognise their close relatives.  
Once patients are bed bound for long periods they become susceptible to other 
infections such as pneumonia. These secondary illnesses are often responsible 
for cause of death (Ganguli et al., 2005). Disease duration is approximately 7-
10 years from initial diagnosis to death (Bekris et al., 2010) and is dependent on 
factors such as those mentioned above. 
 
2.4 Diagnosis 
A true diagnosis of AD cannot be given until a post mortem examination can 
confirm the presence of specific pathological markers representative of the 
disease (Mosconi et al., 2008). The National Institute for Health and Clinical 
Excellence (NICE) has a recommended diagnostic procedure for probable AD 
in the UK (NICE, 2006a).  These guidelines were reviewed in 2011 and state 
that the following should be undertaken with the General Practitioner (GP) who 
is usually the first point of call for most patients (Petersen, 2009):  
 A comprehensive patient history  
 A cognitive and mental examination  
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 Physical examination and blood analysis 
 Review of current medication 
 
The patient’s history should include a check of other health complaints noting 
the presence of vascular disease or associated conditions such as stroke, 
diabetes or hypertension (Feldman et al., 2008).  Cardiovascular diseases 
increase the likelihood of developing AD (Tong et al., 2012). A psychiatric 
history or the diagnosis of any other medical conditions which may affect mental 
state is also needed (Overshott and Burns, 2004).  Obtaining an accurate family 
history can determine whether any immediate relatives possess a history of 
dementia or AD. Having a first degree relative with AD increases the individual’s 
own risk (Green et al., 2002). Green et al., (2002) showed that African 
Americans were 1.6 times more likely to develop a dementia if they have a first 
degree relative with the disease, compared to white Caucasians with a first 
degree relative.  This has implications for considering the patient’s race (Green 
et al., 2002). 
 
The cognitive assessment examines the patient’s current cognitive ability and 
should be carried out using one of the recommended brief cognitive tests such 
as the Mini Mental State Examination (MMSE), the 7 Minute Screen, the 
General Practitioner Assessment of Cognition (GPCOG) or the Clinical 
Dementia Rating Scale (CDR) (NICE, 2011).  Scores on these tests can 
determine whether the patient receives pharmacological intervention (Jacova et 
al., 2007). The patient’s language and educational ability should be considered 
when scoring these assessments as lower educational level has been identified 
as a possible risk factor for the development of the disease (Revett et al., 2013; 
Reitz et al., 2011; Petersen, 2009).  The accuracy and reliability of 
neuropsychological assessments can be affected by many other external 
factors and this thesis explores some of these in later chapters.   
 
Although memory loss is a normal part of the aging process, subjective memory 
complaints in the elderly are associated with a higher risk of AD development 
(Waldorff et al., 2012; Geerlings et al., 1999). The confirmation of a change in 
cognition by an informant such as a spouse or relative also adds reliability to the 
diagnosis as their opinion is more objective (Dubois et al., 2007).   
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Routine blood analysis is useful for the exclusion of abnormalities which are 
associated with cognitive impairment such as alterations in thyroid hormones 
(Bird, 2008, Hogervorst et al., 2008) and B vitamins (Andreeva et al., 2011).  
The patient’s current medication should also be checked as well as any 
symptoms of depression, psychosis, urinary tract infection or syphilis.  These 
may cause the appearance of AD like symptoms, such as confusion or altered 
cognition (Overshott and Burns, 2004). 
 
Within the past decade there has been a considerable increase in the amount of 
research investigating possible biomarkers or sensitive techniques to increase 
the reliability of AD detection and improve the identification of early disease of 
the disease (see chapter three, ‘Early Diagnosis’).  Advances in neuro imaging 
have been promising, however, routine Magnetic Resonance Imaging (MRI) 
and Positron Emission Tomography (PET) scanning are not used for general 
diagnosis (NICE, 2006b) but may be recommended to rule out other cerebral 
pathologies or subtyping (NICE, 2006b).  Atrophy of the Medial Temporal Lobe 
(MTL) as seen on structural MRI scans is common in AD but less frequent in 
normal aging and, therefore, can be used as a possible identifier in 
questionable cases (Dubois et al., 2007).  Cerebrospinal Fluid (CSF) collection 
and profile examination is not recommended by NICE for routine diagnosis 
(NICE, 2011) but abnormalities in CSF amyloid and tau levels are reported in 
AD cases (Okonkwo et al., 2011).  Low levels of amyloid protein 1-42 and high 
total tau concentrations in the CSF are indicative of an AD profile (Shaw et al., 
2009; Petersen et al., 2009; Hansson et al., 2006; Forlenza et al., 2010; 
Okonkwo et al., 2011).  Although the procedure is invasive the results offer 
reliable indicators of plaque and tau burden (Petersen et al., 2009).   
 
2.5 Pathology 
The two main pathological hallmarks of the disease are the presence of 
extracellular senile plaques composed of amyloid β protein (Aβ) and 
intracellular neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein 
(Forlenza et al., 2010). Early studies hypothesised that the presence of these 
markers alone were sufficient for a diagnosis of AD. However, the development 
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of improved imaging techniques and other scientific approaches have since 
shown other abnormalities and changes in neuronal processes.  
 
2.5.1 Senile plaques 
The amyloid hypothesis of AD maintains that Aβ, which is cleaved from the Aβ 
precursor protein (APP), plays an initial crucial role in activating the complex 
cascade of events which leads to the neurodegeneration seen in AD (Pimplikar 
et al., 2010).   Aβ is a neuro peptide composed of between 39-43 amino acids 
(Butterfield and Boyd-Kimball, 2004) and contains a β pleated sheet (Revett et 
al., 2013).  The protein is derived by cleavage from APP which is a 
multifunctional protein involved in cell adhesion and neuritic outgrowth (O’Brien 
and Wong, 2011).  APP is cleaved by two forms of secretase enzymes, the β 
and γ varieties, to form predominantly Aβ40 and Aβ42 (Findeis, 2007).  Fibrils 
of the protein aggregate together to form senile plaques, often termed neuritic 
plaques, which locate in the extracellular space disrupting neuronal 
communication (Forlenza et al., 2010).  Figure one shows a histological slide 
from an AD patient demonstrating the presence of Aβ plaques. 
 
 
Figure one: histological presence of Aβ plaques in an AD patient. Figure taken from 
http://www.liv.ac.uk/researchintelligence/issue30/alzheimers.html. 
 
Senile plaque 
composed of Aβ 
protein 
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The presence of elevated plasma Aβ42 has been linked to an increased risk of 
developing AD but levels of this longer form of amyloid do naturally increase 
during aging (Fukumoto et al., 2003). The ratio of the two isoforms is believed to 
be a more reliable indicator of AD risk (Fukumoto et al., 2003).  An increased 
ratio of the two, (favouring Aβ42) predicts an increased risk of AD whereas a 
lower ratio i.e. a shift towards shorter lengths (Aβ40), decreases toxicity 
(Findeis, 2007).  In early onset AD mutations in the gene encoding APP and 
presenilin 1 and 2 have been discovered (Bird, 2008) and are discussed further 
in section 2.8.2 ‘Genetics’.   
Initial cell based studies demonstrated that the application of Aβ to cell media 
for 24 hours caused massive cell loss, presumably due to the oxidative effects 
of the protein (O’Brien and Wong, 2011).  Multiple studies have now 
investigated how Aβ plaques may lead to degeneration and these have noted 
numerous negative effects on surrounding neurons.  This has included synaptic 
loss (Lacor, 2007), decreases in dendritic spine density (Wilcox et al., 2011), 
increased oxidative stress (Axelsen et al., 2011), initiation of the inflammatory 
response (Herrup, 2010), impaired glutamate signalling (Revett et al., 2013), 
calcium influx (Butterfield and Boyd-Kimball, 2004) and the impediment of long 
term potentiation (LTP) (Lambert et al., 1998). 
As AD patients have elevated extracellular Aβ levels (Karran et al., 2011), 
reducing the amyloid burden was predicted to improve the cognitive deficits 
seen in the disease (Hardy and Higgins, 1992).  Since this hypothesis was put 
forward there has been much research investigating the precise role of the 
protein in cognitive dysfunction. This has concluded that plaque load does not 
seem to correlate with cognition (Karran et al., 2011). Further, Gómez-Isla et al., 
(1996) reported that cognitively normal elderly participants also possess heavy 
plaque loads, thereby complicating the Aβ hypothesis.    
C-Pittsburgh compound B (PiB) is a radio ligand and tracer which is able to bind 
to amyloid plaques in vivo (Jack et al., 2008). Studies have consistently 
reported increased retention of this compound in AD patients and those people 
with a MCI (Reitz et al., 2011). AD patients have a two fold increase in PiB 
retention relative to non demented controls of similar ages (Klunk et al., 2004).  
Areas showing greater retention include the prefrontal cortex (PFC), lateral 
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temperoparietal cortex, posterior cingulate and the striatum (Edison et al., 2007; 
Klunk et al., 2004; Forsberg et al., 2007).  Those AD patients with greater 
retention show elevated rates of atrophy (Archer et al., 2006). Although the 
majority of AD cases possess elevated retention, approximately 30% of the 
cognitively normal elderly also show retention in cortical regions (Mintun et al., 
2006). Consequently, the use of this technique as a possible biomarker for AD 
does not seem reliable when used alone but could add validity to confirm 
questionable cases. Petersen et al., (2009) comment that PiB is a useful 
method for identifying participants who are likely to decline at a rapid rate 
(Petersen et al., 2009). 
 
Immunisation against Aβ has also been trialled. In 2010 over 9000 patients 
were enrolled in such trials (Lemere and Masliah, 2010). Active Aβ 
immunisation involves the direct administration of a synthetic version of Aβ 
combined with a carrier protein, which when injected, results in the production 
of antibodies to Aβ.  Passive immunisation uses the direct injection of actual Aβ 
antibodies (Fu et al., 2010) and both techniques result in the removal of toxic 
amyloid from the extracellular space.  Trials using animal models of the disease 
have shown promising results.  For example, an early study by Schenk et al., 
(1999) administered active immunisation with Aβ1-42 to PDAPP transgenic 
mice.  These mice express elevated human APP and develop many of the 
pathological features seen in human AD.  Immunisation of young mice (6 weeks 
old) before pathological abnormalities were present, prevented the formation of 
Aβ plaques, and immunisation of older animals (aged 11 months) decreased 
the rate of progression of typical AD pathology.    Active immunisation of Tg2576 
mice, which are also genetically modified to develop Aβ plaques, was less 
effective in its ability to clear existing plaques in aged mice (Das et al., 2001).  
Further, 3xTg mice which develop both Aβ plaques and NFTs showed no 
reduction of either pathological hallmark after immunisation.  The study did 
report an improvement in animal behavioural measures (Oddo et al., 2006). 
Similar positive findings have been noted in passive trials (Lemere and Masliah, 
2010).   
 
Human clinical trials have also taken place and an initial phase one trial of 
immunisation using the AN1792 vaccine designed by Elan and Wyeth (Lemere 
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and Masliah, 2010) showed positive outcomes on one behavioural assessment, 
the Disability Assessment for Dementia (DAD) rating scale (Bayer et al., 2005). 
The phase two trial was halted due to the development of meningoencephalitis 
in 18 of the 300 patients enrolled. Although this was not attributed to the 
immunisation itself, the activation of cytotoxic T cell immune responses may 
have lead to an immune reaction in these patients (Fu et al., 2010).  The most 
positive results emerge when animals were immunised prior to the development 
of AD pathology, implicating immunisation is better as an AD prevention method 
rather than a potential treatment.  Work in this area is ongoing. 
 
2.5.2 Tau 
Tau is a neuronal protein encoded on chromosome 17 (Iqbal et al., 2010) and 
exists in six different isoforms which vary in the number of amino acids they 
comprise (Wang and Liu, 2008).  In the normal brain, tau is responsible for the 
assembly of neuronal microtubules and the maintenance of their stability 
(Matus, 1988). In AD tau becomes hyperphosphorylated (Revett et al., 2013; 
Reitz et al., 2011; Boutajangout et al., 2011) forming paired helical filaments 
(Iqbal et al., 2010) which impair the proteins ability to bind to and assemble 
microtubules within the axon and dendrites (Iqbal et al., 2005).  
Hyperphosphorylation promotes the aggregation of tau into intracellular NFTs 
(Boutajangout et al., 2011). NFTs consist of twisted ribbons of tau which clump 
together and form within the neuron (Blackwell et al., 2004) and can be seen in 
figure two. 
 
 
Figure two: histological slide showing the presence of NFTs taken from Callahan et al., 
(1998) 
NFT 
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NFTs are first apparent in the transentorhinal cortex before spreading to the 
hippocampus proper and association cortices (Braak and Braak, 1991). Studies 
of AD brains have shown an elevation in the amount of total tau in comparison 
with normal aged matched controls (Khatoon et al., 1992).   The isoform 4 
variety of tau is the predominant form detected, although it has been suggested 
that it may be the ratio of the different isoforms which predicts the level of 
toxicity induced (Wang and Liu, 2008).  As tangles become more widespread, 
synaptic transmission between neurons becomes impaired.  Tangles block the 
intracellular trafficking of various other intracellular proteins which can lead to 
the loss of axonal transport and ultimately cell degeneration (Iqbal et al., 2010).  
Cognitive decline has been correlated with the number of NFTs (Braak and 
Braak, 1998; Selkoe and Schenk, 2003) as well as the concentration of total tau 
in CSF samples, in particular samples from patients who present with mild 
degrees of cognitive impairment (Arriagada et al., 1992).  This suggests that the 
formation of tau pathology occurs early in the disease process, making the 
measurement of tau a target for the earlier detection of AD. 
Although NFTs can lead to neurodegeneration there has been speculation as to 
whether they may actually be the product of a protective response.  Morsch et 
al., (1999) presented findings that neurons containing NFTs were able to 
survive for up to 20 years, implying that the presence of abnormal tau alone 
does not lead to immediate cell death. In addition, Wang and Liu (2008) believe 
that NFTs may actually protect neurons and neighbouring cells from oxidative 
stress. There is decreased oxidative damage in areas with elevated NFTs 
signifying that they may be a compensatory neuronal response aimed at 
reducing damage from Reactive Oxygen Species (ROS). 
 
2.6 Anatomy and key neurological processes 
2.6.1 Atrophy 
Post mortem examinations of AD patients and the use of neuro-imaging have 
consistently shown generalized atrophy, correlated with neuronal loss, in the 
temporal, frontal, parietal and hippocampal areas (Whitwell et al., 2007; 
Hämäläinen et al., 2007; Frisoni et al., 2010).  This deterioration is particularly 
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extensive in the cortex, hippocampus, amygdala, locus coereleus and raphe 
nuclei (Frisoni et al., 2010; Reid and Evans, 2013) and can be seen in figure 
three. 
 
Figure three: temporal lobe atrophy seen in dementia. (A) mild atrophy and (B) severe 
atrophy. Images have been taken from Chan et al., (2009) in their paper entitled ‘The 
Clinical Profile of right temporal lobe atrophy’. 
2.6.2 Neuronal and synaptic alterations 
Loss of synaptic structure and function are important in the advancement of AD 
(Herrup, 2010).  Decreased dendritic mass and spine density is present in post 
mortem studies of AD patients (Uylings and de Brabander, 2002) and these are 
noted early in the disease process (Yu and Lu, 2012).  Synaptic loss is closely 
correlated with the degree of cognitive impairment the patient presents with 
(Spires et al., 2005). Loss of synaptic markers is considered a reliable indicator 
of disease progression and correlates well with clinical symptoms (Selkoe, 
2002). There is also evidence of alterations in synaptic processes such as LTP 
and long term depression (LTD) which are important for learning and memory 
(Malenka and Bear, 2004). The cause of synapse loss is thought to be due to a 
combination of factors such as the presence of NFTs, Aβ, inflammation or 
oxidative stress (Spires et al., 2005). 
 
2.6.3 Glucose metabolism 
The brain uses adenosine tri phosphate (ATP) as its major energy resource 
(Mosconi et al., 2008). ATP is formed from the mitochondrial oxidation of 
glucose and a disruption to this process can lead to synaptic dysfunction. 
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Glucose metabolism, therefore, would appear to be a reliable indicator of 
neuronal activity or lack thereof (Mosconi et al., 2008).  Altered glucose 
metabolism occurs early in AD and correlates well with clinical manifestations of 
the disease (De Leon et al., 2001).  Disruption to the regulation of these 
metabolic systems can result in the elevated production of toxic ROS and 
changes in calcium transport.  This leads to over excitability and local tissue 
damage (Mosconi et al., 2008).   
AD is associated with high levels of oxidative stress and early research showed 
that this too correlates with neuropathological markers of the disease such as 
tangles and plaques (Lambert et al., 1998).  Imaging studies using PET and the 
glucose tracer, 2-[18F] fluoro-2-deoxy-D-glucose (FDG) have revealed specific 
hypometabolism in AD in the parieto-temporal regions, posterior cingulate 
cortices and the frontal lobes (Mosconi et al., 2008).  This consistent pattern 
across research groups has meant that hypometabolism appears to be a 
reliable indicator of AD (Frisch et al., 2013; Prestia et al., 2013; Minoshima et 
al., 1997).   
 
2.6.4 Oxidative stress 
Oxidative stress refers to the unnecessary oxidation of molecules leading to 
cellular damage by ROS (Behl and Moosmann, 2002). Neuronal systems are 
incredibly sensitive to oxidative damage and there are high levels of oxidative 
stress present in the AD brain (Axelsen et al., 2011). Furthermore, studies have 
shown low levels of natural antioxidants, such as vitamin A and E in AD patients 
(Axelsen et al., 2011). The presence of elevated deoxyribonucleic acid (DNA) 
and ribonucleic acid (RNA), lipids and protein oxidation has been found in both 
AD patients and individuals with a MCI (Baldeiras et al., 2010).  This indicates 
that oxidative stress occurs early in the disease process (Nunomura et al., 
2001).  ROS disrupt neuronal processes and induce apoptosis exacerbating the 
atrophy and neuronal death occurring in AD (Nunomura et al., 2007).  
Oxidative stress has been linked to the presence of Aβ plaques with some 
discrepancies as to whether Aβ induces oxidative stress or actually protects 
against it.  Some studies proposed that Aβ plaques were formed as a protective 
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response against oxidation (Atwood et al., 2003; Berthon, 2000) as the density 
of plaques was inversely correlated with markers of oxidative stress (Cuajungco 
et al., 2000).  The majority of research seems to favour the opposite theory and 
has found that Aβ plaques actually induce oxidative stress in AD brains 
(Butterfield and Boyd-Kimball, 2004; Markesbery, 1999).   Furthermore, some 
studies have reported that oxidative stress is present prior to plaque (Pratico et 
al., 2001) and tangle formation (Resende et al., 2008) and may initiate the 
production of these markers. 
Antioxidants act to inhibit free radical formation, scavenge free ROS and 
support natural self defence mechanisms (Behl and Moosmann, 2002). 
Research has investigated whether natural antioxidants such as co-enzyme 
q10, acetyl carnitine, vitamin E, curcumin and polyphenols are able to minimise 
the oxidative stress in AD (Feng and Wang, 2012). Most studies investigating 
the use of the aforementioned antioxidants in animals have shown beneficial 
effects although results from human trials have been less positive and further 
research is required (Feng and Wang, 2012).  
 
2.6.5 Inflammation 
Neuro-inflammation is present in AD brains and can be confirmed by the 
presence of elevated levels of activated complement proteins, cytokines, 
chemokines, free radicals and arachidonic acid (Wilcock, 2012).  Inflammatory 
processes are balanced via negative feedback mechanisms and these can alter 
during aging and neurodegeneration (Glass et al., 2010).  The presence of 
NFTs and senile plaques has been shown to induce inflammation and activate 
microglia which exacerbates the problem leading to further localised tissue 
damage (Pimplikar et al., 2010). The incidence of AD seems to be lower in 
individuals using Non-Steroidal Anti Inflammatory Drugs (NSAIDs) (Breitner et 
al., 2009; Herrup, 2010), however, there have been conflicting findings. For 
example, a meta-analysis by Szekely et al., (2004) showed that individuals 
taking NSAIDs had a 40% lower incidence of developing AD, whereas Brietner 
et al., (2009) in their sample of 351 participants, concluded that those 
participants who were heavy NSAID users were at an elevated risk of dementia.  
The reasons for these discrepancies are unclear and further work investigating 
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the length of time patients use NSAIDs, the dose taken, the condition treated 
and the age of onset medications are initiated is needed. These factors may 
affect the overall outcomes.  
The use of NSAIDs as a possible treatment for established AD patients has 
yielded inconclusive findings and in general no significant improvements have 
been noted (Brietner, 2003). This may be due to the fact that inflammation over 
many years causes too many detrimental effects to the surrounding neuronal 
tissue which are unable to be reversed by acute NSAID administration. The 
exact mechanisms of inflammation in AD are beyond the scope of this chapter 
but it is important to acknowledge that inflammatory processes do seem to 
contribute to the pathological and anatomical features of AD. 
 
2.7 Neurochemistry 
2.7.1 Cholinergic hypothesis 
Bartus et al., (1982) put forward the cholinergic hypothesis of memory 
dysfunction. This stated that the cognitive impairments seen in AD and other 
dementias were due to disruptions in the activity of the neurotransmitter 
acetylcholine (Ach). This hypothesis was reinforced by the fact that drugs which 
block acetylcholinesterase, the enzyme responsible for the breakdown of Ach, 
improved cognitive performance (Hansen et al., 2008). Likewise, Ach 
antagonists such as scopolamine interfere with cognitive performance on 
memory tasks (Auld et al., 2002). 
The basal forebrain cholinergic system consists of the nucleus basalis of 
Meynert (nbM), the horizontal and vertical bands of broca and the medial septal 
nucleus (Auld et al, 2002). These structures can be seen in figure four. This 
system maintains cholinergic input to the limbic and cortical brain structures and 
densely innervates the hippocampus and its association areas (Brousseau et 
al., 2007).  In AD there is a significant reduction of neurons in the nbM 
(Whitehouse et al., 1982) accompanied by dense tau deposition (Mesulam et 
al., 2004). Further, cell loss in the nbM correlates with dementia severity (Perry 
et al., 1977; Baskin et al., 1999; Grothe et al., 2010; Pappas et al., 2000). 
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Figure four: projections from the nucleus basalis of Meynert and other cholinergic cell 
groups in the septum pellucidum to the hippocampus and neocortex. Figure taken from 
Gauthier (2002). 
Early studies such as Bierer et al., (1995) administered cholinergic agonists to 
both healthy human subjects and rats and found a marked improvement in 
information processing, learning and memory following drug administration.  
This was further supported by additional studies such as Levin, (1992) and 
Nathan and Stough, (2001). Conflicting findings were put forward by Oken et 
al., (1994).  These authors used cholinergic antagonists and found that no 
attention or memory impairment was apparent in healthy adults and AD 
patients.  Many of these studies recruited healthy participants in order to prove 
or disprove the cholinergic hypothesis. Increasing cholinergic transmission in 
individuals who already possess a normal baseline Ach concentration may 
simply lead to a threshold whereby further stimulation has no additional 
beneficial effect.  Also those authors who did use AD patients when 
administering cholinergic agonists do not state the stage of the patients’ disease 
and it may be that these patients show no improvement due to advanced 
pathological changes.  There may be a threshold/cut off point in the disease 
pathway whereby the drugs are only effective up until a certain point. 
The drugs used to treat AD, namely the acetylcholinesterase inhibitors 
(AchEIs), only have modest effects and this has lead to the questioning of the 
cholinergic hypothesis (Dumas and Newhouse, 2011).  Enhancing cholinergic 
transmission may improve the cognitive symptoms of the disease but it will not 
slow the disease’s progression.  It has, therefore, been proposed that the 
cholinergic system may be responsible for the modulation of attention rather 
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than memory and that other factors and neurotransmitter systems may be 
involved in the cognitive symptoms of AD (Voytko, 1996; Dumas and 
Newhouse, 2011; Sarter et al., 2005; Herholz et al., 2008). 
 
2.7.2 Other neurotransmitter systems 
There is evidence for a role of serotonin (5-Hydroxytryptamine (5HT)) in the 
behavioural and cognitive symptoms of AD (Francis et al., 2010).  Post mortem 
studies have reported decreased levels of 5HT and its metabolites (Garcia-
Alloza et al., 2005), similarly NFTs and neuronal loss are present in the raphe 
nucleus, the major serotonergic hub, early in the disease (Francis et al., 2010).  
Specific loss of the 5HT1A receptor is found in temporal areas and this has been 
associated with the displays of aggressive symptoms seen in certain patients 
(Lai et al., 2003).  Interestingly, 5HT1A loss in the hippocampus correlated with 
cognitive decline (Kepe et al., 2006).  The serotonergic system appears to be 
more central to the neuropsychiatric manifestations of the disease.  Selective 
serotonin reuptake inhibitors (SSRIs), which are used for the treatment of 
depression, have shown some efficacy in treating AD patients with depressive 
symptoms, noting positive effects on behaviour and cognition (Taragano et al., 
1997). 
In addition to the 5HT system, the glutaminergic system has also been 
implicated in AD.  There is a decrease in glutaminergic pyramidal neurons in AD 
(Francis et al., 1993). The hippocampai of AD patients contain lower 
concentrations of glutamate receptors (Francis, 2003).  There is also a 
decrease in the ability of glial cells to remove excess glutamate from the 
synaptic cleft leading to over excitability and toxicity (Procter et al., 1988).  
Inadequate removal of glutamate from the synaptic cleft leads to ‘background 
noise’ at glutamate receptors which then affects the functioning of other 
receptors. This may contribute to certain aspects of cognitive impairment seen 
in AD (Francis et al., 2010). Memantine, a glutamate receptor antagonist, has 
proved useful in the management of AD cognitive symptoms (see section 2.9 
‘Treatment’). 
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2.8 Risk Factors and genetics 
2.8.1 Common risk factors  
A number of risk factors have been identified for the development of AD and 
some of the main factors are outlined in table one.  These risk factors have 
received a considerable amount of research interest but there are many more.  
The consensus so far is that AD is caused by a combination of genetic and 
environmental factors (Cole et al., 2009, Cummings and Cole, 2002; Bennett et 
al., 2005; Boutajangout et al., 2011). 
Table one: risk factors associated with AD 
Risk Factor Evidence 
Age AD risk increases with age due to a cumulative effect of aging 
(Rountree et al., 2013). 
Gender Females have a higher risk of developing AD (Hogervorst et al., 
2000). This may be due to increased female life expectancy, but may 
also be a result of decreased oestrogen with age (Markou et al., 
2005). 
MCI Those individuals who possess a MCI have an elevated risk of 
developing AD (Alzheimer’s Association, 2013; Petersen, 2009). 
Family history Individuals with a first degree relative who has AD have an increased 
risk of developing the disease (Green et al., 2002; Mayeux et al., 
1991). 
APOE gene allele This gene is implicated in heart disease and also has a high 
predictability in the development of AD, specifically if the individual 
possesses the APOE4 allele (Prasanthi et al., 2010). The APOE2 
allele seems to be protective against AD (Jorm et al., 2007). 
Low levels of 
physical activity 
Individuals with low levels of physical activity have an increased risk 
of developing AD (Scarmeas et al., 2009). 
Cardiovascular 
disease and high 
cholesterol 
Heart disease, high blood pressure and elevated cholesterol all 
increase the risk of developing AD (Rosenberg et al., 2008). 
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Chronic 
inflammation 
Inflammatory markers are present in the AD patient and can induce 
tissue damage leading to increased neuronal apoptosis and 
degeneration (Meinert et al., 2009). 
Low levels of 
education 
The longer an individual spends being educated the lower the risk of 
developing AD, this is known as cognitive reserve (Stern, 2012). 
Poor diet and 
obesity 
A diet high in saturated fat increases Aβ load and plaque formation, 
thereby increasing AD risk (Englehart et al., 2004). The 
Mediterranean diet which is high in olive oil, fish and low in red meat 
has shown to be a deterrent against AD (Scarmeas et al., 2009).  
Increased Body Mass Index (BMI) and being overweight in midlife at 
approximately age 50 years, increases the risk of developing AD in 
later life (Kivipelto et al., 2005) 
Elevated 
homocysteine (HCy) 
Elevated HCy is a risk factor for the development of AD (Aisen et al., 
2008; Smith et al., 2010).  HCy is a toxic amino acid and can induce 
apoptosis and synapse loss.  Those individuals with elevated HCy 
concentrations have a higher risk of developing AD (Lehmann et al., 
1999). HCy levels are linked to B vitamins, low B12 levels are 
associated with elevated HCy. The administration of can decrease 
levels of HCy (Cunnane et al., 2009) and slow cognitive decline (de 
Jager et al., 2012). 
Head injury Some studies have reported that a head trauma or traumatic brain 
injury (TBI) increases the risk of developing AD (Jellinger et al., 
2001).  The exact reasons behind this are still poorly understood, one 
study found that TBI initiates the formation of NFTs (Smith et al., 
2001). 
Low social 
engagement 
Those individuals who have low social engagement, particularly 
when they reach old age (over 60 years) have an elevated risk of 
developing AD.  The elderly who are isolated and have less frequent 
contact with relatives or friends are also at an elevated risk (Povova 
et al., 2012). 
Mental activity The engagement in activities which require a mental effort such as 
reading, sewing, knitting, completing puzzles and watching television 
have been associated with a lowered risk of developing dementia 
and AD (Ruthirakuhan et al., 2012). 
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2.8.2 Genetics 
Early onset AD accounts for 1-6% of all AD cases and has a high genetic 
heritability (Bird, 2008) with approximate ages of onset between 30-60 years 
(Bekris et al, 2010).  Late onset AD occurs between 60-85 years of age and 
accounts for over 90% of total AD cases (Bekris et al., 2010).  Multiple genes 
have been implicated in early onset cases and the main three are discussed.  
For late onset AD a genetic mutation in the APOE gene has been implicated 
and this too is discussed.  The primary genes implicated in early onset AD 
cases are all related to the functioning and production of Aβ (Bird, 2008). 
2.8.2.1 APP  
APP is the amyloid precursor protein from which Aβ is proteolytically derived 
(Iqbal et al., 2010).  The gene for APP is located on chromosome 21 and so far 
32 mutations have been found (Bekris et al., 2010). Mutations within the APP 
protein account for only 10-15% of early onset cases and do not usually occur 
in sporadic cases (Bekris et al., 2010). 
2.8.2.2 Presenilin 1 (PSEN1) 
PSEN1 is a membrane protein located on chromosome 14 (Bekris et al., 2010) 
and is responsible for the cleavage of APP by γ secretase.  Mutations of PSEN1 
are the most common cause of early onset AD accounting for 18-50% of 
autosomal dominant cases (Theuns et al., 2000). At present over 176 PSEN1 
mutations have been identified (Bekris et al., 2010). PSEN1 mutations result in 
a decrease of γ secretase activity leading to an increase in the production of 
Aβ42, the form of amyloid associated with higher toxicity and a higher likelihood 
of aggregation to form senile plaques.  Mutations to this gene lead to the most 
severe of AD cases and are associated with the earliest ages of onset (Bekris et 
al., 2010).   
2.8.2.3 Presenilin 2 (PSEN2) 
PSEN2 also plays an important role in the cleavage of Aβ and mutations to its 
structure lead to an elevated production of the Aβ42 form (Schneuer et al., 
1999).  The gene encoding PSEN2 is located on chromosome one and 
mutations are rare (Bekris et al., 2010). 
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 2.8.2.4 APOE 
APOE is implicated in both early and late onset AD.  The gene is located on 
chromosome 19 and exists in four alleles of which possession of the APOE4 
genotype carries elevated risk for AD (Bekris et al., 2008).  The direct 
mechanism by which APOE4 is linked to AD is not fully understood, however, 
APOE plays a role in cholesterol management and metabolism.  High 
cholesterol is a risk factor for AD development (Rosenberg et al., 2008), 
likewise APOE4 carriers have higher total and low density lipoprotein (LDL) 
cholesterol levels as well as poorer clearance of cholesterol from neurons 
(Michikawa et al., 2000).  Importantly, Bekris et al., (2010) comment that at least 
50% of individuals who carry at least one APOE4 allele do not develop 
Alzheimer’s disease.  This suggests that possession of APOE4 alone is 
insufficient to explain all cases of AD. 
 
2.9 Treatment 
2.9.1 Cholinesterase inhibitors 
AchEIs are recommended for the management of mild to moderate cases of AD 
and include donepezil (Aricept®), rivastigmine (Exelon®) and galantamine 
(Reminyl®).  All of these drugs work through similar mechanisms of action and 
inhibit the enzyme acetylcholinesterase which is responsible for the degradation 
of Ach in the synaptic cleft.  This increases the availability of Ach and, therefore, 
improves memory and cognitive performance.  See figure five for a diagram 
representing this mechanism of action.  
There is no evidence to suggest that there are any significant differences 
between these three drugs in terms of their benefits.  Research has shown that 
the use of AchEIs is able to stabilise and slow cognitive decline in AD patients 
(Hansen et al., 2008).  The recommended dose for each drug varies and side 
effects are common which can impact on usability and compliance.  The most 
common side effects are gastro intestinal related and include nausea, vomiting, 
diarrhoea and flatulence (Atri, 2011).  Side effects become notably worse as the 
dose is increased.   
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Figure five: cholinergic nerve terminal highlighting the mechanism of action of the 
AchEIs. Picture taken from Gauthier, (2002) 
In the USA a higher maximum dose of 23mg of donepezil has recently been 
approved.  Farlow et al., (2011) noted that in a large trial of 1467 patients those 
taking the higher dose of 23mg showed significant improvements in cognition 
after six months compared to those taking 10mg.  Gastro intestinal disturbances 
were more common in those prescribed the higher dose, however, these 
seemed to stabilize after four weeks.  Of the three AchEIs mentioned, 
galantamine has the most reported side effects, followed by rivastigmine 
(Lockhart et al., 2009).  
Many studies have investigated whether AchEIs can improve or stabilise 
cognitive performance.  Rogers et al., (2000) stated that donepezil was practical 
and beneficial for up to five years in AD patients.  Likewise Evans et al., (2000) 
and Cameron et al., (2000) gained similar beneficial results.  More recent 
studies such as Molinuevo et al., (2011) demonstrate that patients with mild AD, 
taking daily donepezil, remained cognitively stable on the MMSE after six 
months suggesting that donepezil is able to slow the rate of deterioration.  In a 
Spanish cohort, six months of treatment with donepezil was able to improve 
MMSE score comparative to placebo (Lopez-Pousa et al., 2005).  Seltzer et al., 
(2004) noted significant cognitive improvement following 24 weeks of donepezil 
on the MMSE and the Alzheimer’s Disease Assessment Scale (ADAS). 
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2.9.2 N-methyl-D-aspartate (NMDA) antagonists 
Memantine is a NMDA non competitive receptor antagonist and inhibits 
glutamate binding (Martorana et al., 2010).  Elevated glutamate levels are 
present in AD and can lead to neuronal toxicity and cell death (Farrimond et al., 
2012). In the USA memantine is recommended for the treatment of moderate to 
severe cases of AD and has less reported side effects than the AchEIs.  
Negative side effects may include confusion, dizziness and headache (Atri, 
2011).  
Winblad and Poritis (1999) showed an improvement on the Clinical Global 
Impression of Change Scale following three months treatment with 10mg of 
daily Memantine.  This study used both AD and vascular dementia patients 
which show different pathological and cognitive profiles.  Reisberg et al., (2003), 
using a sample of 181 moderate to severe AD patients, reported significant 
improvements on the ADL scale for those patients prescribed 20mg of 
memantine in comparison to placebo.  
A combination approach has also been trialled to include a treatment profile of a 
AchEI alongside Memantine. Tariot et al., (2004) recruited 404 participants with 
a probable diagnosis of AD.  All participants had baseline scores of between 5-
14 on the MMSE, and had been taking a stable dose of donepezil for at least 
three months.  Those participants who received memantine (20mg per day) in 
combination with their existing dose of donepezil demonstrated stable cognitive 
performance, as measured by the MMSE, comparative to baseline, after six 
months of treatment. The placebo group who continued to take only their 
prescribed donepezil showed a significant decline in cognitive performance.  
Summary 
The information provided within the first part of this chapter has shown that AD 
is a complex disease with numerous associated pathologies, processes, 
cognitive and behavioural profiles.  The progressive nature of AD means that 
these occur over a long period of time.  This chapter will now discuss MCI which 
is believed to be a transitional stage between healthy aging and AD (Markwick 
et al., 2012). 
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2.10 Mild Cognitive Impairment 
The term MCI was first used by Reisberg and colleagues in 1988 to describe 
patients who were cognitively impaired but who did not meet the full AD 
diagnostic criteria. The term was later adopted by Petersen et al., (1999) who 
defined a set diagnostic criteria for the condition.  MCI is believed to be a 
prodromal stage of AD or a transitional stage between healthy aging and AD. 
This sub group of individuals have an increased risk of progression to full AD 
pathology and symptomology (Petersen et al., 1999; Petersen, 2011; Hughes et 
al., 2011).  The concept of MCI as a precursor to AD came into question when it 
was discovered that not all those with MCI do indeed develop AD and that the 
conversion rate, although higher than normal aging (1-2%), (Roberts et al., 
2009), was approximately 10-18% per year for individuals aged 70 years or 
older (Petersen, 2009). In addition, some cases of MCI revert back to a ‘normal’ 
cognitive classification (Forlenza et al., 2010; Petersen, 2011). MCI has since 
been sub typed depending upon the predominant impairment present at 
baseline.  MCI can be subdivided into the amnestic type (aMCI), where there is 
a predominant impairment in memory, and the non-amnestic type (naMCI), 
where the predominant impairment falls within another cognitive domain 
(Petersen, 2011) for example language, spatial skills or naming. The higher 
conversion rate of the aMCI type to AD has meant that impairments on 
assessments of memory are the strongest predictors of conversion to AD.   
However, Mapstone et al., (2003) suggest that in its earliest form, MCI is indeed 
more likely to present with an impairment in another cognitive domain such as 
language or spatial ability.  This highlights the need for a thorough assessment 
taxing a variety of cognitive domains at baseline. Recently, Petersen et al., 
(2013) note that there is a possibility that naMCI may be a preclinical phase of 
other, non AD dementias. 
In the literature, some research has further divided aMCI and naMCI into single 
domain and multiple domain depending on the number of cognitive domains 
affected (Hughes et al., 2011). Sub typing the condition enhances the reliability 
and validity of research so that the clinical and cognitive profiles of each type 
can be more accurately understood.  In the following sections of this chapter 
MCI will be discussed in terms of its subtypes, diagnosis and symptoms, 
pathology, anatomy and treatment.  
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2.11 Symptoms and diagnosis 
MCI is defined by clinical, cognitive and functional criteria (Albert et al., 2011).    
Those with a MCI do not meet the full diagnostic criteria for AD, however, their 
symptomology is significantly different to the non demented elderly (Forlenza et 
al., 2010).  It can be challenging to distinguish between normal forgetfulness 
that occurs during aging and a genuine MCI (Petersen, 2011). MCI is usually 
awarded a CDR score of 0.5, or if the Global Deterioration Scale (GDS) is used, 
a score of two or three.  The core clinical criteria for a diagnosis of MCI include 
the following points as discussed in Albert et al., (2011). 
1. There must be a concern that there has been a change in cognition 
which can either be obtained from the individual themselves or an 
informant. 
2. There must be a clear impairment in at least one cognitive domain which 
is greater than would be expected for the individual’s age and education 
level.  Wherever possible this should be monitored over time to confirm 
an objective decline in neuropsychological test performance.  In aMCI 
this change is predominantly apparent in a memory domain, usually 
episodic memory, however, in naMCI a decline can be seen in another 
domain such as spatial ability, language or executive function (EF).  
3. Despite the above points the individual should still remain independent in 
the completion of functional activities and daily living tasks.  Even though 
certain errors or changes in tasks may be noted, such as forgetting to 
pay bills or taking longer to prepare meals, individuals with MCI generally 
maintain the ability to live in the community relatively unaided. 
4. The individual must not be demented and any cognitive changes noted 
should be mild. There should not be any evidence of severe impairment 
in social and/or occupational activities. 
 
Objective confirmation of a cognitive deficit is required and this is obtained via 
the use of a neuropsychological assessment.  The MMSE, a test of general 
cognitive ability, which is a commonly used instrument in the diagnosis of AD, is 
not reliable for the detection of MCI as it is not sensitive to mild degrees of 
impairment (Jacova et al., 2007; Petersen, 2011; Mitchell, 2009).  It is, 
therefore, necessary for clinicians to use more sensitive tests.  Cases of aMCI 
28 
 
usually demonstrate poor performance on episodic memory tests and delayed 
recall.  These types of assessment can predict to some extent whether a 
suspected MCI case is likely to progress to a full AD diagnosis (Dubois et al., 
2007; Albert et al., 2011).  The fact that MCI has different sub types and 
different cognitive profiles has meant that a thorough assessment of other 
cognitive domains is required such as EF, attentional control and visuospatial 
ability.  These can be assessed using tests such as the Trail Making Test 
(TMT), figure copying and digit span respectively (Albert et al., 2011). 
Neuropsychological assessments are discussed in more detail in chapter four. 
 
2.12 Progression to AD 
Confirmations of biomarkers associated with AD are obtainable in some cases 
depending on the protocol in use by the institution (i.e. the hospital, NHS, clinic). 
These can be useful indicators of the likelihood that the individual will progress 
to a full diagnosis of AD (Forlenza et al., 2010).  For example, confirmation of 
Aβ plaques (Markesbery, 2010), hippocampal and MTL atrophy as seen on MRI 
(Jack et al., 1999), hypometabolism of tempoparietal regions (Jagust et al., 
2009) as measured by PET, a CSF profile which mirrors that seen in AD 
(Hansson et al., 2006; Shaw et al., 2009) and possession of the APOE4 allele 
(Artero et al., 2008) all of which are associated with a high probability of 
progression. 
 
The ability to predict which cases will decline further is complicated by the fact 
that not all MCI cases go on to develop AD. In addition, progression rates differ 
for MCI sub types (Albert et al., 2011). There is a higher rate of progression for 
aMCI than naMCI (Hughes et al., 2011). Markesbery (2010) stresses the 
importance of considering the source of the samples used in MCI research. For 
example, those attending memory clinics with a subjective memory complaint 
are more likely to have a MCI and are also more likely to present with more 
advanced stages of neuropathology and anatomical changes associated with 
AD than samples of healthy elderly (HE) participants who are recruited in the 
community.  Of these community dwellers, some may indeed meet the 
diagnostic criteria for MCI but they are more likely to be in early stages of the 
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condition as they still continue to live independently (Petersen et al., 2009; 
Forlenza et al., 2010). 
 
2.13 Neuropathological and anatomical features of MCI 
Typical AD pathology namely the presence of Aβ plaques and NFTs, atrophy, 
inflammation and hypometabolism are present in MCI supporting the notion that 
MCI is in fact early AD. Each of these are discussed in the following sections. 
 
2.13.1 Aβ plaques 
Amyloid plaques are present in cases of MCI and measures of total plaque load 
and plaque distribution fall between the levels expected for healthy aging and 
AD (Markesbery, 2010). Autopsies from non demented HE participants show 
similar plaque distributions and levels to MCI participants which has made the 
presence of Aβ plaques unreliable as a true pathological marker of MCI (Mufson 
et al., 2012).  Differences between MCI and the HE have however been noted 
in specific brain areas.  For example, in MCI, plaque distribution is significantly 
greater in the frontal cortex and amygdala (Markesbery et al., 2006). Those MCI 
cases with low Aβ1-42 CSF levels are believed to be at a higher risk of a more 
rapid progression to AD (Hansson et al., 2006). Recently Petersen et al., (2013) 
showed that in a group of aMCI participants 43% of the sample did not show 
any evidence of Aβ plaques. 
 
2.13.2 Tau 
Advanced AD is associated with severe NFT pathology specifically in the nbM, 
the major cortical cholinergic hub (Mesulam et al., 2004).  Mesulam et al., 
(2004) demonstrated that the formation of NFTs starts during cognitively normal 
aging and progresses along a continuum, whereby MCI cytopathology is 
significantly different to normal aging but less severe than in AD.  The fact that 
the cholinergic neurons are affected early in the disease pathway is also 
important to consider as this supports the cholinergic hypothesis of the disease. 
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NFTs are significantly greater in number in the amygdalae, entorhinal cortex 
(EC) and inferior parietal cortex of MCI cases comparative to aged matched 
controls (Braak and Braak, 1991; Guillozet et al., 2003). The number of NFTs 
present has been found to correlate well with the level of cognitive impairment 
the subject demonstrates, making tau load a suitable indicator of MCI status 
(Forlenza et al., 2010). 
In the Religious orders Study which recruited 180 catholic clergy and has a 
good autopsy rate, evidence of neuropathology associated with AD was 
reported in 60% of the subjects (Bennett et al., 2005).  This study also noted 
that the presence of vascular disease was also associated with AD pathology.  
The fact that 40% of subjects did not present with pathological markers typical 
of AD again questions the prototype of MCI. 
 
2.13.3 Atrophy 
Different patterns of brain atrophy have been noted between MCI and HE and 
aMCI and naMCI.  Hippocampal atrophy correlates well with pathology, 
cognition and behavioural measures of the disease (Shen et al., 2011).  MCI 
cases have been found to exhibit smaller EC and hippocampal volumes relative 
to aged matched controls (Schuff and Zhu, 2007).  A study investigating 153 
MCI participants, 218 cognitively healthy individuals and 68 AD patients, 
revealed significant differences between the three groups on measures of total 
brain atrophy and hippocampal volumes.  Of the MCI cases, those classified as 
single or multi domain aMCI showed greater hippocampal atrophy relative to 
naMCI and the HE (He et al., 2009). A similar finding was found by Van de Pol 
et al., (2009) in a multi centre approach, where MTL atrophy was significantly 
greater in aMCI relative to naMCI and was also modified by age. 
Apostolova et al., (2006) followed a group of MCI participants for three years 
and carried out regular structural MRI scans.  Those participants who 
developed AD within the follow up period had greater volumetric loss in the CA1 
region of the hippocampus.  Voxel Based Morphometry has allowed the 
longitudinal measurements of total brain grey matter and has been able to map 
the change in grey matter over time in MCI cases.  Initial grey matter loss was 
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predominant in the amygdala, anterior hippocampus and EC before spreading 
to the entire hippocampus, parietal cortex and finally the frontal cortices (Schuff 
and Zhu, 2007).  Diffusion Tensor Imaging (DTI), a new variant of MRI, has 
been used to track white matter changes in MCI and has also revealed 
alterations in hippocampal fibre integrity (Fellgiebel et al., 2004).   Furthermore, 
temporal lobe atrophy correlates well with cognitive performance.  Grundman et 
al., (2002) showed that larger hippocampal volumes were associated with better 
performance on memory tasks and assessments of general cognitive function. 
Structural imaging offers a reliable way to monitor volumetric changes in tissue 
viability and appears to correlate with disease severity.  It should be noted, 
however, that the EC and hippocampus are affected in other types of dementia 
such as frontotemporal dementia and vascular disease.  Relying on MRI 
measures alone may not be sufficient to confirm the presence of MCI or the 
likelihood of progression to AD. 
 
2.13.4 Hypometabolism 
Hypometabolic changes are seen in AD and have been confirmed also in cases 
of MCI.  Similar patterns of metabolic abnormality occur in MCI (Petersen et al., 
1999) but these are more widespread.  FDG-PET scanning has revealed 
hippocampal hypometabolism in MCI (Mosconi et al, 2009).  In naMCI different 
patterns are observed, whereby, there is a general absence of hypometabolism 
or mild disturbances in regions around the parieto temporal cortices (Clerici et 
al., 2009).  Amnestic cases show more prominent changes in glucose 
metabolism.  Figure six is taken from Mosconi et al., (2009) and shows regional 
decreases in cerebral glucose metabolic rates for AD patients, MCI participants 
who went on to develop AD after two years and stable MCI participants.  De 
Leon et al., (2001) followed 48 HE participants over a period of three years and 
found baseline reductions in metabolism in the EC could accurately predict 
future decline. 
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2.13.5 Inflammation and oxidative stress 
As in AD, there is evidence of neuro-inflammation in MCI (Roberts et al., 2009).  
In a sample of 313 MCI participants and over 1000 cognitively normal elderly 
participants, MCI was associated with elevated C-reactive protein (CRP) levels, 
a marker of inflammation (Roberts et al., 2009).  Likewise, there is evidence of 
oxidative stress in MCI cases indicating this too occurs early in the disease 
process (Nunomura et al., 2007). 
 
Figure six: regions of hypometabolism (as seen in red) in AD and MCI patients who 
went onto develop AD, taken from Mosconi et al., (2009) 
2.14 Therapeutic interventions and treatment 
There are a number of interventions which can be offered in order to prevent 
further cognitive decline or optimise current cognitive functioning in MCI.  A 
review of intervention approaches by Gates et al., (2011) stated that new 
innovative programs for the treatment of MCI are vital if clinicians and 
researchers wish to decrease the number of cases progressing to AD.  
Currently there is no effective pharmacological treatment for MCI (Aisen et al., 
2008). Initially trials with AchEIs were disappointing and in general studies have 
reported no significant benefit in the delaying of disease progression (Raschetti 
et al., 2007; Feldman et al., 2007; Winblad et al., 2008).  AchEIs such as 
rivastigmine and donepezil also have significant side effects and are therefore 
not ideal for long term use (Atri, 2011).   
Petersen, (2011) stated that rather than pharmacological treatment, individuals 
with MCI should be encouraged to increase their involvement in social and 
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cognitive activities particularly as these are low risk and have shown positive 
outcomes.  Cognitive plasticity refers to alterations in synaptic organisation 
brought about by cognitive practice such as task learning or mental activity 
(Sanz Simon et al., 2012).  Participation in mentally stimulating tasks is 
associated with a lower incidence of AD, and may, therefore, offer some degree 
of protection against cognitive decline (Wilson et al., 2002). Furthermore, 
cognitive training programs in the HE can decrease the risk of developing 
cognitive impairment (Valenzuela and Sachdev, 2009). Increased learning 
potential and cognitive activity in MCI participants has been shown to be 
associated with a decreased decline in cognitive performance as measured by 
the Auditory Verbal Learning Test (AVLT) of Learning Potential (Calero and 
Navarro, 2004).  This suggests that cognitively stimulating tasks are useful in 
MCI through the enhancement of cognitive plasticity mechanisms. 
Various intervention programs now exist and include cognitive stimulation, 
which is usually carried out in a group setting to encourage social and cognitive 
functioning.  Cognitive training, which implements ways to maximise cognitive 
performance, and cognitive rehabilitation which focuses on ADL where the 
individual sets their own goals to achieve tasks which they may currently 
struggle with (Clare et al., 2003).  
 
2.15 Chapter summary 
This chapter has outlined the symptoms and diagnostic procedures for both AD 
and MCI as well as reviewing some of the key pathological, anatomical and 
neurochemical features of each condition.  It is clear that AD is a highly complex 
neurodegenerative condition with multiple risk factors and underlying 
processes.  This makes detecting and treating the condition difficult.  MCI is 
believed to be a prodromal stage of AD and this is supported by the fact that 
many MCI cases go onto develop AD and possess some of the key pathological 
hallmarks of AD.  Treating patients at the time of symptomatic onset is sub 
optimal as changes in the brains systems and underlying pathology have 
already been altered, sometimes decades beforehand.  This is an important 
issue and therefore earlier diagnosis is needed if these detrimental changes are 
to be halted, this is discussed in more detail in the following chapter.  
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Chapter 3 
Early diagnosis of Alzheimer’s disease 
 
3.1 Introduction 
The previous chapter provided an overview of AD and MCI. This chapter will 
discuss the early diagnosis of AD in more detail including the positives and 
negatives this approach may have on the patients, their families, the healthcare 
systems and the economy.  The chapter evaluates some possible techniques 
which could be employed to detect early signs of the disease and what early 
interventions could then be of use in delaying cognitive decline should a 
diagnosis occur at an earlier point in the disease pathway. 
 
3.2 The growing burden of AD 
Worldwide a number of countries including the UK, USA, and the Netherlands 
have recognised that AD and other dementias must be prioritised in terms of the 
treatment, care and support that is made available to patients (Alzheimer’s 
disease International (ADI), 2011).  The UK government has recently made AD 
one of its top priorities due to the significant crisis which is escalating in terms of 
the social, health and economic impact that the increasing number of diagnosed 
cases will bring (Department of Health, 2009). There is currently a large 
treatment gap where it has been estimated that only 20-50% of all AD cases 
actually receive a formal diagnosis (ADI, 2011).  Of the estimated 36 million 
people suffering from dementia worldwide, there are potentially 28 million who 
are not diagnosed and are, therefore, not receiving any treatment or support 
(ADI, 2011).   
Without a diagnosis there is a barrier between the patient and their ability to 
access relevant health care.  This makes it difficult to improve the individual’s 
quality of life and prevent any worsening of their symptoms.  ADI state in their 
2011 world report, which specifically focussed on early diagnosis, that a timely 
diagnosis is imperative.  Early diagnosis may be able to reduce the ‘treatment 
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gap’.  Delaying diagnosis wastes valuable time for the patient and may mean 
that by the time their condition is formally diagnosed they may not gain the 
maximum benefits from drug interventions.  
AD is receiving increased attention and the general population is becoming 
more aware of the disease, its symptoms and what can be done to help those 
affected. This has largely occurred due to increased reporting in the media and 
via organisations such as the Alzheimer’s Society, Alzheimer’s Research Trust 
(ART) and ADI who have published fact sheets, magazines and leaflets  
Early diagnosis may help to reduce some of the stigma associated with the 
disease and assist in altering society’s views, opinions and attitudes towards 
AD.  People often feel uncomfortable discussing AD (Werner et al., 2013; 
MacRae, 1999).  There are also a number of misconceptions about the disease 
which creates further barriers for diagnosis and early detection.  For example, 
many believe that losing one’s memory is a normal part of the aging process 
and if they do notice changes in their own memory they are unlikely to seek 
help for this (ADI, 2011).  Many also believe that there is nothing that can be 
done for AD patients and they do not inform their GP of their symptoms until 
they are moderate or severe (Department of Health, 2009).  Increasing public 
awareness could encourage carers and those affected to seek help earlier 
when symptoms are milder.  People are more likely to reach out for additional 
support if it is readily available and accessible to them (ADI, 2011) and 
hopefully an earlier diagnosis could facilitate and improve this process.   
In AD research there has been a prominent focus to try and detect and 
diagnose the disease as early as possible (Forlenza et al., 2010).  Early 
detection of AD has been recommended as a priority in the most recently 
published NICE dementia guidelines (Ballard et al., 2011).  This was set as a 
precedence due to the findings from many research groups that the underlying 
pathological changes associated with the disease could be detected possibly 
decades before subtle symptoms begin to appear (Forlenza et al., 2010; 
Dickerson et al., 2011; Petersen, 2009; Sperling et al., 2011).  This meant that a 
diagnosis at the time of symptomatic onset was suboptimal and in the majority 
of cases too late to alter the disease’s progression.  The long preclinical phase 
of the disease, therefore, offers opportunities to intervene earlier (Zamrini et al., 
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2004). This approach is seen elsewhere in other medical conditions.  For 
example, in cardiovascular disease high cholesterol can be monitored and 
treated with statins years before hand, thereby reducing the risk of heart 
disease or heart attack (Rosenberg et al., 2008).   
As mentioned in chapter two, the amnestic form of MCI is likely to be a 
transitional stage between normal aging and AD (Markwick et al., 2012, 
Petersen, 2011).  These individuals are likely to be in an early stage of the 
disease, although detection even at this stage may be too late (Petersen, 2009).  
Finding a definitive cure for AD is as yet impossible and methods to halt the 
progression may be of benefit both to those affected, the health care systems 
and the economies worldwide (Petersen, 2009). 
 
3.3 Why is early diagnosis needed? 
3.3.1 Increase in expected incidence 
The incidence of AD continues to increase on an annual basis (Alzheimer’s 
Association, 2013).  Age remains the major risk factor for developing AD 
(Rountree et al., 2013).  The increasing life expectancy of the elderly means 
that by 2040 there will be over 40 million people affected worldwide 
(Alzheimer’s Association, 2013).  This will place an even larger burden on 
global economies and makes AD care a major concern.  Detecting cases as 
early as possible, whilst individuals still live in the community, could significantly 
decrease the cost burden for care.  These individuals are then more likely to 
remain independent for longer if their disease pathology can be halted keeping 
them in the milder stages of the disease for longer (Petersen, 2009).  
 
3.3.2 Decrease the economic burden 
The economic costs of AD are huge and in 2010 it was estimated that 
worldwide $604 billion were spent on AD care (ADI, 2011). A large proportion of 
these costs were directly derived from social care and it was further estimated 
that between 30-50% of those suffering from AD resided in care homes (Knapp 
and Prince, 2007).  With the increasing incidence of the disease, which is likely 
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to reach 115 million by 2050, care costs will continue to soar (ADI, 2009).  
Although early diagnosis may initially cost governments additional expense to 
cover the cost of diagnostic tests and procedures, delaying the need for social 
care and nursing home placement would benefit the economy in the long run 
(ADI, 2011). There are currently no studies which have directly compared the 
benefits in terms of cost for early versus later diagnosis.  Likewise, there is 
currently no direct evidence that earlier initiation of medication can delay 
institutionalisation and this is mainly because clinical trials have been short in 
duration (usually between 6-12 months) (Rountree et al., 2013).  Despite this it 
is the expert opinion of many researchers and organisations that early diagnosis 
would greatly reduce the growing economic burden of AD care (ADI, 2011; 
Alzheimer’s Association, 2013).   
 
3.3.3 Maximise treatment efficacy 
Drug treatments for AD which target the cholinergic systems are the most cost 
effective when symptoms are mild.  Early initiation of pharmacological 
treatments may optimise cognitive symptoms allowing patients to remain in their 
own homes for longer thus maintaining higher levels of cognitive function 
(Markwick et al., 2012). The efficacy of the drugs decreases as the disease 
progresses with limited benefits in severe cases (Gauthier et al., 2013).  See 
chapter two section 2.9 ‘Treatment’ for more detail.  
 
3.3.4 Identify reversible causes of cognitive dysfunction 
Some individuals who present with mild cognitive changes may indeed have a 
MCI or early AD but their symptoms may be caused by another underlying 
condition such as cardiovascular disease or depression which are treatable and 
manageable (Overshott and Burns, 2004). Early diagnosis or screening for AD 
would identify individuals, who if were left untreated, would likely progress to a 
form of dementia (Ashford et al., 2006). Furthermore, the elderly with generally 
poor health are at a higher risk of developing AD.  Frailty in particular seems to 
be highly correlated with AD development (Reitz et al., 2011) due to its 
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association with poor nutrition, lack of exercise and lower levels of social 
interaction.   
 
3.3.5 Identify MCI and prevent further decline 
MCI is a risk factor for the subsequent development of AD (Petersen et al., 
2009) but this is complicated by the fact that not all cases will progress to a full 
AD diagnosis (Chapman et al., 2011).  The conversion rate of MCI to AD is 
approximately 10-18% per year for cases aged 70 years or over (Petersen, 
2009).  Subjective memory complaints are found in over 50% of those over 65 
years of age (Bassett and Folstein, 1993) and are highly predictive of decline to 
MCI and AD.  This highlights the need to screen these individuals and monitor 
them more closely (NICE, 2006a).  If MCI can be detected as soon as possible 
there may be hope of preventing further cognitive decline or slowing the 
trajectory to AD.  In addition, the MCI population are an ideal cohort for future 
research and the majority of ethical issues which are encountered when 
recruiting AD patients are no longer problematic (Ashford, 2006; Gauthier et al., 
2013).  For example, MCI participants are able to give their informed consent 
and there are no doubts of competency. Unfortunately, trials of AchEIs in MCI 
cohorts have not provided beneficial results in their ability to delay disease 
progression (Gauthier et al., 2013). Although there is no validated treatment for 
MCI, those affected can be informed about interventions and lifestyle factors 
which may help maintain ADLs and cognitive ability.  For example, cognitive 
activities, a healthy diet and the rule out of the presence of co morbid medical 
conditions (Petersen, 2009).  
 
3.4 Considerations for early diagnosis 
Doctors are currently not sufficiently reliable in their ability to detect very mild 
signs of cognitive impairment.  Further, GPs reportedly miss over 50% of mild 
AD cases which then leaves the patient to deteriorate even further to a 
moderate stage of the disease before an intervention is initiated (Ashford et al., 
2006). Another study reported that 91% of mild cases are overlooked in the 
primary care setting (Valcour et al., 2000).  By the time these patients have their 
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condition formally diagnosed there is then substantial disease related pathology 
and medications may be of limited benefit. For early, accurate detection to be 
possible GPs require additional resources and guidance. The GP, who is often 
the first point of call for suspected AD cases (Petersen, 2009), will ultimately 
decide whether or not the patient requires a referral onto a specialist memory 
centre (NICE, 2006a,b). It is imperative that GPs are sufficiently confident and 
trained in their ability to recognise and document the most subtle of symptoms if 
the effectiveness of this process is to be maximised.  Further, more organised 
co-ordination and communication between the primary and secondary care 
centres (i.e. the GP practices and memory clinics) is necessary if early 
diagnosis is to occur in a timely fashion (ADI, 2011).  Valcour et al., (2000) 
reported that only 20-50% of AD cases were actually documented in primary 
care practice.  Although it is acknowledged that diagnosis is ‘easier’ and more 
reliable when symptoms are moderate to severe, it can be challenging to notice 
mild alterations in cognition (Petersen, 2011).  This must be improved and 
addressed quickly if reliable early diagnoses are to be made (ADI, 2011).   
GPs have very little time for each appointment (Cooper et al., 1992; O’Connor 
et al., 1988).  Clinicians often state that they find giving a diagnosis of AD 
challenging as they do not have sufficient time to sit with the patient and go 
through all of the available options and treatments.  This is particularly difficult 
when AD is such as sensitive and distressing issue (Werner et al., 2013).  In the 
1990s it was often the opinion of medical professionals that a diagnosis would 
bring more harm to the patient and in many cases those affected by AD were 
not informed (Werner et al., 2013). Turner et al., (2004) carried out a survey of 
UK GPs which revealed that almost one third felt that they lacked the 
confidence in their ability to detect and diagnose AD, mainly because they did 
not have enough specialist specific knowledge regarding early diagnosis.  The 
AD world report 2011 also showed that educational intervention programmes, 
which were specially designed for general practice, received low levels of 
participation.  For example, only 28% of invited practices in the UK took part 
even though they were reimbursed for their time, suggesting that this type of 
education needs to be made mandatory if diagnostic procedures are to be 
improved (ADI, 2011).  
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3.5 Implementing early diagnosis 
In order to implement early diagnosis there must be tools in place which are 
sensitive to mild cognitive symptoms (Chapman et al., 2011).  Cognitive 
changes may only be subtle but the underlying brain systems may show a 
different level of severity.  Some have argued that early screening for AD is 
itself highly expensive.  The cost of early identification for one patient in the US 
has been calculated to be approximately $4000 and screening may not actually 
be a cost effective mechanism in the short term (Ashford et al., 2006). However, 
the UK national audit office recommended in a report published in 2007 that the 
government should indeed spend to save (National Audit Office, 2007). 
There are a number of techniques in use that could detect some of the 
hallmarks of early AD for example neuro-imaging, blood analysis, immunisation 
and neuropsychological testing.  Researchers disagree which technique is the 
best and most reliable to use with some suggesting that a combination of 
biomarkers need to be checked. Unfortunately this increases the cost and the 
time needed to thoroughly assess each patient.  Another important factor to 
consider is that in the UK waiting times to see specialists can take up to 18 
weeks (NHS, 2012) and appointments with a GP are time limited (Cooper et al., 
1992).  This makes it difficult to obtain a detailed patient history and 
examination including medical history, family patterns of disease, blood tests 
and physical examination. The following section discusses some of the possible 
tools available for use in earlier detection and diagnosis. 
 
3.5.1 Neuro-imaging 
The imaging of underlying brain structures implicated in AD can reveal slight 
volumetric alterations, identifying those individuals who may be at risk but who 
are currently cognitively normal (Velayudhan et al., 2012; Zamrini et al., 2004).  
Small alterations in MTL and parietal volumes in cognitively normal elderly 
participants can identify those who are likely to decline (Morris et al., 2009). 
Studies which have recruited MCI participants have also demonstrated that 
those with elevated levels of hippocampal atrophy, specifically in the EC, have 
an elevated risk of decline to AD.  Therefore, the use of imaging as a screening 
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option would seem viable (Fennema-Notestine et al., 2009; Jack et al., 2004; 
Varon et al., 2011).   
Velayudhan et al., (2012) showed that EC volume was more strongly 
associated with baseline cognitive performance than total hippocampal volume. 
AD patients with the most significant tissue loss in this area experienced the 
most rapid rates of cognitive decline.  An earlier study also noted decreased 
MTL grey matter volumes in a group of 23 cognitively normal individuals who 
went on to develop a MCI (Smith et al., 2007). Measurements of EC volume 
may offer a reliable method for early detection. 
As discussed briefly in chapter two section 2.5.1 ‘Senile Plaques’, advanced 
imaging techniques such as PET can utilise radioligands such as PiB which can 
bind to and detect early deposition of amyloid plaques (Jack et al., 2008). In AD 
and MCI participants there is increased PiB retention compared to the HE, 
however, some HE who are classified as cognitively normal also show some 
levels of retention (Mintun et al., 2006).  Using PiB as a biomarker for early 
detection may not be reliable when used as a stand alone method.  It may be 
useful for the identification of patients who require further, more detailed 
investigations and neuropsychological testing, to confirm or rule out a 
suspected diagnosis.  
Another potential approach is to focus on the monitoring of whole brain 
volumes.  McDonald et al., (2009) showed that in the non-demented elderly 
there is minimal whole brain atrophy annually. In MCI cases and AD patients 
there is, however, considerable atrophy acceleration and this is significantly 
increased in the medial and lateral temporal and inferior parietal cortex, areas 
which are implicated in AD. Annual variances in atrophy offer a higher 
sensitivity to subtle alterations in brain tissue and could be useful for early 
diagnosis or prediction of future possible AD cases. The authors of this 
research stress that the interpretation of a single MRI scan does not reliably 
indicate the rate of subsequent progression nor can it be compared to earlier 
images (McDonald et al., 2009). Longitudinal follow up annually gives a more 
accurate picture of underlying processes and possible neurodegeneration 
(McDonald et al., 2009).  Again, the longitudinal monitoring of the elderly over 
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time is expensive and time consuming and may not be the most economic way 
of assessing patients for early detection. 
In summary, imaging techniques provide an accurate picture of the brain’s 
underlying volume and functioning.   Negatives of this approach include the high 
expense (Zamrini et al., 2004), and the requirement of highly trained staff to 
carry out the procedure. There is also the risk of exposure to radiation 
particularly if repeated scans are required.  A positive of neuro-imaging is its 
lack of cultural bias, as seen with some cognitive assessments.  Likewise, it is 
not affected by external variables such as concentration, mood, tiredness, 
language or education level (Zamrini et al., 2004). 
 
3.5.2 CSF profiling 
The CSF is a fluid which is continuously circulated throughout the brain and its 
cavity ventricles (Bear et al., 2001).  Sampling CSF and measuring specific 
levels of proteins and biomarkers would offer an accurate representation of 
brain activity and processes (Forlenza et al., 2010).  A sample is obtained via 
lumbar puncture which requires the patient to lie on their side while a sample of 
CSF is collected via a needle inserted into the dural space of the spine between 
the lower lumbar vertebrae (Medline Plus, 2011).  The procedure takes 
approximately 20-30 minutes, after which the patient is required to lay flat for a 
period of preferably four hours (Medline Plus, 2011).   
MCI participants with CSF profiles similar to those reliably detected in AD i.e. 
low levels of Aβ and high levels of total tau, usually decline at a faster pace than 
those MCI cases without this typical profile (Petersen, 2009).  Hansson et al., 
(2006) used CSF profiling and accurately divided their sample of MCI 
participants into those who were at a high probability of decline/non decline 
based on CSF levels of AD proteins. CSF sampling may, therefore, be a useful 
tool for early detection but the collection of such samples is invasive with a risk 
of side effects (Ashford et al., 2006).  The report of headaches after a lumbar 
puncture occurs in 2-4% of patients (Andreasen et al., 2001) and may deter 
patients from consenting to this procedure. Other side effects may include sore 
back and less common, more serious adverse effects, can include infection, 
43 
 
haematoma and nerve damage (Medline Plus, 2011). The collection of CSF can 
only be carried out by trained clinicians and requires further laboratory 
processing making this option expensive and time consuming. Further, following 
a lumbar puncture, patients must be kept under observation before being 
allowed to go home which would require specialist facilities/centres as this type 
of procedure would not be possible in general practice. NICE do not 
recommend CSF collection and comparisons for a diagnosis of AD regardless 
of the stage of disease (NICE, 2006b; 2011). 
 
3.5.3 Blood tests 
Obtaining a blood sample is quick, can be carried out by a phlebotomist, has 
minimal side effects and can be processed quickly and relatively cheaply 
(O’Bryant et al., 2011).  Sampling can be carried out at the GP surgery and 
does not require admission to a hospital or specialist clinic. Blood analysis 
would provide a useful way of indentifying possible candidates for research 
trials and would flag those individuals who may require a more detailed and 
thorough set of testing via imaging or CSF sampling (O’Bryant et al., 2011). 
Amyloid plaques are a hallmark of the disease (Forlenza et al., 2010) and Aβ 
can be detected in the serum, but, whether levels in the blood correlate with 
brain concentrations has been questioned (O’Bryant et al., 2011). One issue in 
previous research has been the type of blood fraction, (i.e. plasma or serum) 
that is analysed which can lead to discrepancies in data findings across studies.  
For example, Mayeux et al., (2003) measured plasma amyloid levels of Aβ42 
and Aβ40 in 530 individuals including AD patients and healthy controls. They 
reported increased Aβ1-42 levels at baseline testing for AD patients and those 
individuals who went on to develop AD within three years.  Luis et al., (2009) on 
the other hand measured serum Aβ levels and reported that Aβ1-42 was 
elevated in MCI participants compared to controls but that established AD 
patients had levels in-between the values for controls and MCI participants. 
O’Bryant et al., (2010) used a different approach and created a biomarker risk 
score using the measurement of serum proteins obtained from blood samples 
from 197 AD patients and 203 cognitively normal controls.  This risk score could 
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accurately identify 91% of the sample.  When demographic variables such as 
age, education level and clinical laboratory values of other risk factors such as 
cholesterol were taken into account the accuracy of the algorithm to identify 
participant’s clinical group was increased to 95% (O’Bryant et al., 2011). 
Routine blood testing is also useful for highlighting any other reversible 
deficiencies/abnormalities which could exacerbate cognitive symptoms.  
 
3.5.4 Neuropsychological testing  
Mild alterations in cognition are common during aging and it is sometimes 
difficult to discriminate between normal aging and a pathological abnormality 
(Hedden and Gabrielli, 2004).  Likewise some neuropsychological tests show a 
decline in performance during normal aging (Sperling et al., 2011). There are 
many neuropsychological tests available which assess different cognitive 
domains, although not all tests are validated for the detection of milder degrees 
of impairment and therefore may not be useful for early diagnosis.  Johnson et 
al., (2009) note that there appears to be an inflection point several years before 
diagnosis where cognitive deficits first become apparent.   Although this 
occurred approximately three years before diagnosis for visuospatial ability 
noticeable deficits in verbal and working memory were not detectable until one 
year before clinical diagnosis.  This highlights the need to assess a range of 
different cognitive domains when making an initial diagnosis (Johnson et al., 
2009).    
The MMSE is an assessment of general cognition used in the diagnosis of AD 
but there is currently no one instrument internationally recognised as a tool for 
the reliable detection and diagnosis of MCI (Guo et al., 2012).  In order to detect 
slight cognitive changes the neuropsychological test used must have high 
sensitivity and must be able to reliably detect early disease.  The MMSE is 
discussed in more detail in chapter four ‘Neuropsychological testing’ see page 
62 for further details.  A more sensitive general test of cognition is the Montreal 
Cognitive Assessment (MoCA) (Nasreddine et al., 2005).  This test, like the 
MMSE, also assesses multiple cognitive domains but unlike the MMSE, also 
includes assessments of working memory and EF (Markwick et al., 2012).  
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Nasreddine et al., (2005) showed that 73% of their sample who possessed an 
abnormal MoCA score (26 or less out of a possible thirty) had a normal MMSE 
score (26 or more) creating a conflicting diagnosis based on these results 
alone.  Consequently scoring within the normal range on the MMSE does not 
necessarily confirm that the individual is AD risk free.  This creates important 
considerations when giving a diagnosis based on a single test score. Both the 
MMSE and MoCA are discussed in more detail in chapter four 
‘Neuropsychological testing’. 
The fact that general cognitive tests may not thoroughly test specific cognitive 
domains has meant that many studies have then investigated the HE and those 
individuals with a MCI to determine whether one cognitive domain appears to 
be the first affected over another. As alterations in cognitive ability are an early 
manifestation of the disease, it is feasible that cognitive assessments which are 
sensitive enough will detect these subtle changes (Chapman et al., 2011).  As 
mentioned earlier Johnson et al., (2009) note that there appears to be an 
inflection point several years before diagnosis where cognition alters suggesting 
that regular longitudinal checks from middle age onwards may be needed, 
however, this is time consuming. 
Mapstone et al., (2003) suggest that in its earliest form MCI is indeed more 
likely to present as an impairment in another cognitive domain such as 
language or spatial ability.  This again highlights the need for a thorough 
assessment taxing a variety of cognitive domains at baseline. Tests assessing 
MCI must also be sensitive to change over time in order to accurately monitor 
the rate of subsequent decline (Stein et al., 2010).  This would require 
longitudinal follow up which is time consuming and adds expense (Carrillo et al., 
2009). 
Data from imaging studies can complement and narrow down the type of 
cognitive testing which is required.  As previously mentioned research studies 
sampling participants with MCI (i.e. those who do not yet fully meet the criteria 
for dementia), have revealed an elevated volumetric decline in the EC of the 
hippocampus.  This area is crucial for memory function (Feczko et al., 2009) 
and has been implicated in early AD in many research studies.  Developments 
and improvements in imaging techniques have greatly improved the accuracy of 
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imaging the MTL and as a result these volumetric data can identify anatomical 
change in the earliest stages of the disease (Pruessner et al., 2002).   In 
addition to a decline in EC volume, the earliest signs of the presence of 
pathological markers are also found in this area in the form of NFTs.  The fact 
that these participants present with pathological biological markers which are 
hallmarks of AD suggests they are in a prodromal early stage of the disease.  
Lesion studies and imaging studies carried out on the EC have found this area 
to be highly sensitive to tests stimulating visuospatial associative memory.  This 
type of memory typically involves learning the association between a visual 
stimulus and a distinct spatial location (Égérhazi et al., 2007).  Some of the 
earliest signs of early disease may be detectable by assessments of 
visuospatial skills (Johnson et al., 2009). An example of an existing test from 
the Cambridge Neuropsychological Automated Test Battery (CANTAB) which 
recruits this type of memory is the CANTAB Paired Associates Learning task 
(CANTAB PAL) (Égérhazi et al., 2007).  This test is discussed in detail in 
chapter four ‘Neuropsychological Testing’ and could be a useful pre-clinical tool 
as a AD screening tool in the future.   
The most common complaint associated with AD is a deficit in episodic memory 
(Ahmed et al., 2008) and assessments which tax this domain such as delayed 
word recall, are useful for the prediction of decline (Dubois et al., 2007; Albert et 
al., 2011; Jacova et al., 2007).  Using this measure alone may not be reliable 
due to individual variability (Zamrini et al., 2004).  In addition, tests of speeded 
EF such as the Stroop test and the TMT have also proven useful for predicting 
decline (Chapman et al., 2010).  EF relies heavily on the frontal lobes and is 
crucial for the changing demands and situations experienced in daily living 
(Schroeter et al, 2012). The frontal lobes are highly sensitive to the aging 
process and experience a large decline in volume with age (Hedden and 
Gabrieli et al., 2004). It is, therefore, expected that increasing age would be 
associated with poorer EF performance. Both the Stroop and TMT require the 
ability to quickly switch between two stimuli and also have an inhibitory 
component (Chapman et al., 2010).  These tests may also be useful for early 
diagnosis. 
In summary, the border between normal aging and cognitive impairment is not 
defined.  Instead there is a gradual continuous decline in cognition making it 
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difficult to determine the exact time of disease onset (Carrillo et al., 2009).  
Consequently, the use of a single cognitive test alone is inadequate for the 
reliable detection of early cognitive alterations. Negatives of neuropsychological 
testing include the long administration times for detailed cognitive batteries 
(Zamrini et al., 2004) and the need for validation and consideration of multiple 
external factors such as age, education, mood and cognitive reserve (Jacova et 
al., 2007). There is considerable variability in normal cognitive performance 
(Zamrini et al., 2004).  For example, an individual may have been poor at spatial 
ability since young adulthood and failure to score well on a test of spatial ability 
may not signify underlying disease but may simply be due to individual 
differences (Zamrini et al., 2004).  This is one such danger of interpreting a 
single test score for a diagnosis.  Nevertheless, using neuropsychological 
assessment is less expensive than other procedures such as imaging, is non 
invasive and safe (Chapman et al., 2011) and has high potential as a tool for 
use in early screening and diagnosis. 
 
3.6 Recent research for early diagnosis 
Korff et al., (2013) recently reported that α synuclein levels were elevated in 
CSF samples of MCI and AD participants relative to HE controls.  The amount 
of α synuclein present also significantly correlated with participants’ MMSE 
score suggesting that monitoring levels of this protein in CSF samples may also 
be of clinical relevance for early detection. 
Roe and Rentz (2013) investigated glucose metabolism in those with a high 
cognitive reserve as these individuals are likely to score normally on brief 
screening instruments creating ceiling effects (Markwick et al., 2012).  
Unexpectedly the authors found that those with increased cognitive reserve 
showed patterns of decreased brain glucose metabolism.  The results imply that 
higher levels of education may allow these individuals to cope for longer with 
underlying detrimental processes associated with AD before symptoms first 
become apparent. 
There is a link between sense of smell and neurodegeneration (Hüttenbrink et 
al., 2013). Olfactory dysfunction is detectable in early AD (Hüttenbrink et al., 
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2013) and in those with a MCI (Wilson et al., 2009).  Braak and Braak (1991) 
note that the EC which plays a role in olfactory processing is one of the earliest 
affected sites in the disease. Assessments of olfactory function and sensitivity 
may be useful as an early indicator of potential disease if cognition is normal.  
Frost et al., (2013) investigated retinal vascular markers of AD on the premise 
that the retina is a direct outgrowth of neural tissue and may show signs of AD 
pathology. In diagnosed AD patients there are visual changes including 
alterations to the optic disc and retinal arteries.  Retinal screening could 
potentially be useful for early detection.  Frost et al., (2013) investigated 148 
participants which comprised 125 HE and 25 AD. Clear retinal vasculature 
abnormities were seen in the AD participants although further study is needed 
to determine the earliest point at which these changes are noticeable if this is to 
be used as an early diagnostic tool. 
 
3.7 What treatments could be offered if diagnosis were to occur earlier?  
3.7.1 Pharmacological interventions 
As discussed in chapter two AchEIs, including donepezil, rivastigmine and 
galantamine, and the NMDA non competitive receptor antagonist, memantine, 
are commonly used as the pharmacological drugs of choice in the treatment of 
AD and other dementias (Rountree et al., 2013; Atri, 2011).  AchEIs increase 
the concentration of Ach within the synaptic cleft via the inhibition of the 
acetylcholinesterase enzyme (Rountree et al., 2013) whereas memantine 
inhibits glutamate binding and this is discussed in chapter 2 ‘Alzheimer’s 
disease and Mild Cognitive Impairment’. The AchEIs have all shown positive 
effects in the treatment of mild to moderate AD and memantine has been 
beneficial in the treatment of moderate to severe cases.  All three licensed 
AchEIs have a similar efficacy for the treatment of mild to moderate cases and 
there is a great deal of evidence to suggest that these drugs are useful in early 
cases (Birks, 2006).  Research has also shown that these drugs help maintain 
ADLs and prevent further cognitive decline (Feldman et al., 2001; Holmes et al., 
2004). Consequently early diagnosis would be beneficial for the timely 
prescription of these medications.  It is however important for the patient and 
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their families/carers to understand that these drugs do not bring about a cure 
and more research is needed to determine the long term effects as current trials 
have been short in duration over a number of weeks (ADI, 2011). Another issue 
which has made it difficult to evaluate the use of these drugs in the prevention 
of further cognitive decline or the stabilisation of cognition is that of compliance.  
Families often stop medication if they believe they are not seeing an 
improvement, even though the drugs may be stabilising the patient’s symptoms 
(Geldmacher et al., 2006).  
 
3.7.2 Hormone replacement therapy (HRT) 
Women are at an elevated risk of developing AD (Hogervorst et al., 2000).  This 
may be due to their higher life expectancy but may also be a result of changes 
in oestrogen levels with age (Markou et al., 2005).  After the menopause 
women experience a decrease in their levels of circulating oestrogen and 
gonadal hormones (Hogervorst et al., 2000; Markou et al., 2005).  Research 
studies have shown that oestrogen has many beneficial mechanisms in the 
brain including its ability to enhance cholinergic transmission (Gibbs and 
Aggarwal, 1998; Ryan et al., 2008, Markou et al., 2005), prevent cellular death 
(Harms et al., 2001), increase dendritic spine density in the hippocampus 
(Murphy et al., 1998), decrease levels of Aβ  (Ryan et al., 2008) and decrease 
levels of neurotoxic glutamate (Ryan et al., 2008).  Oestrogen also influences 
certain aspects of cognition including verbal fluency, memory, and spatial skills 
(Markou et al., 2005; Ryan et al., 2008).  Due to these findings it was 
hypothesised that the administration of HRT to postmenopausal women would 
benefit cognition and brain health and perhaps decrease the risk of developing 
AD.  
The decline in oestrogen after the menopause can be counteracted through the 
use of HRT which delivers synthetic oestrogen (Wnuk et al., 2012).  A number 
of different preparations exist which vary in the type of oestrogen used and 
whether it is combined with a synthetic progesterone (Hogervorst et al., 2000). 
Early studies carried out in the 1990s appeared to suggest beneficial effects of 
HRT on dementia risk and cognition.  Later studies such as Mulnard et al., 
(2000) and Espeland et al., (2004) have revealed discrepant findings and have 
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noted detrimental effects of HRT (Hogervorst and Bandelow, 2010). A meta 
analysis carried out by Hogervorst and Bandelow (2010) revealed that the 
strongest effects of HRT were noted on cognitive assessments of verbal 
memory and in some cases EF and concentration.  Duration of HRT was also 
an important factor, although, the effect of age on treatment outcome was not 
as strong.  Furthermore, the addition of a progesterone was associated with a 
greater number of negative outcomes (Hogervorst and Bandelow, 2010).    
Discrepant findings between studies may be due to the type and dosage of the 
HRT administered, the duration of the treatment, the cognitive measures and 
analysis carried out, the participant’s age at menopause and treatment onset 
and also any prior exposure to oestrogenic medications (Ryan et al., 2008).   
Hogervorst et al., (2000) comment that HRT may only have beneficial effects 
during a limited window of time or in specific cohorts.  For example, surgically 
menopausal women or those with depressive symptomology.  There are also 
concerns regarding the side effects of HRT such as an elevated risk of certain 
cancers including breast and ovarian types, pulmonary embolism, coronary 
heart disease and stroke (Ryan et al., 2008).  Currently oestrogens cannot be 
recommended as an early intervention for preventing cognitive decline in 
women.   
 
3.7.3 B vitamins 
The B vitamins are molecules which are able to bind to and break down HCy, a 
toxic sulphur amino acid (Aisen et al., 2008), essential for numerous metabolic 
actions. HCy levels significantly increase during aging (Li et al., 2008) and as a 
consequence of this they have become a therapeutic treatment option to reduce 
AD risk and progression (Aisen et al., 2008).  AD has been linked to an increase 
in HCy (Lehmann et al., 1999); further, increased HCy concentrations in the 
brain are associated with an increased rate of medial temporal lobe atrophy 
(den Heijer et al., 2003).  If low B vitamins are detected during early diagnosis 
of AD or MCI, reversing this deficiency may halt further decline and optimise 
current cognitive function. 
den Heijer et al., (2003) investigated HCy concentrations and brain atrophy in 
the non demented elderly using a large sample of 1077 participants aged 
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between 60-90 years.   The authors used MRI to visualise global cortical brain 
atrophy and correlated this with fasting plasma HCy concentrations.  
Participants with increased HCy had a significantly decreased hippocampal 
volume bilaterally compared to those with normal HCy values. This was also 
confirmed in a study by Tseng et al., (2009).  Further, increased HCy was also 
correlated with increased cortical atrophy in general.  Multivitamin users 
constituted 5.9% of the sample and these individuals possessed lower HCy 
concentrations.   
HCy is also associated with vascular dementia, cardiovascular disease and high 
cholesterol (Smith, 2002; Smith et al., 2010). If lowering HCy via specific vitamin 
administration could occur, the number of individuals suffering from MCI who go 
onto to develop AD would be reduced significantly (Smith, 2002). 
Whether supplementation with B vitamins is beneficial to cognitive decline, or 
for use in those diagnosed early, remains unclear as studies have yielded 
conflicting data (Luchsinger and Mayeux, 2004).  Clarke et al., (1998) studied 
76 AD patients and 108 HE participants and found that AD patients had lower 
levels of folate and B12 in blood samples.  Aisen et al., (2008) carried out a 
reliable supplementation study to see if they could shed any light on previous 
inconsistencies.  Their double blind placebo versus treatment experiment took 
place over a period of 18 months and recruited 409 participants.  Participants 
were recruited from multiple sites in North America from their local health 
centres. All participants were over the age of 50 and scored between 14 and 26 
on the MMSE at baseline.  The treatment group were given a daily tablet 
containing 5mg of folic acid, 1mg of vitamin B12 and 25 mg of B6.  The placebo 
group received a tablet identical in appearance but that contained no active 
ingredients.  All participants received regular checkups at three monthly 
intervals. In order to determine whether a beneficial effect was observed 
patients completed the ADAS, a 70 point scale consisting of a series of 
cognitive tests assessing multiple dimensions including memory, attention, 
language and orientation.  A higher score represents greater impairment.  The 
authors considered a 25% reduction in score to be the equivalent of a beneficial 
effect.   
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Of the 409 participants who took part 371 were taking AchEIs and 166 were 
multivitamin users.  Surprisingly, there was an increase in reported cases of 
depression in the treatment group which the authors believe was not a result of 
the treatment, rather just the patient’s stage in their illness.  As expected 
analysis showed an increased vitamin concentration in the treatment group 
which correlated with a decrease in HCy levels in this group also.  Overall in the 
treatment group there was a 27% decrease in HCy, a 19% decrease in the 
multivitamin users and a 31% decrease in the non multivitamin users. 
Although the authors concluded that there was a significant beneficial effect of 
taking a high dose vitamin B supplement in reducing HCy concentration, there 
was no significant reduction in ADAS score.  This may signify that the study 
needed to have used a more thorough method of determining cognition and 
should possibly have used a range of tests and assessments rather than one 
single scale. Participants were also at different stages in disease progression 
when recruited into the study and this may have impacted on their response to 
treatment and scores of cognitive function. Recently B vitamin treatment over a 
period of two years, in comparison to placebo, was able to slow the rate of 
cognitive decline particularly when baseline HCy was in the upper quartile range 
(de Jager et al., 2012) in a group of MCI participants.  
Currently there appears to be no significant benefit of B vitamin treatment for 
early AD or for the prevention of further cognitive decline.  However, in their 
quick referencing guide, NICE do recommended that clinicians should check 
levels of B vitamins and folate (NICE, 2011).   
 
3.7.4 Vitamin E 
Vitamin E is a powerful antioxidant (Uneri et al., 2006) found in a number of 
dietary foodstuffs including vegetable oils, nuts and seeds (Farina et al., 2012).  
As previously mentioned in chapter two, AD and MCI are associated with 
elevated levels of oxidative stress and low levels of antioxidants (Axelsen et al., 
2011). High doses of vitamin E (>3000ug/day) are toxic and can cause fatigue 
and stomach upset.  Furthermore, even at low habitual levels there are some 
health considerations such as altered bleeding rates (Farina et al., 2012). 
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400ug/day of vitamin E increased prostate cancer risk in men (Klein et al., 
2011) and also increased the risk of stroke in another study (Shürks et al., 
2010).  A recent Cochrane review revealed that across 46 trials, vitamin E 
administration increased mortality risk significantly (Bjelakovic et al., 2012).  
Despite this vitamin E has been linked to cognitive function, for example, aged 
rats show improved cognition following vitamin E administration (Socci et al., 
1995).   Vitamin E levels are decreased in the serum and CSF of AD and MCI 
cases (Mangialasche et al., 2012) but this may be due to alterations in dietary 
intake in these conditions in later stages of the disease.  
Farina et al., (2012) carried out a review to determine whether vitamin E would 
be useful in the treatment of AD and MCI.  Early diagnosis may facilitate the use 
of this micronutrient in AD care. From this review the authors concluded that 
vitamin E should not be recommended as an early intervention for MCI and AD.  
Studies such as Sano et al., (1997), Lloret et al., (2009) and Petersen et al., 
(2005) reported no significant differences between vitamin E and placebo on 
cognitive outcomes or risk of conversion to AD.  There is no evidence at present 
that vitamin E improves the outcomes of AD patients and it is also associated 
with a number of serious health side effects (Farina et al., 2012).  Although 
these studies have yielded negative results it may be that the administration of 
vitamin E in capsule form delivers doses which are too high.  It may be better to 
investigate whether a diet rich in vitamin E containing foodstuffs would be more 
beneficial to those with MCI or AD. 
 
3.7.5 Ginkgo biloba 
Ginkgo Biloba is derived from the Maidenhair tree and is commonly used in 
Chinese medicine for the treatment of a number of medical conditions (Birks 
and Grimley Evans, 2009). Ginkgo increases blood supply via its vasodilatory 
ability, decreases blood viscosity and possesses antioxidant properties (Birks 
and Grimley Evans, 2009).  There have been a number of trials which have 
assessed the use of Ginkgo as a cognitive enhancer useful in the treatment of 
dementia.  For example Le Bars et al., (1997) and Schneider et al., (2005), 
These studies have revealed inconsistent results with some earlier studies 
reporting benefits but with more recent studies showing no positive effects.  The 
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lack of significance does not seem to be modified by dose or trial duration. 
Despite the lack of positive effects, Ginkgo is safe to use with no reported 
serious adverse effects and may be suitable as an optional supplement 
although it cannot be specifically recommended for use in the prevention of 
further cognitive decline in MCI.  
 
3.7.6 Physical activity  
Individuals with high levels of physical activity have a lower risk of developing 
AD (Podewils et al., 2005; Laurin et al., 2001; Larson et al., 2006).  
Furthermore, levels of exercise have been shown to correlate with cognitive 
performance in the elderly (Laurin et al., 2001, Brown et al., 2010). One study 
has shown that the non demented elderly who are physically active show 
decreased PiB retention and higher Aβ42 levels in the CSF (the opposite profile 
to AD patients) (Liang et al., 2010).  Exercise programs or interventions may, 
therefore, be useful in decreasing the risk of further decline, maintaining current 
brain function and improving quality of life for those with an early diagnosis 
(ADI, 2011). Exercise results in many positive health benefits for AD patients 
and these include increased resting blood flow to cerebral areas which 
subsequently increases the delivery of vital nutrients, improved muscular 
strength, promotion of plasticity mechanisms and increased brain volumes 
(Ruthirakuhan et al., 2012).  All of these mechanisms may improve cognitive 
performance and maintain ADLs during aging.  Exercise programmes are also 
likely to take part in a group setting thereby facilitating higher levels of social 
interaction (Ruthirakuhan et al., 2012).   
There has been very little research investigating the use of exercise 
interventions in early AD or MCI but studies which have investigated this have 
reported positive effects on cardiovascular fitness, behaviour and cognition 
(Heyn et al., 2004; Teri et al., 2003).  It would seem feasible that patients with 
AD would be able to take part in some form of physical activity even if this was 
seated for short intervals (ADI, 2011).  
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3.7.7 Cognitive engagement and stimulation 
Engaging in stimulating cognitive activity has been linked to a decreased risk of 
developing AD (Ruthirakuhan et al., 2012).  For example, Wilson et al., (2010) 
demonstrated that those non demented elderly who were cognitively active had 
a decreased risk of MCI and AD.  Cognitive interventions can benefit AD 
patients in terms of facilitating improvements in ADLs and cognitive functions 
(Valenzuela and Sachdev, 2009).  There is evidence to suggest that engaging 
in hobbies such as reading, puzzles, games and watching television for a few 
hours per week can also decrease the risk of cognitive decline during aging 
(Hughes et al., 2010).  Cognitive engagement can not only decrease the risk of 
AD but could be useful in the early stages of the disease to prevent further 
cognitive decline.  For example, Treiber et al., (2011), reported that high 
participation in stimulating activities in early AD slowed the rate of disease 
progression.  Cognitive stimulation and information regarding this type of 
therapy would be useful in the early diagnosis of AD.  
 
3.8 Additional factors to consider for early diagnosis 
Early diagnosis and/or screening for early signs of disease is important for 
those individuals who are non symptomatic but have a family history of the 
disease.  Possessing a first degree relative with AD increases the individual’s 
own risk of developing the disease by 4-10 % (Cupples et al., 2004). Honea et 
al., (2010) reported that cognitively normal individuals with a maternal history of 
AD had decreased grey matter volumes in AD related areas of the brain 
compared with those individuals who either have a paternal family history or no 
family history of AD.  In those with a maternal history of AD there was significant 
evidence of progressive atrophy in the parietal and parahippocampal cortices 
(Honea et al., 2011).  The exact reasons why maternal transmission appears to 
be more significant than paternal cases is still not fully understood but highlights 
the need to monitor and screen those with a strong family history.  
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3.9 Pros and cons of early diagnosis 
3.9.1 Closer monitoring 
An earlier diagnosis would enable the closer monitoring and tracking of the 
disease’s progression (Pesini et al., 2012) but would also allow the clinician to 
check for reversible causes of cognitive complaints.  For example, low levels of 
B vitamins, infection, depression and/or altered thyroid hormones (Overshott 
and Burns, 2004). Likewise, earlier detection could help the management of 
associated conditions which can exacerbate the cognitive problems present in 
AD such as depression (Overshott and Burns, 2004). Closer monitoring of early 
AD or MCI cases would allow the clinician to check for, and monitor, other risk 
factors for subsequent cognitive decline such as poor nutrition, lack of social 
interaction and/or vascular complaints (such as high cholesterol or high blood 
pressure) all of which, if left untreated or addressed, could increase the rate of 
cognitive decline. 
The earlier administration of treatments may also halt the disease’s progression 
and optimise cognition whilst underlying brain systems are still relatively intact 
with normal neurotransmitter concentrations.  Early treatment interventions aim 
to maintain the highest level of cognitive functioning for as long as possible in 
order to prevent further decline to more severe stages of the disease (Seltzer et 
al., 2004).  The longitudinal monitoring of patients would be beneficial but such 
monitoring would be expensive and time consuming (Dickerson et al., 2011). 
 
3.9.2 Improved understanding 
Receiving an early diagnosis, or knowing that they possess an increased risk of 
developing AD, allows the patients and their families time to educate 
themselves about the disease, its symptoms and what they can do to aid their 
condition.  This may include the implementation of certain diet and lifestyle 
habits, some of which have been discussed in this chapter. Families often 
report feeling relieved that a diagnosis has been confirmed which can reduce 
anxieties and can help them to adjust to life with a diagnosis (ADI, 2011).  An 
earlier diagnosis then allows the patient to be fully involved in their own 
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treatment pathway so that they can make informed decisions about their own 
care and experience (Ashford et al., 2006).   
 
3.9.3 Reducing harm 
Early diagnosis could reduce the numbers of harmful incidents reported in AD 
populations.  For example, in the early stages of AD, patients are known to 
become lost or forget about electrical appliances for example leaving a frying 
pan on the stove. This can lead to dangerous risks and the involvement of the 
emergency services (Ashford et al., 2006). 
 
3.9.4 Time to prepare  
An early diagnosis may offer some relief to patients who have been concerned 
about their memory and would give them time to prepare for the future.  For 
example, making a will if they have not already done so, or giving consent to 
treatments that at some stage they may not be competent to give or understand 
(Mattsson et al., 2010). It also allows families to consider safety and security 
issues with living arrangements, cooking, driving and medication use.  
 
3.9.5 Reducing care costs 
Early diagnosis could decrease the cost of AD care for the government but also 
for the families and individuals affected.  Receiving a diagnosis earlier in the 
disease pathway can allow the patient to continue living independently for 
longer which would delay the time when additional care such as nursing home 
placement is required. 
 
3.9.6 Psychological implications 
Although positive steps can be taken after an earlier diagnosis, such as closer 
monitoring and educating, there is a high probability that this may cause 
increased anxiety or depression in these patients.  There may be feelings of 
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hopelessness and despair (Mattsson et al., 2010) and also the possibility of an 
increased risk of suicide.  It is unclear from previous research whether this is a 
direct result of feelings of despair at receiving a diagnosis, or a direct 
consequence of the underlying disease (Draper et al., 2010).  Depression and 
anxiety will be even greater in those individuals who live alone or perhaps do 
not have the support of close relatives or friends.  In addition, depression can 
accelerate cognitive and physical decline in established AD patients therefore 
exacerbating the initial cognitive symptoms (Overshott and Burns, 2004).   
An early diagnosis, or high likelihood of AD development, may induce 
symptoms of anxiety and depression in relatives (van der Cammen et al., 2010), 
placing a higher burden on the family and possibly their ability to care for the 
patient.  There may be legal implications for an early diagnosis, for example, 
insurance premiums may be more expensive or no longer obtainable.  There is 
the added possibility that early diagnosis may result in the earlier removal of 
driving licences isolating individuals living in the community even further 
(Mattsson et al., 2010).   
 
3.9.7 Stigma 
AD is perceived negatively by the general public (Gauthier et al., 2013).  The 
elderly reported in a recent survey that AD phobia is the most worrying concern 
for the aging population and this may indicate that the elderly may not wish to 
be screened or diagnosed earlier (Draper et al., 2010).  Some of the elderly 
often state that they would rather die earlier than live with a diagnosis of 
dementia (Mattsson et al., 2010).  Information about AD is now more readily 
available and often the elderly know or are aware of friends and/or relatives who 
have suffered from the disease.  As a result they may be more willing to be 
screened (Draper et al., 2010).  Losing one’s memory can have a profound 
effect on personality, identity and sense of self which can also lead to 
symptoms of depression (Ashford et al., 2006).  Stigma associated issues also 
create implications for the individual in terms of employment and insurance 
(Sperling et al., 2011).  
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3.9.8 Diagnostic uncertainty 
No one biomarker test useful for early detection has 100% sensitivity and 
accuracy and this indicates that false positive diagnoses may occur in some 
cases.  This will cause unnecessary worry or the administration of testing or 
invasive treatments which are not actually needed.  This has the potential to 
cause unnecessary harm and unwanted side effects and is a prominent issue in 
the implementation of early detection of AD.  Although a diagnosis of MCI could 
be given not all MCI cases do go onto to develop AD and again this may cause 
needless anxiety and stigma (Sperling et al., 2011).   
 
3.10 Chapter summary 
This chapter has outlined some of the benefits that an early diagnosis could 
bring.  For example, the earlier prescription of AchEIs, information regarding 
lifestyle and dietary factors such as maintaining B vitamins and antioxidants, 
using Gingko Biloba, cognitive stimulation and social interaction and using 
support groups.  It has also highlighted some of the potential barriers to early 
diagnosis including, costs, stigma and lack of diagnostic accuracy.  In order to 
combat these issues GPs must be further educated and trained to become 
more reliable in their ability to detect mild symptoms because they are often the 
first point of call for suspected cases of early AD. Stigma surrounding AD must 
also be tackled by increasing public awareness.  Memory clinics need to 
become more accessible to those with suspected AD in order to correctly 
identify questionable cases. 
One of the main questions posed in this area of research is ‘will early diagnosis 
be beneficial to the patient or just the economy?’  Early detection may be able 
to decrease the time the patient spends in care facilities but it will not prevent 
subsequent decline until methods are found to halt disease progression. It is 
clear that no one biomarker seems to be 100% reliable in its ability to diagnose 
early cases and ideally all elderly individuals should be entitled to imaging and 
neuropsychological screening.  Cost restrictions are currently making this an 
impossible task at present.  The UK government has, however, recently made 
dementia care in the UK a priority.   
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Chapter 4 
Neuropsychological testing: review and methodology 
 
4.1 Introduction 
In the previous chapter neuropsychological testing was discussed as one 
potential method for the early diagnosis of cognitive impairment.  Unfortunatley 
the testing process can be affected by external factors which have the potential 
to affect the accuracy of the scores obtained.  The experiments of this thesis will 
utilise neuropsychological testing to assess cognitive performance in the HE. 
This chapter will discuss neuropsychological testing in more detail and will 
include detailed descriptions of the neuropsychological tests which will be 
included in the cognitive batteries administered to participants.  
Neuropsychological assessment is one method used to diagnose a cognitive 
impairment (Chapman et al., 2010).  The assessment process is useful for 
clinicians and researchers to distinguish between normal aging and whether a 
clinical impairment is present (Zamrini et al., 2004). Numerous tests exist which 
vary in their levels of specificity and the type of cognitive domain that they 
assess.  The scores obtained are used by health care professionals to 
determine which treatments can be offered, whether pharmacological 
intervention is initiated and potentially what care programme is delivered in the 
community (Jacova et al., 2007).  Scores from these tests can determine 
whether individuals are suitable to be included in research trials (Gauthier et al., 
2013) which often have very specific inclusion criteria.  It is essential for test 
scores to be accurate to ensure that those recruited are indeed suitable.  
Patients diagnosed with a cognitive impairment may then be monitored over 
time and will often be re tested to follow their progression (Overshott and Burns, 
2004).  
Aging is a continuous process and is progressive in nature.  The effects of 
aging become more noticeable with increasing age due to the cumulative 
effects which have built up over time (Chan et al., 2009).  At present a 
comprehensive neuropsychological assessment is delivered when the patient 
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begins to show signs of AD symptoms such as a rapid decline in memory, 
language, spatial awareness or changes in personality (Brousseau et al., 2007).  
Testing at this stage is problematic as underlying pathological changes can 
occur many years, perhaps even decades prior to symptomatic onset (Blackwell 
et al., 2004; Forlenza et al., 2010).  These changes are irreversible and so it is 
important to catch the disease in its early stages.  This will enable treatment to 
be initiated and maximised with the aim of slowing progression and preventing 
further cognitive decline (as discussed in chapter three ‘Early Diagnosis’). 
 
4.2 Brief tests of general cognitive function 
Brief tests of general cognitive function are used to determine the presence and 
severity of any memory impairment (Feldman et al., 2008).  They are usually 
administered by the GP at the GP surgery and take approximately 10-15 
minutes to complete.  They are quick to administer and are easily accessible to 
the primary care setting, however, they do have lower sensitivities to milder 
degrees of cognitive impairment which is somewhat problematic if an early 
diagnosis is to be made (Feldman et al., 2008). An abnormal score on one of 
these tests can identify individuals who may require further, more in depth 
neuropsychological testing, or another type of dementia screening such as 
neuro-imaging or blood analysis (Jacova et al., 2007). Some brief tests can be 
affected by the participant’s demographic variables such as their age, education 
level, mood and race (Revett et al., 2013).  Examples of brief tests include the 
MMSE, the MoCA, the Seven Minute Test, the GPCOG and the clock drawing 
test (CDT), amongst others. For the purpose of this thesis the MMSE and the 
MoCA will be discussed in further detail.  These tests will be used as a part of 
the cognitive batteries administered to participants in this thesis. 
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4.2.1 The Mini Mental State Examination (MMSE) 
The MMSE was developed in 1975 by Folstein et al., and is a quick assessment 
of general cognitive ability.  The test consists of 19 components which tax a 
variety of cognitive domains including orientation, short term memory, recall, 
language, attention, copying and verbal understanding (Folstein et al., 1975).  A 
copy of the MMSE can be seen in figure seven. The MMSE is considered the 
most widely used cognitive assessment in the primary care setting and is useful 
for the rule out of suspected dementia cases (Mitchell, 2009).  The test takes 
approximately ten minutes to complete and the patient receives a score out of a 
possible 30 points.  The interpretation of cut offs can vary with some 
researchers using a cut off of 24 for impairment.  According to the NICE 
dementia guidelines a score of 26 or above signifies that no impairment is 
present, 21-26 represents mild AD, 10-20 signifies moderate AD, 10-14 equates 
to moderately severe AD and scores less than ten represent severe AD (NICE, 
2011). 
The MMSE has been criticised for its inability to reliably detect mild cases of 
cognitive impairment which is problematic for patients who score on the 
borderline (Tombaugh and McIntyre, 1992, Tombaugh, 2005).  There is only a 
six point difference between a normal and an abnormal diagnosis and within 
these six points both MCI and mild AD are also included (Marioni et al., 2011).  
Another issue with the scoring of the MMSE is the occurrence of ceiling and 
floor effects (Crum et al., 1993).  This creates clusters of patients scoring the 
test’s maximum (30/30), and severe cases clustering at lower scores (<10/30).  
Demographic variables including age, education, race, culture and language 
ability have also been shown to affect scores (Ballard et al., 2011; Davey and 
Jamieson, 2004; Crum et al., 1993; Tombaugh and McIntyre, 1992; Tombaugh, 
2005).  This is problematic as the test may not be reliably sensitive for those 
with a large cognitive reserve or a higher level of education (Jacova et al., 2007; 
Tombaugh, 2005).  As mentioned in chapter two, a higher education level 
(cognitive reserve) has been associated with a decreased risk of developing AD 
and MCI.  As a result it has been suggested that for highly educated individuals, 
a higher cut off of possibly 27 out of 30 should be used (Markwick et al., 2012) 
for defining an abnormal score.  This may increase the risk of false positive 
results.  In addition, non Caucasian individuals may be at a disadvantage, 
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particularly if English is not their first language or if culturally, they are not 
familiar with the phrases or objects that they are asked to remember or recall as 
a part of the test. The revised NICE dementia guidelines (NICE, 2011) have, 
therefore, incorporated this and note that MMSE score alone should not be 
used to give a diagnosis or determine care if the patient is not fluent/familiar 
with English or is not of Caucasian background (NICE, 2006b).  
The NICE dementia guidelines were highly criticised for recommending MMSE 
cut off scores for the prescription of AchEIs (Davey and Jamieson, 2004). 
Researchers had argued that the MMSE is not reliably sensitive as a suitable 
assessment for the determination of treatment interventions (Ballard et al., 
2011) or for assessing treatment response over time (Bowie et al., 1999). These 
guidelines stated that cholinesterase inhibitors should only be prescribed to 
those patients with a moderate form of dementia which, therefore, implied that a 
patient with mild cognitive difficulties would not be treated until they continued to 
decline further.  The guidelines also stated that medications should be removed 
if MMSE score fell below 10 points (NICE, 2006b).  This contradicted the widely 
acknowledged goal that earlier detection of AD was needed.  The revised 
guidance in 2011 still recommends the MMSE as a tool used in the diagnosis of 
AD but states the following ‘’.... treatment should be continued only when it is 
considered to be having a worthwhile effect on cognitive, global, functional or 
behavioural symptoms....’’ (NICE, 2011).  A review of neuropsychological 
testing by Jacova et al., (2007) concluded that the MMSE was not superior and 
gave no additional advantage in comparison to other brief cognitive screens.  
Future NICE guidelines may need to place a larger emphasis on the 
recommendation of other brief cognitive assessments. 
Consequently, the MMSE is better as a method for the exclusion of AD rather 
than a tool which diagnoses the severity of impairment the patient initially 
presents with (Tombaugh, 2005). Even though researchers and clinicians are 
aware of the problems associated with the MMSE scoring system it is 
recommended by NICE to determine whether or not they should consider 
prescribing medication.   
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Figure seven: a paper copy of the MMSE (Folstein et al., 1975) 
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4.2.2 The Montreal Cognitive Assessment (MoCA) 
The MoCA was specifically created as an assessment for the detection of MCI 
(Nasreddine et al., 2005).  It is a brief cognitive test which assesses short-term 
memory, visuospatial ability, EF, attention, concentration, working memory, 
language and orientation to both time and place (Markwick et al., 2012).  The 
MoCA is similar to the MMSE in that it assesses multiple domains of cognitive 
ability and is scored out of a maximum score of 30; however the cut off for 
impairment is a score of 26/30 rather than the cut off of 24/30 used in the 
MMSE (Jacova et al., 2007).  A copy of the MoCA can be seen in figure eight. 
Studies have reported good internal consistency and retest reliability for the 
MoCA (Markwick et al., 2012).  The MoCA includes more thorough testing of 
memory, including a delayed recall question and also assesses EF and more 
complex visuospatial skills.  Tests of these two domains have previously been 
found to be sensitive to early cognitive impairment (Blackwell et al., 2004; 
Mapstone et al., 2003; Dubois et al., 2007). Unlike the MMSE, the MoCA takes 
into account if the participant has a lower level of education and awards them 
an additional point if their level of education falls below 12 years (Nasreddine et 
al., 2005).  This is determined purely by the participant’s recollection.  A review 
revealed that the MoCA has excellent sensitivity to detect MCI and AD, 90% 
and 100% respectively, compared to the MMSE, which has sensitivities of 18% 
and 78% (Feldman et al., 2008). Nasreddine et al., (2005) reported that the 
mean score of a sample of MCI participants fell within the normal range on the 
MMSE but in the abnormal range on the MoCA suggesting that the MoCA is a 
more reliable method for detecting milder forms of cognitive impairment. 
Likewise Smith et al., (2007) reported 83% sensitivity for the MoCA to identify 
MCI participants compared to only 17% by the MMSE. 
Recently Markwick et al., (2012) compared the MoCA and MMSE scores from 
107 healthy elderly participants with a mean age of 76 years.  All of the subjects 
had an MMSE score of 24 or higher.  The MMSE scores for the cohort ranged 
from 24-30 whereas scores obtained on the MoCA ranged from between 13-30. 
Of those scoring normally on the MMSE, 40.2% had an abnormal MoCA score, 
supporting claims that the MMSE may not be sensitive to MCI.  These findings 
were in accordance with previous work such as Nasreddine et al., (2005) and 
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Pendlebury et al., (2010). Damian et al., (2011) noted in their study that the 
orientation items of the MoCA correlated the strongest with the degree of 
cognitive impairment but that the animal naming portion of the assessment did 
not and was, therefore, possibly too easy.  In summary, these findings indicate 
that the MoCA is a superior cognitive test to the MMSE for the detection of early 
AD and MCI.  
 
4.2.3 Brief tests: summary 
Brief cognitive tests are useful aids for the GP. They provide a quick method of 
obtaining a picture of a participant’s overall global cognitive function.  The quick 
administration time is useful for application in clinics and is not too taxing for the 
participant.  One of the major disadvantages to some, but not all, of these tests 
is their inability to detect mild degrees of impairment which is crucial if earlier 
diagnosis is to be implemented.  The issue of intra individual variability must 
also be taken into consideration. For example, is it reliable to state that two 
participants who both score 28/30 on the MMSE have the same level of 
cognitive function?  What if one patient goes onto to develop AD within the next 
twelve months but the other patient remains cognitively stable?  The fact that 
this type of problem does indeed occur suggests that the use of one total score 
alone is not a reliable or accurate enough method to be used for the diagnosis 
of AD.  It may be useful to consider the participant’s reaction time and 
processing speed for each item in order to combat this issue.   No single brief 
cognitive test has been found to be better than the rest and none can be 
recommended for the differentiation of subtypes, i.e. MCI or AD (Feldman et al., 
2008).  It may be better to re test the patient regularly over the following six 
months before a diagnosis is made. However, this is time consuming and 
delays the administration of treatment if it is indeed required. The remainder of 
this chapter will now discuss the tests which will be used in the experiments of 
this thesis. 
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Figure eight: the Montreal Cognitive Assessment (MoCA). Picture taken from 
www.mocatest.org. 
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4.3 CANTAB PAL 
The CANTAB battery consists of multiple assessments, one of which is the PAL 
(Égérhazi et al., 2007).  As briefly mentioned in chapter three, the PAL is an 
assessment of visuo-spatial associative memory and requires the participant to 
learn an association between a visual stimulus and a spatial location (Égérhazi 
et al., 2007).  This type of task recruits the hippocampus and hence provides an 
indication of underlying hippocampal integrity (de Rover et al., 2011). The test is 
delivered via a touch screen computer and takes approximately ten minutes to 
complete (Wild et al., 2008). The computer based scoring system offers a 
higher degree of accuracy for the recording of responses compared to 
traditional pen and paper tests and, therefore, removes some of the potential for 
subjective researcher error. 
The participant is presented with a computer screen depicting six white boxes 
which open up in a random order.  The participant is asked to remember which 
box a pattern appears in and must record their response by pressing the 
appropriate box on the touch screen.  The task progressively becomes more 
difficult and the participant is then required to remember the location of two 
different patterns, then three and then six.  The number of errors made at the 
six pattern stage is of importance as this level has previously been shown to be 
highly sensitive to MCI and early AD (Blackwell et al., 2004; de Rover et al., 
2011).  Participants’ performance at the six pattern level significantly correlates 
with subsequent deterioration in global cognitive function over the following 
eight months (Swainson et al., 2001).  Further, the earliest signs of underlying 
pathology, which are the presence of NFTs, are present in the EC (Braak and 
Braak, 1991). Imaging studies have found this area of the brain necessary for 
visuospatial associative learning (Blackwell et al., 2004), therefore, this test may 
be the most useful for detecting the presence of early neuropathological 
abnormalities.  
Fowler et al., (2002) reported that a six month decline in the PAL performance 
of participants with mild cognitive difficulties predicted later progression to AD.  
Likewise, de Rover et al., (2011) report impaired performance in a group of MCI 
participants on both the four, six and eight pattern stages of the PAL relative to 
controls.  The PAL’s high discriminability (Nestor et al., 2004) and usefulness in 
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identifying early cases of impairment could, therefore, make it a useful pre 
clinical tool/biomarker (Beddington et al., 2008).  The PAL could be used as a 
dementia screening assessment in the future.  The PAL may also be useful for 
employment in the evaluation of new treatment interventions or strategies (de 
Rover et al., 2011) to trace longitudinal improvement or deterioration.  Its longer 
administration times mean it is not an ideal option for use by GPs due to their 
limited appointment times (Cooper et al., 1992).  This means it is more likely to 
be used at specialist clinics by trained neuropsychologists.  For the purpose of 
this thesis the score at the six pattern stage will be recorded. 
 
4.4 The Graded Naming Test (GNT) 
The GNT is also a test from the CANTAB battery and is an assessment of 
semantic memory (McKenna and Warrington, 1980). The test requires the 
participant to correctly name 30 black and white line drawings presented on a 
computer screen.  A pen and paper version of the GNT is also available. The 
objects presented in the GNT becoming progressively harder to identify, 
beginning with easy objects such as a scarecrow, and ending with harder, less 
easily recognisable objects, such as a retort (Lambon Ralph et al., 2001). The 
participant receives a score out of 30.  It is important to consider that the 
drawings presented during the GNT may not be cross culturally applicable.  
This should be considered when administering the test to a non UK sample. 
Naming and vocabulary skills usually improve with age (Kahlaoui et al., 2012) 
however some studies have reported a clear semantic deficit in AD and this is 
mirrored by poor GNT performance by AD patients compared to aged matched 
controls.  For example Lambon Ralph et al., (2001) investigated semantic 
deficits in 10 AD patients, 10 Dementia with Lewy Body (DLB) patients and 10 
cognitively normal controls.  AD patients and DLB patients performed similarly 
on the GNT. The AD sub group, (mean score 20.6), achieved significantly 
worse scores compared to the cognitively normal controls, (mean score 25.1). 
Similar results were also reported by Graham et al., (2004) and Thompson et 
al., (2005). 
MCI participants have also shown impaired performance on the GNT 
suggesting that a semantic deficit occurs early in the disease process (Chan et 
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al., 1997).  Dudas et al., (2005) investigated MCI, AD and cognitively normal 
participants.  Although some of the MCI participants performed normally on the 
MMSE they were significantly worse than the controls, but better than the AD 
patients, on the GNT.  Likewise, Ahmed et al., (2008) reported poorer 
performance on the GNT by 32 MCI participants, (mean score 19.7), compared 
to 37 cognitively normal older adults, (mean score 26.1).  
Blackwell et al., (2004) demonstrated in a regression analysis that the number 
of errors made at the six pattern stage of the CANTAB PAL, the score obtained 
on the GNT and the subjects age at the time of testing could identify converters 
to AD with 100% accuracy within a 32 month period using a sample of 40 
patients.  The results of all of these studies imply that the GNT may, therefore, 
also be a useful test to be used in the detection of early AD cases. 
 
4.5 The Trail Making Test (TMT) 
The TMT (Reitan and Davison, 1974) is a commonly used neuropsychological 
instrument which assesses multiple cognitive processes (Lezak et al., 2004).  
The test comprises two parts, the first section, referred to as Trails A or the TMT 
part A, requires the subject to join a series of numbered circles in increasing 
numerical order as quickly as possible.  This part of the test assesses visual 
search (O’Rourke et al, 2011) and processing speed.  Part B of the test, 
referred to as Trails B or TMT part B, requires the subject to join a sequence of 
circles containing numbers and letters, alternating between numbers and 
letters, in increasing numerical/alphabetical order.  This part of the assessment 
is a measure of EF, particularly visual search and set switching (O’Rourke et al., 
2011).  The most commonly used scoring system is the time taken to complete 
each part in seconds (Ashendorf et al., 2008). Other scoring methods which 
take into account the number of errors, ratio scores (Giovagnoli et al., 1996) 
and the difference in score between part A and B have also been investigated 
(Arbuthnott and Frank, 2000).  Arbuthnott and Frank (2000) stated that 
subtraction of the time to complete part A from part B removes the motor 
component of TMT part A and gives a better index of EF.  The time to 
completion still remains the most common scoring method, as even cognitively 
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normal participants are known to make errors on this test (Ashendorf et al., 
2008).   
Some studies have noted main effects of age (Coffey et al., 2001; Tombaugh, 
2004) and education (Horton and Roberts, 2001) on this assessment. Hammar 
and Ardal (2009) found significant effects of depression on TMT score, 
whereby, depressed individuals took longer to complete both parts of the test.  
This is an important consideration for AD research as depression is a common 
co morbid condition in both MCI and AD (Overshott and Burns, 2004).  
Symptoms of depression can present as a cognitive impairment, highlighting the 
need to check for depressive symptoms before the interpretation of 
neuropsychological test scores. 
Research has shown that the score on TMT part B may be useful in predicting 
the likelihood of progression from aMCI to AD.  Chen et al., (2000) reported that 
TMT part B was sensitive to group differences of pre symptomatic AD patients 
and healthy controls.  Further, a combination of delayed word recall scores and 
TMT part B score were the optimal set of cognitive measures used to predict 
conversion.  Likewise, Ewers et al., (2012) reported that the TMT part B has 
significant value for the prediction of AD development in MCI cases.  In their 
sample of 81 AD patients and 101 cognitively normal elderly individuals, TMT 
part B score was one of the best single predictors of subsequent conversion to 
AD.  Similar findings were also found by Samtani et al., (2012). 
Brown et al., (2011) found that the processing speed component of TMT part A 
correlated with greater functional impairment in 394 aMCI participants in 
comparison with 229 cognitively normal participants and 193 mild AD patients.  
From their study of 42 MCI participants, Chapman et al., (2011), suggest that 
measures of speeded EF, such as the TMT part B, may serve as an early 
detection tool as they are sensitive to conversion from MCI to AD.  Impairments 
in rapid switching between sets may be useful as a potential screening method.   
Scores recorded for the purpose of the experiments of this thesis will be the 
time in seconds taken to complete each part of the test. 
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4.6 Dual Tasks (DT)  
The DT is a pen and paper test of EF.  Participants are given an A4 piece of 
paper depicting a string of connected boxes and are first timed for one minute to 
put a cross in each box following the direction of the string (Baddeley et al., 
1997).  Participants then repeat the task but are simultaneously required to 
remember and repeat strings of numbers based on their digit span score (see 
section 4.3.7).  They are, therefore, required to place a cross in each box at the 
same time as repeating aloud strings of digits.  The scores used in the 
evaluation of test performance are the difference in the number of boxes 
crossed between the first and second times (DT T1-T2) and the dual task ratio 
(DTR) which is calculated as the ratio of boxes crossed to the number of digit 
strings remembered.  
Generally it is expected that performance will decline when two tasks are 
performed simultaneously due to the larger cognitive demand and the 
requirement of dividing attention between the two tasks (Nebes et al., 2001).  
Baddeley et al., (1986) and (1991) stated that in AD patients there is a clear 
deficit when completing two tasks simultaneously, an effect which is not 
common in normal aging (Della Sala and Logie, 2001).  This is likely to be a 
result of a deficit in the central executive component of working memory 
(Baddeley et al., 1991).  This would suggest that both AD and MCI participants 
would be impaired on the DT (Lonie et al., 2009).  There are conflicting results 
surrounding the time of onset of divided attention impairments in AD.  Both 
Baddeley et al., (2001) and Logie et al., (2004) report impaired DT performance 
in AD patients, even in the early stages of the disease.  Furthermore, Baddeley 
et al., (1991) report that the size of the dual task deficit increases as the disease 
progresses. Lonie et al., (2009), however, report that in aMCI, there is no 
impairment of dual task performance in comparison to healthy non demented 
elderly participants.  Likewise, there was no impairment in early AD participants 
either.  Early AD patients were, however, impaired on the TMT part B, an 
alternative assessment of divided attention which has a speeded component 
(discussed in the previous section 4.3.3).  Further, Greene et al., (1995) 
reported that dual task impairment occurs only in the later stages of AD when 
MMSE score falls below 23 out of 30.   
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The discrepancies between these studies may be due to slight differences in 
the methodology employed.  For example, differences in the time used to 
complete each stage, Lonie et al., (2009) used a total time of 90 seconds 
whereas Baddeley et al., (2001) used a longer duration of 120 seconds.  It is 
difficult to make direct comparisons between the data sets.  There may have 
been differences in disease severity between participants groups.  The results 
of these studies, therefore, suggest that the DT is not sufficiently sensitive for 
the detection of early AD (Lonie et al., 2009) but maybe useful alongside 
another assessment. 
 
4.7 Stroop Test  
The Stroop test was devised in 1935 by Stroop and assesses both EF and 
processing speed. The Stroop consists of a list of colour words, some of which 
are presented in an incongruent colour (Trenerry et al., 1989).  Participants are 
given 30 seconds to read down each column of words, first stating the word as 
the text appears, this stage of the task is referred to throughout this thesis as 
the ‘Stroop Word’ and assesses processing speed. Secondly the participant is 
timed for a further 30 seconds and is required to read aloud the colour of the ink 
the word is presented in ignoring the semantics of the written word. This is 
referred to throughout the thesis as the ‘Stroop Interference’ and this stage 
involves inhibition of the irrelevant material and tests EF.  Subjects are 
generally slower at the second phase of the test and multiple explanations for 
this slowing have been suggested such as the creation of a response conflict, 
failure of response inhibition or failure of selective attention (Lezak, 1995). 
Imaging studies have revealed activation of the PFC during completion of the 
Stroop test with specific activation of the lateral PFC and the anterior cingulate 
cortex (De Pisapia and Braver, 2006).  These areas have previously been 
implicated during inhibitory tasks of EF (Schroeter et al., 2012). 
Previously, a larger interference effect on the Stroop test has been noted in 
early AD patients relative to the cognitively normal HE.  AD patients took longer 
to complete the second phase of the Stroop and made more errors (Spieler et 
al., 1996).  Hutchinson et al., (2010) replicated these findings in a sample of 64 
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HE participants and 32 mild AD cases.  Duchek et al., (2009) investigated 291 
elderly participants and noted more errors in the incongruent trial for those 
classified as mild AD.  These findings suggest that the Stroop test may be 
useful as an early cognitive assessment for the detection of mild cognitive 
changes.   
Chapman et al., (2010) investigated a group of 43 MCI patients, 14 of which 
went on to convert to a probable AD diagnosis.  Using baseline assessment 
scores on a battery of tests, the authors investigated which tests were the best 
predictors of likely conversion.  After memory, the second best predicator of 
conversion was speeded EF performance as measured by the Stroop and the 
TMT.  Convertors were worse at inhibiting irrelevant stimuli and, therefore, had 
difficulty completing the second stage of the Stroop.  The results of this study 
support the notion that scores on the Stroop may be a useful indicator of the 
probability of conversion to AD. 
In some instances participants have reported that they find this assessment 
uncomfortable and poor concentration can be detrimental to Stroop 
performance.  Further, visual competence is required and individuals who are 
colour blind will be unable to complete the task (Lezak, 1995). 
 
4.8 Symbol Digit Modalities Task (SDMT)  
The SDMT was devised by Smith in 1968 as an assessment to detect general 
neuropsychological dysfunction.  It is now a popular assessment of choice in 
multiple medical fields and is minimally affected by education level and 
language abilities (Lopez et al., 2008).   The SDMT involves multiple cognitive 
strategies such as processing speed, attention, concentration, visual scanning 
and EF (González et al., 2007).  
The test requires the participant to complete a grid using a key of symbols and 
corresponding numbers (Smith, 1968).  After a practice, the participant is given 
90 seconds to work through the grid using the key to write the correct number 
underneath each corresponding symbol. The number of errors and the total 
number of correctly matched symbol number pairs are noted.  A higher score 
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signifies a better performance. The test can also be completed orally if the 
participant is unable to complete the written version (Lezak, 1995). 
An early study by Pfeffer et al., (1982) [noted in Spreen and Strauss (1998)] 
found SDMT score to be a better assessment over the MMSE for the 
discrimination of cognitively normal and abnormal elderly subjects.  Richardson 
and Marottoli (1996) investigated elderly drivers with differing levels of 
education.  They reported that in those elderly with over 12 years of education, 
aged between 76-80 years, the mean SDMT score was 32.75 and for those 
aged 81-91, the mean score was 28.84.  The results demonstrated that 
increasing age was associated with poorer performance which is likely to be 
due to impaired processing speed and EF with age.  This is in agreement with 
Bowler et al., (1992) and Feinstein et al., (1994) who also report that score on 
the SDMT declines with advancing age. In a Hispanic sample of 106 mild to 
moderate AD patients, Lopez et al., (2008) revealed a significant increase in 
SDMT score following 12 weeks treatment with Donepezil highlighting that this 
test is useful for the monitoring of cognition during drug intervention.  
 
4.9 Digit Span and Digit Score  
The digit span assessment is a component of the Wechsler adult intelligence 
scale revised (WAIS-R) (Wechsler, 1981).  Digit span assesses working 
memory and includes both digit span forwards and digit span backwards.  In the 
forward stage of the task a series of numbers are read aloud to the participant 
starting with a sequence length of three numbers, increasing to a sequence of 
nine.  Numbers are read aloud by the researcher at a rate of one word per 
second (Lezak, 1995).  The test ends when the subject is unable to recall two 
sets of a certain length in the same order they were stated by the researcher.  
For example, if the researcher states 592 the subject repeats 592.  In backward 
span the subject must repeat the sequence of digits in the reverse order, e.g. if 
the researcher states 592 the subject states 295. The digit span score is the 
number of digits in this last set.  Digit Score is the total number of strings 
correctly repeated. 
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Previous research has shown impaired digit span in AD patients relative to non-
demented aged matched controls, e.g. Belleville et al., (1996) and Cherry et al., 
(1996).  AD patients are, however, better at digit recall than word recall (Cherry 
et al., 2002).  This is possibly because digit words are shorter, perhaps easier to 
remember and easier to organise in short term memory.  Words in a recall list 
may be unfamiliar to the subject, longer in length and may place a larger 
demand on short term space.  Cherry et al., (2002) investigated 35 mild to 
moderate probable AD patients and 38 non demented older adults.  The non 
demented adults were significantly better at digits span forwards and backwards 
compared to the AD patients.  The mean digits forward score for AD patients 
was 5.1, compared to 7.1 for the control group.  AD patients also performed 
worse at digit span backwards, (mean score 2.6), compared with the control 
group (mean score 5.7).  Better preservation of digit forward ability is likely to be 
due to the lower demand on long term stores which are deficient in AD.   
 
4.10 Letter Comparison Speed (LCS) and Pattern Comparison Speed 
(PCS) 
The LCS and PCS are assessments of processing speed (Salthouse and 
Babcock, 1991). In the LCS task participants are asked to state whether two 
strings of letters are the same or different.  The letters are presented in strings 
of three, six, or nine letters and participants have 20 seconds to complete as 
many pairs as possible. PCS also assesses processing speed (Salthouse and 
Babcock, 1991) and participants are required to state whether two geometric 
shapes (patterns) are the same or different.  They are timed for 20 seconds and 
are required to compare as many pairs as possible.  
Both of these assessments involve multiple cognitive processes such as a 
visual component, short-term memory, the ability to visually compare two 
stimuli, motor speed and response selection (McCabe and Hartman, 2008). 
McCabe and Hartman (2008) showed that older adults, aged between 61-81 
years, performed worse on both of these tasks in comparison to younger adults 
aged 18-27 years.  Older adults received lower scores which may be due to 
decrements in processing speed with age but may also be due to impairments 
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in short term memory.  This is in agreement with Salthouse and Babcock, 
(1991) who also note that increasing age leads to progressive declines in ability. 
Lustig et al., (2006) used the LCS and PCS to investigate processing speed in 
young and older adults.  In general, older adults are perceived to be poorer at 
speeded tasks and this may be due to their inability to ignore distracting stimuli.  
The pen and paper versions of the PCS and the LCS are deemed to have a 
high level of distractibility as there are many strings/patterns presented on a 
single page, therefore, in order to successfully complete the pattern/letter pairs, 
the subject must ignore the other distracting stimuli above and below.  For the 
LCS, Lustig et al., (2006) reported higher error rates in both groups of subjects 
as string length increased.  For the PCS, however, older adults performed 
significantly worse than younger adults. It is unclear whether this is due to 
impaired spatial comparison ability with age or whether older adults are 
generally slower when assessing and comparing two shapes.  AD patients 
would be expected to be significantly worse at both of these tasks, however, 
there is little research investigating the use of these tests specifically in MCI or 
AD sub populations. 
 
4.11 Word recall 
Word recall assesses short term memory and there are a number of existing 
tests available. Due to financial constraints, for the purpose of this thesis a word 
recall test was created by the researcher using the MRC Psycholinguistics 
database to control for word length, frequency and imaginability (Coltheart, 
1981).  
Two of the most widely used word recall assessments are the California Verbal 
Learning Test (II) (CVLT II) (Delis et al., 2000) and the Hopkins Verbal Learning 
Test (HVLT) (Brandt, 1991).  The CVLT II is an assessment of verbal learning 
and memory which involves a multi trial approach of list learning (Strauss et al, 
2006). The original version was developed by Delis et al., (1987) but has since 
been improved.  The CVLT II can be administered to a large age range of 
participants between 16-89 years but has been shown to be affected by age, 
gender and education (Strauss et al., 2006).  For the first five trials of the 
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assessment the participant is required to immediately recall words from list A 
which consists of 16 words belonging to four separate semantic categories: 
vegetables, means of transport, animals and furniture.  Following this 16 
interference words from list B are introduced.  There is then a 20 minute delay 
before participants are required to recall words from list A.  A shorter version 
also exists for those with a severe cognitive impairment.  The administration 
time is approximately 50 minutes and the test is scored by hand although 
software is available to record responses (Strauss et al., 2006). 
The Hopkins Verbal Learning Test – Revised (HVLT-R) is a brief assessment of 
learning and memory (Brandt and Benedict, 2001). It can be administered to 
participants aged 16-80+ years and involves six alternate forms of 12 nouns 
belonging to three semantic concepts.  Three learning trials are followed by a 
delayed recall trial (which is given without forewarning after 20 minutes). There 
is then a yes/no recognition trial.  The delayed recall trial was included in the 
revised version and was absent from the original (Brandt, 1991).  Delayed recall 
is believed to be more sensitive to MCI and early AD and is also able to predict 
further cognitive decline (Dubois et al., 2007; Chapman et al., 2011). Age, 
gender and education effects have been noted on this assessment (Strauss et 
al., 2006).  Brandt and Benedict, (2001) noted impaired performance on the 
HVLT R in AD patients who made more false positive recognitions.  Likewise, 
Hogervorst et al., (2002) noted that the combined HVLT score was more 
sensitive as a screen for dementia than the MMSE and was less likely to have a 
ceiling effect. 
AD patients perform poorly on word recall tasks due to deficits in short term 
memory. As discussed in section 4.2, both the MMSE and the MoCA 
incorporate a word recall item but the MoCA involves a delayed word recall 
question (Nasreddine et al., 2005).  Delayed recall has been shown to be more 
sensitive to AD and MCI (Dubois et al., 2007).  AD patients struggle to complete 
word recall assessments.  For example, Cherry et al., (2002) investigated 35 
probable AD patients and 38 non demented HE participants using a ten item 
simple word recall task.  The probable AD patients recalled significantly less 
words than the control group with a mean number of words recalled of 1.7, 
compared to 5.7 words, recalled by the control group.  This is in agreement with 
other studies such as Teng et al., (1989). 
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For the purpose of this thesis an immediate word recall test was created. This 
test required the participant to immediately recall as many words as possible 
from a list of 15 words read aloud by the researcher. 
 
4.12 Chapter summary 
This chapter has described and evaluated some common assessments used in 
the cognitive evaluation of AD and MCI.  The onset of cognitive alterations is 
difficult to determine and the occurrence of an abnormality is not instantaneous 
but is the result of progressive deterioration (Zamrini et al., 2004).  
Neuropsychological tests need to be sensitive to early, subtle alterations in 
cognition if they are to be used as an early diagnostic tool for the detection of 
AD and MCI. Some cognitive tests, such as the CANTAB PAL, the MoCA and 
the TMT, have been shown to be sensitive to the detection of MCI and early AD 
disease stages.  
Using a battery of tests which assess multiple cognitive domains is 
advantageous as brief tests of general cognition may not accurately reflect the 
participant’s actual ability.  Mapstone et al., (2003) comment that in its earliest 
stages MCI is more likely to present as an impairment within another cognitive 
domain aside from memory.  This highlights the need for a thorough 
assessment taxing a variety of different cognitive domains at baseline. 
Neuropsychological testing now includes some computerized assessments 
such as the CANTAB battery. Traditional pen and paper tests are still widely 
used and are still valuable.  There are strengths and weaknesses associated 
with using both these types of tests.  For example, using a computerized 
assessment can improve the accuracy of the recording of the participant’s 
responses, especially when recording parameters such as reaction time (Wild et 
al., 2008). There is also improved noting of errors and less reliance on the 
opinion of the administrator.  Another advantage is the potential cost saving as 
some computerized assessments do not need a researcher present and are self 
explanatory.  Pen and paper tests are often favoured by the elderly as some 
older subjects do not have prior computer experience and may feel anxious 
about completing a computerised test.  This may impact on their performance.  
Tests which require the participant to write a response will require the 
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participant to be competent at performing a motor response. Computer based 
assessments could also be useful in the implementation of early screening for 
AD as they can be quickly applied to large populations (Wild et al., 2008).  This 
would require access to computer facilities and the participant’s prior knowledge 
and use of computers is, therefore, an important factor to consider.   
When interpreting test scores there are external factors which need to be 
considered and this is the main focus of this thesis.  An abnormal test score on 
one occasion does not necessarily signify the presence of underlying disease.  
The participant’s mood, current medication or level of tiredness may affect their 
performance (Jacova et al., 2007).  Some participants may be particularly 
nervous or anxious which may affect their ability (Zamrini et al., 2004).  As 
briefly mentioned in chapter two, education level can affect score on some 
assessments.  The MoCA accounts for this and awards subjects with an 
additional point if their education level is less than 12 years (Nasreddine et al., 
2005).  It is necessary to note the participant’s education in years and to take 
this into consideration when interpreting test scores. Prior exposure to tests is 
also a factor when longitudinal or repeated testing is used (Zamrini et al., 2004) 
as practice effects may occur (Blatter and Cajochen, 2007). Age is the major 
risk factor for the development of a cognitive impairment and, therefore, is a 
factor which influences performance.  Tests of processing speed such as the 
PCS and the Dual Tasks are affected by age.  Age related deficits are common 
but abnormal scores are exaggerated compared to relative age groups.   
Neuropsychological testing is not recommended for a routine work up/diagnosis 
by NICE.  Testing is useful for research trials and for participants whose 
predominant impairment may not be memory.  Neuropsychological testing is 
useful for categorising MCI and also for the prediction of whether a participant is 
likely to decline and at what rate (Jacova et al., 2007).  The clear advantage of 
neuropsychological testing is its ability to test a wide range of cognitive 
domains.  The scores obtained can, therefore, be useful in the evaluation and 
management of treatment and some care based decisions.  Table two 
summarises the tests mentioned in this chapter and the cognitive domains they 
assess. 
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Table two: summary of neuropsychological tests by cognitive domain 
Cognitive Domain Test name 
General Cognitive Function MMSE 
 MoCA 
 GPCOG 
 7 Minute Screen 
Processing Speed Stroop Word 
 PCS 
 LCS 
 TMT part A 
 SDMT 
Executive Function SDMT 
 TMT part B 
 Stroop Interference 
 Dual Tasks Ratio 
 Dual Tasks T1-T2 
Semantic Memory GNT 
Short Term Memory Word Recall 
Working Memory Digit Span and Digit Score 
Visuo spatial associative Memory PAL 
Visual Search TMT 
Attention SDMT 
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Chapter 5 
The effect of prior caffeine on neuropsychological 
testing in the elderly 
 
5.1 Introduction 
The accuracy of neuropsychological testing is vital if a diagnosis is to occur 
earlier in the disease pathway when symptoms are mild.  Neuropsychological 
testing is a useful diagnostic tool but performance on some tests can be 
affected by external factors, which if not controlled for or taken into 
consideration may affect the overall outcome, particularly as scores are often 
compared to population norms (Lesk et al., 2009). This has the potential to 
affect test accuracy and the diagnosis given.  Such factors can include the 
patient’s mood at the time of testing, age, tiredness and the presence of certain 
medications or foodstuffs (Jacova et al., 2007). 
This chapter explores whether caffeine, one of the world’s most commonly 
consumed stimulants (Nawrot et al., 2003; Butt and Sultan, 2011; Nehlig, 2010), 
can affect cognitive performance in the elderly.  Caffeine is present in a number 
of commonly consumed foodstuffs such as tea, coffee, soft drinks, chocolate, 
sweets and also some medications (Nehlig, 2010).  Caffeine possesses many 
different cerebral mechanisms of action and has been shown to minimise and 
counteract AD associated pathology and processes. Examples include its ability 
to decrease amyloid plaque load and Aβ levels (Zeitlin et al., 2011), the ability to 
inhibit both β and γ secretase (Arendash et al., 2006), decrease the expression 
of pro inflammatory markers (Cao et al., 2009), and down regulate pro apoptotic 
signalling factors (Zeitlan et al., 2011) amongst others.  As a result of these 
findings, a number of studies have investigated whether caffeine consumption 
(in the form of caffeinated foodstuffs) throughout adulthood can affect the 
overall risk of developing AD in old age (Ritchie et al., 2007; Eskelinen et al., 
2009; Lindsay et al., 2002; Van Gelder et al., 2007; Santos et al., 2010).  
To date there has been little study into the affect of caffeine on 
neuropsychological test performance at the actual time that these assessments 
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are administered. Consequently this chapter explores the effect of 200mg of 
pure caffeine on some of the neuropsychological tests used in the diagnosis of 
AD and cognitive impairment.   
 
5.1.1 Caffeine 
Caffeine is present in many commonly consumed food stuffs such as tea, 
coffee, soft drinks, cocoa, sweets and medicines (Nehlig, 2010; Nawrot et al., 
2003; Butt and Sultan, 2011).  A survey investigating caffeine consumption 
revealed that 70% of caffeine intake is derived primarily from coffee drinking 
(Frary et al., 2005).  Globally daily habitual caffeine consumption in humans is 
estimated to fall between 70-350mg/person/day, which is approximately the 
equivalent of three cups of coffee (Chen et al., 2010). Habitual caffeine 
consumption does vary with location and culture.  In the UK caffeine 
consumption is estimated to be approximately 4mg/kg of body weight whereas 
in Denmark consumption is higher at 7mg/kg of body weight (Nawrot et al., 
2003).  At these concentrations positive effects of caffeine are noted such as an 
increase in alertness, decreased feelings of subjective tiredness, improved 
attention and concentration, improved problem solving and faster reaction times 
(Glade, 2010).  In doses exceeding 400mg there is a larger likelihood of side 
effects which can include anxiety, raised blood pressure, headaches, confusion, 
tachycardia and gastrointestinal disturbance (Chen et al., 2010; Sweetman, 
2009).     
 
5.1.2 Pharmacology and mechanism of action 
Chemically caffeine is known as 1, 3, 7 trimethylzanthine and is a non selective 
adenosine receptor antagonist (Cunha et al., 1995; Constenla et al., 2010). 
Adenosine acts as a neuromodulator and initiates and controls multiple synaptic 
functions including the release of other neurotransmitters (Gomes et al., 2011; 
Rahman, 2009).  There are four adenosine receptor subtypes expressed within 
the brain, including the high affinity A1R and A2AR receptors and the low affinity 
A2B receptor (Boison, 2008).  There is a low abundance of the A3 receptor and 
this receptor is not widely expressed (Boison, 2008).  A1R receptors have the 
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highest expression in the cortex, cerebellum and hippocampus (Ribeiro et al., 
2002). The A2AR receptors are less widely distributed in these areas but are 
predominantly found in the olfactory bulb and on striato-pallidal GABAergic 
neurons (Ribeiro et al., 2002).  
Adenosine’s predominant action is to decrease excitatory transmission via A1R 
receptors (Dunwiddie and Haas, 1985) and both the A1R and A2AR control the 
release of other neurotransmitters including Ach which is depleted in AD 
(Gomes et al., 2011).  Animal studies have shown that adenosine receptors 
undergo adaptive changes during aging resulting in a decrease in A1R receptor 
density but an increase in A2AR density in limbic cortex (Cunha et al., 1995, 
Cunha, 2001).   In AD, alterations in the expression of adenosine receptors 
have also been noted (Cunha and Agostinho, 2010; Gomes et al., 2011).  A 
post-mortem study revealed that there were increased numbers and densities of 
the A1R and A2AR in the frontal cortex of early AD patients  (Albasanz et al., 
2008) as well as a redistribution of these receptors particularly in the 
hippocampus and cortex (Angulo et al., 2003). This pattern was not seen in 
control samples. 
The binding of caffeine to adenosine receptors results in the indirect stimulation 
of cholinergic transmission in the MTL, specifically the hippocampus, the area 
prominently affected by AD pathology (Dall’Igna et al., 2004).  Further 
supporting the role of caffeine in the modulation of cholinergic transmission, in a 
group of healthy young adults aged 25-35 years of age, consumption of three 
cups of coffee was shown to be able to inhibit the effects of scopolamine, an 
Ach receptor antagonist (Riedel et al., 1995).  This suggested that when there is 
CNS dysfunction (mimicked in this experiment by scopolamine administration) 
caffeine acts as a cognitive enhancer rather than a stimulant.    
The use of adenosine receptor knock out (KO) mice has also provided insight 
into the functioning of adenosine receptors during caffeine administration.  KO 
A2AR mice, which lack the A2AR receptor, do not show the usual behavioural 
effects of caffeine administration such as an increase in psychomotor activity, 
suggesting a role for this particular adenosine receptor and caffeine selectivity 
(Chen et al, 2010).  Furthermore, KO A2AR mice show impaired learning and 
memory, and mice with an over expression of this receptor perform poorly on 
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tasks such as the Morris Water Task (MWT) (Gimenez-Llort et al., 2007) which 
assesses spatial memory and requires the animal to successfully locate a 
raised escape platform in an opaque water pool (Morris et al., 1982).  
 
5.1.3 Caffeine and risk of AD 
Due to caffeine’s variety of neuro modulatory and antioxidant properties, there 
have been a number of longitudinal studies which have investigated whether 
caffeine consumption over time can impact on the risk of developing AD 
(Camouse et al., 2005).  Some studies have investigated the effects of caffeine 
containing food stuffs (CCFS) particularly coffee, on the risk of developing AD. 
For example, Jarvis (1993), utilising a large sample of 9003 participants aged 
18 and over revealed that increased coffee consumption was associated with 
better performance on assessments of reaction time, verbal memory and 
visuospatial reasoning. The Canadian Study of Health and Aging (CSHA) 
investigated a large cohort of 6343 individuals over 65 years of age via the use 
of a risk factor questionnaire.  This was designed to gather information on a 
number of factors which may be linked to the development of cognitive 
impairment.  The questionnaire asked participants about their 
sociodemographic characteristics, occupational and environmental exposures, 
lifestyle habits including smoking, alcohol consumption, intake of specific foods 
(including tea and coffee) and exercise levels.  The questionnaire also asked 
participants about their family and medical history specifically noting any 
occurrence of head injury or loss of consciousness.  After a five year follow up 
period, the study reported that daily coffee drinking was associated with a 
decreased risk of developing AD (Lindsay et al., 2002).  The Cardiovascular risk 
factors, Aging and Dementia (CAIDE) study, recruited 1409 participants and 
reported that consumption of 3-5 cups of coffee per day in midlife was 
associated with a decreased risk of developing AD by 64% (Eskelinen et al., 
2009). The Finland, Italy and the Netherlands Elderly (FINE) study showed that 
elderly men consuming an average of three cups of coffee per day experienced 
the lowest decline in cognition in comparison to non-consumers (Eskelinen and 
Kivipelto, 2010). Interestingly Ritchie et al., (2007) found that drinking three 
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cups of coffee a day was associated with a smaller decline in verbal cognitive 
fluency in women only.   
Although these studies are useful for investigating risk over time they rely upon 
the self-report of caffeine consumption which does not take into account the 
variance in dose or the preparation method used.  This may be subject to 
inaccurate estimation of consumption. 
 
5.1.4 Caffeine and cognitive testing 
There has been little investigation into whether immediate prior caffeine 
consumption at the time of testing can have an effect on neuropsychological 
test scores during aging. If caffeine does elicit an effect this could have 
implications for the diagnostic process of AD and the interpretation of 
neuropsychological data.  Individuals who have consumed caffeine prior to 
being tested may perform differently than on an occasion when they have not.  
As a result they may score differently which has the potential to affect their 
diagnosis. 
Studies such as Swift and Tiplady (1988) administered 200mg of pure caffeine 
to a small number of elderly participants and reported improvements in 
cognition specifically for tasks of attention.  However, Lorist et al., (1995) 
reported no significant differences in cognition between elderly (mean age 64.5 
years) and young participants (mean age 21.1 years) after the administration of 
250mg of caffeine dissolved in decaffeinated coffee, 90 minutes prior to the 
neuropsychological assessment. Lesk and Womble (2004) reported strong 
interactions between the prior consumption of 200mg of caffeine or placebo and 
phonological priming on the tip-of-the-tongue state in both young participants 
(Lesk and Womble, 2004) and in a patient with anomic aphasia (Lesk et al., 
2007).  Given this striking effect of prior caffeine intake on this paradigm Lesk et 
al., (2009) then investigated prior caffeine intake on neuropsychological test 
scores in the elderly.  This study used a questionnaire to investigate 
participants’ caffeine consumption by simply asking participants about their 
intake of CCFS (tea, coffee, chocolate and cola), four hours before the testing 
session. An interaction effect of age and intake of CCFS prior to the 
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neuropsychological assessment was found on six of the nine assessments used 
whereby the older elderly (over approximately the age of 80) performed 
significantly worse if they had consumed CCFS and the younger elderly 
performed significantly better if they had consumed CCFS.  Significant 
interactions were specifically reported for three assessments of processing 
speed, PCS (Salthouse and Babcock, 1991), LCS (Salthouse and Babcock, 
1991) and the Stroop word (Trenerry et al.,1989), one assessment of semantic 
memory, the GNT, (McKenna and Warrington, 1980), one assessment of 
visuospatial associative memory, PAL 6 pattern error score, (Sahakian et al., 
1988), one assessment of episodic memory, The Placing Test (TPT), (Anderson 
et al., 2006) and one assessment of EF, the SDMT total score (Smith,1968).  
There were no reported significant interactions for global cognitive function 
[MMSE, (Folstein et al., 1975)], working memory [digit span and digit score 
(Wechsler, 1981)], DT T1-T2 or the DTR (Baddeley et al., 1997), which along 
with the SDMT (which did show significance), is a test of EF (Smith, 1968). 
There was no main effect of CCFS present as compared to the CCFS absent 
group on any of the assessments.  
The results of Lesk et al’s., (2009) study have important implications for the 
neuropsychological testing process.  Another consideration that remains 
unclear is whether it is the caffeine contained in these foodstuffs which has 
caused the interaction effect or whether it is because of any of the other 
substances contained within CCFS. For example, coffee also contains 
chlorogenic acid, cafestol and kahweol (Eskelinen and Kivipelto, 2010) which 
are powerful antioxidants (Butt and Sultan, 2011). Furthermore, tea is 
concentrated in polyphenols which have also been shown to enhance memory 
(Lindsay et al., 2002) although some studies have reported non-significant 
effects for tea drinking and overall AD risk (Lindsay et al., 2002; Eskelinen et al., 
2009). The preparation method of caffeinated beverages should also be 
considered as this can influence the final amount of caffeine contained within 
the drink (Eskelinen and Kivipelto, 2010).  For example, brewed coffee contains 
the highest amounts of caffeine (56-100mg per 100ml) whereas instant coffee 
and tea contain significantly less (20-73mg) and are dependent on the amount 
of spoonfuls that are added to each drink (Nawrot et al., 2003). The size of the 
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drink should also be noted and controlled for in experimental investigations 
(Stavric et al., 1988). 
 
5.2 The present study: research aims 
Given that caffeine is present in all of the CCFS consumed in the Lesk et al., 
(2009) study, this chapter will specifically investigate the influence of 200mg of 
pure caffeine on the neuropsychological assessment.  In Lesk et al., (2009) the 
average amount of caffeine intake was calculated to be 70.3mg.  The dose of 
caffeine to be administered in this study is 200mg which is the equivalent of one 
medium black filter coffee (Starbucks, 2011).  This dose is considered to be 
safe for adults (Nawrot et al., 2003) and similar doses have been used 
elsewhere in the elderly (Hogervorst et al., 1998; Lorist et al., 1995; Carrier et 
al., 2009). 
If caffeine is able to affect neuropsychological test scores, then by simply asking 
a participant to abstain from caffeine, or to at least note how much caffeine they 
have consumed, will allow for more accurate results and clinical interpretation.   
This chapter extends upon the findings of Lesk et al., (2009) and will investigate 
whether it is the caffeine contained within CCFS which affects cognitive scores 
and interacts with age (as seen in Lesk et al., 2009) or one of the other 
ingredients by specifically investigating the effect of pure caffeine intake prior to 
the neuropsychological assessment in a group of elderly participants.  
 
5.3 Methods 
5.3.1 Participants 
Forty participants from the University of Bradford, Division of Psychology, over-
60s participant pool were recruited to take part in the study.  Ethical approval 
was obtained from the University of Bradford Research Ethics Committee and 
all participants gave their informed written consent to take part.  The mean age 
of participants was 73.40 years (± 6.55 years) with a mean number of years 
spent in education of 15.53 years (± 3.93 years). The sample consisted of nine 
males and 31 females. 
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The inclusion criteria specified that participants must be at least 60 years of age 
and must not possess a current neurological medical condition or an existing 
diagnosis of a memory impairment.  In order to avoid any adverse reactions to 
caffeine, participants were required to be regular caffeine consumers with a 
habitual consumption of between 1-3 cups of coffee per day. Excessive 
consumers, (defined in this study as a habitual consumption of four or more 
cups of coffee per day - approximately 400mg of caffeine) were not permitted to 
take part to reduce the likelihood of withdrawal effects occurring during the 
abstinence period.  In addition, participants must not have been advised to 
avoid caffeine by their GP or health care professional and must be non-smokers 
as smoking increases the metabolism of caffeine (Stavric and Gilbert, 1990, 
Nawrot et al., 2003). Participants were required to be fluent in English and must 
not have a severe visual impairment. 
 
5.3.2 Design 
The study utilised a double blind caffeine vs. placebo experimental design and 
all the participants completed all of the neuropsychological tests in the same 
order. 
 
5.3.3 Materials 
Neuropsychological assessments 
A detailed description of the neuropsychological assessments used in this 
chapter can be found in chapter four ‘Neuropsychological Testing’ however a 
brief description of each test is listed below. 
MMSE - the MMSE is a test of general cognitive function assessing a variety of 
cognitive domains (Folstein et al., 1975). Participants receive a score out of 30. 
Immediate word recall - an assessment of short-term memory, requiring the 
participant to recall as many words as possible from a list of 15 common nouns 
read aloud by the researcher.  This test was created by the researcher using 
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the MRC Psycholinguistics database to control for word length, frequency and 
imaginability (Coltheart, 1981). 
CANTAB PAL - an assessment of visuo spatial associative memory (Sahakian 
et al., 1988) which requires the participant to learn an association between a 
visual stimulus and a spatial location (Égérhazi et al., 2007).  
GNT - an assessment of semantic memory (McKenna and Warrington, 1980) 
which requires the participant to name 30 objects presented in black and white 
on a computer screen. 
SDMT - an assessment of EF which requires the participant to complete a grid 
using a key of symbols and corresponding numbers (Smith, 1968).  After a 
practice, the participant is given 90 seconds to work through the grid using the 
key and writing the correct number underneath each corresponding symbol. 
The number of errors and the total number of correctly matched symbol number 
pairs are noted.   
Stroop Test - this test assesses both EF and processing speed. The Stroop 
consists of a list of colour words which are all presented in an incongruent 
colour (Trenerry et al., 1989).  Participants are first given 30 seconds to read 
down each column of words stating the word as the text appears. Secondly they 
are timed for 30 seconds and are required to read the colour of the ink the word 
is presented in ignoring the semantics of the written word. 
PCS - this test assesses processing speed (Salthouse and Babcock, 1991).  
Participants are asked to state whether two shapes (patterns) are the same or 
different.  They are timed for 20 seconds and are required to compare as many 
pairs as possible.  
LCS - this is an assessment of processing speed (Salthouse and Babcock, 
1991), where participants are asked to state whether two strings of letters are 
the same or different.  The letters are in strings of three, six, or nine letters and 
participants have 20 seconds to complete as many pairs as possible.  
Digit Span and Digit Score - digit span assesses working memory (Wechsler, 
1981).  A series of numbers are read aloud to the participant starting with a 
sequence length of three numbers, increasing to a sequence of nine.  The test 
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ends when the subject is unable to recall two sets of a certain length. The digit 
span is the number of digits in this last set.  Digit score is the total number of 
strings correctly repeated. 
DT - this is a test of EF where participants are given a page with a string of 
boxes and are required to put a cross in each box following the direction of the 
string (Baddeley et al., 1997).  Participants are timed for 60 seconds.  
Participants then repeat the task but are simultaneously required to remember 
strings of numbers (based on their digit span score; see previous section).  
Scores used are the difference in the number of boxes crossed between the 
first and second times (DT T1-T2) and the DTR which is calculated as the ratio 
of boxes crossed to the number of digit strings remembered.  
 
5.3.4 Procedure 
Participants within the participant pool database were sent an invitation letter 
and information sheet via the post and were telephoned one week later to 
enquire if they would be interested in participating.  Those who wanted to take 
part, and met the inclusion criteria, completed a brief telephone checklist to 
ensure they were regular caffeine consumers, had not been advised by a 
medical professional to avoid caffeine consumption, were non-smokers and 
consented that they were aware that they may receive 200mg of caffeine as a 
part of the study. Those individuals who successfully completed the checklist 
were given an appointment and told to abstain from caffeinated drinks and 
foodstuffs for 12 hours prior to the appointment and to abstain from alcohol for 
24 hours prior to the appointed time.  A confirmation letter outlining each of 
these points was then sent out to each participant.   
On arrival to their appointment the researcher checked with each participant 
that they had remembered to abstain from caffeine for 12 hours prior and 
alcohol 24 hours prior.  Participants were then administered a cup of 
peppermint tea which may or may not have contained 200mg of dissolved 
caffeine.  The study was performed double blind and a research assistant 
prepared and administered the drink.  Participants were then required to wait for 
a period of forty minutes before cognitive testing commenced (this was to 
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ensure that caffeine levels in the brain had plateaued which occurs at 
approximately 45 minutes after initial administration (Arnaud,1987; Smith, 
2002).  Participants were not permitted to consume any food or drink during this 
time period. 
After 40 minutes, cognitive tests of MMSE, word recall, Stroop, PCS, LCS, digit 
span; DT, CANTAB PAL and GNT were then administered to each participant in 
the same order. Participants were then thanked for their time and told they may 
prefer to avoid consumption of caffeinated beverages in the following few hours 
to avoid any potential side effects of excess caffeine intake. 
 
5.4 Results 
The aim of the current study was to investigate whether 200mg of prior caffeine 
can effect scores on some neuropsychological tests used in the diagnosis of AD 
and MCI in a group of 40 HE participants over the age of 60 years.  Table three 
shows the demographic characteristics of participants in the caffeine and 
placebo group. There were no significant differences between the participants in 
each group in terms of any of the listed demographics. 
 
Table three: Demographics of participants randomly assigned to the caffeine and 
placebo groups 
 Caffeine (n=20) Placebo (n=20) 
Age (mean ±SD) 73.25 (6.52) 73.45 (6.74) 
Education (mean ±SD) 15.97 (3.59) 15.00 (4.32) 
Males/females 5/15 4/16 
 
There were no main effects of gender or education on any of the tests 
administered. There were significant main effects of age on the DT T1-T2 
interval score and the Stroop Interference score. A regression analysis revealed 
a negative linear relationship on both of these tests, with scores decreasing as 
age increased. [DT T1-T2 [β = -0.66, (F (1, 38) = 10.34, p <0.01), ƞ2 = 0.77, y-
axis intercept = -43.13 with regression correlation coefficient r = -0.45, p <0.01]; 
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Stroop Interference [β = -0.69, (F (1, 38) = 9.46, p <0.01), ƞ2 = 0.66, y-axis 
intercept = 78.53 with regression correlation coefficient r = -0.45, p <0.01].  
 
5.4.1 Main effects of caffeine vs. placebo 
To investigate the effect of caffeine on the tests administered all of the tests 
were submitted to a multivariate analysis of variance (MANOVA) with all the test 
scores entered as the dependent variables and caffeine or placebo entered as a 
fixed factor.  There was no main effect of drug group on any of the assessments 
used. 
 
5.4.2 Age interactions 
Following on from the results obtained by Lesk et al., (2009) which showed an 
interaction effect between caffeine, age and scores on the PCS, LCS, Stroop 
word, GNT, PAL and SDMT total, to formally assess whether prior caffeine 
consumption had an effect on performance with increasing age, each cognitive 
test was submitted to a univariate General Linear Model (GLM) with drug group 
(caffeine or placebo) as a fixed factor and age as a covariate.  An interaction 
term was also included in the model. The results of this can be seen in table 
four. Figure nine depicts scatter plots of those test scores that showed a 
significant interaction between drug group and age. 
There is a clear interaction effect of drug group x age on the SDMT total score, 
the DTR and DT T1-T2 interval, the Stroop Interference, the PCS and the LCS.  
No significant interaction effect is present for the MMSE, digit span and digit 
score, the PAL, the GNT, word recall or the Stroop word test. There were no 
significant linear trends for the placebo group on any of the tests administered. 
Although there is no interaction between drug group and age for the GNT, a 
regression analysis did reveal a linear decrease in performance with age for 
those participants who received caffeine (see figure ten). 
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Table four: Univariate GLM results for the interactions between age and drug group 
and the outcomes of the linear regression analysis for each drug group separately. 
Testing Domain Assessment Caffeine Placebo P and ƞ
2
 value 
of interaction 
caff/plac x 
age 
Caffeine 
regression 
Placebo 
regression 
General cognition MMSE 28.75 ± 
1.21 
28.40 ± 
0.94 
N.S N.S                      N.S 
Visuoassociative 
memory 
CANTAB PAL 
6 errors 
7.35 ± 
6.40 
7.90 ± 
6.67 
N.S N.S N.S 
Semantic 
memory 
Graded 
Naming Test 
26.30 ± 
2.98 
25.65 ± 
2.64 
N.S r = 0.44, p = 
0.05 
N.S 
Working memory Digit  Span 6.50 ± 
1.00 
6.25 ± 
0.79 
N.S N.S N.S 
 Digit Score 8.95 ± 
1.82 
8.60 ± 
1.64 
N.S N.S N.S 
Executive 
function 
Dual Tasks 
T1-T2 
7.30 ± 
11.66 
3.65 ± 
6.17 
f(2,37) = 6.51, 
p < 0.01,  ƞ
2 
=0.26 
r = 0.49, p 
<0.05 
N.S 
 Dual Tasks 
ratio 
0.92 ± 
0.22 
0.10 ± 
0.12 
f(2,37) = 7.55, 
p < 0.01, ƞ
2 
= 
0.29  
r = 0.64, p 
<0.05 
N.S 
 SDMT total 
correct 
40.10 ± 
9.03 
38.70 ± 
7.45 
f(2,37) = 6.67, 
p < 0.01, ƞ
2
 = 
0.27 
r = 0.68, p < 
0.01  
N.S 
 Stroop 
Interference 
30.05 ± 
10.92 
25.80 ± 
9.02 
f(2,37)= 5.64, p 
< 0.01 , ƞ
2 
= 
0.23 
r = 0.62, p < 
0.01  
N.S 
Processing speed PCS 25.25 ± 
3.96 
22.45 ± 
4.94 
f(2,37) = 3.65, 
p <0.05, ƞ
2 
= 
0.17 
r = 0.56, p < 
0.05 
N.S 
 LCS 15.35 ± 
3.72 
12.80 ± 
2.95 
f(2,37) = 6.91, 
p < 0.01, ƞ
2 
= 
0.27 
r = 0.58, p < 
0.01 
N.S 
 Stroop word 54.55 ± 
12.61 
50.15 ± 
9.99 
N.S N.S N.S 
Short term 
memory 
Word Recall 5.35 ± 
1.76 
4.80 ± 
1.44 
N.S N.S N.S 
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Figure nine: interaction effects between caffeine x age and score for (A) Dual Task 
ratio,(B) DT T1-T2 interval, (C) SDMT total score, (D) Stroop Interference, (E) PCS and 
(F) LCS. There is a significant linear decrease in performance with increasing age 
E 
F 
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Figure ten - Scores on the GNT for participants in the caffeine condition, demonstrating 
a linear decrease in GNT performance as age increases, an effect not seen for 
participants in the placebo condition. 
 
5.5 Discussion 
5.5.1 Main findings 
The aim of this chapter was to extend upon the results of Lesk et al., (2009) by 
investigating whether 200mg of pure caffeine could influence score on cognitive 
tests in the over 60s.  The main findings were (1) there was no main effect of 
caffeine or placebo on any of the tests which were administered (2a) significant 
interaction effects between drug group, age and tests of executive function, 
(specifically the number of boxes crossed at time point one v time point two of 
the DT and DTR, the SDMT total score and the score for the Stroop 
Interference) and processing speed, (specifically the scores on the LCS and 
PCS tasks) were found.  The third assessment for processing speed, the Stroop 
word test, did not show the same interaction effects; (2b) in the tests that did 
show this interaction, for the caffeine subgroup, participants’ scores declined 
with increasing age, an effect which was not seen in the placebo condition.   
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Table five summarises the results of the current chapter and the results of Lesk 
et al., (2009) to allow clear comparisons between the data sets. 
 
Table five: Comparison of significant interactions between caffeine/placebo, age and 
cognitive scores between Lesk et al., (2009) and the results of the current chapter 
Test Lesk et al., (2009) Present Study 
MMSE X X 
PAL  X 
GNT  X 
Digit Span X X 
Dual Tasks X  
SDMT   
Stroop Interference trend  
Stroop word  X 
PCS   
LCS   
Word Recall X X 
 
X – no significant interaction, - significant interaction.  Tests highlighted in 
yellow show a discrepancy in result between the two studies. 
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Consistent with the CCFS subgroup in Lesk et al., (2009), the present study 
also shows that for the caffeine subgroup there is a significant linear decrease 
with age and scores on assessments of EF (SDMT, Stroop Interference), 
processing speed (PCS and LCS) and semantic memory (GNT) revealing that 
as age increases performance on these assessments decreases.  The results 
also showed a significant linear decrease for the caffeine subgroup with 
increasing age on one other test of EF, the DTR.  Unlike the results of this 
study, Lesk et al., (2009) also reported significant regressions for the CCFS 
present subgroup on the PAL six pattern error score, Stroop word, and the TPT. 
For both the placebo group in this study and the CCFS absent group in Lesk et 
al., (2009) there were no effects of age on test scores. 
The discrepancies between this study and Lesk et al., (2009) particularly in 
terms of the CANTAB PAL and the GNT are important as these tests have 
previously been shown to be highly sensitive for their ability to discriminate 
between AD and other forms of dementia.  Blackwell et al., (2004) 
demonstrated in a regression analysis that the number of errors made at the six 
pattern stage of the CANTAB PAL, the score obtained on the GNT and the 
participant’s age at the time of testing, could identify converters to AD with 
100% accuracy within a 32 month period using a sample of 40 patients. Lesk et 
al., (2009) reported significant interactions of age and CCFS on the PAL and 
GNT, whereas in the present study, in which caffeine was more controlled, no 
significant interactions for the CANTAB PAL or GNT were found. This highlights 
the importance of noting the effect of prior caffeine intake which may affect 
scores used in predictive analysis.   
The finding that increasing age was associated with a decrease in GNT score 
for the caffeine subgroup in the present study is important as vocabulary, 
naming skills and semantic memory usually improve with increasing age 
(Kahlaoui et al., 2012), nevertheless the present data contradicts this. It is 
unclear why this is the case but it does highlight that the consumption of small 
amounts of caffeine prior to testing (200mg is approximately the same amount 
of caffeine in one strong cup of coffee) can significantly affect the results.  
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5.5.2 Decline in EF with age 
The predominant interactions with caffeine and age in the present study were 
for tests of EF and processing speed. For those participants who received 
caffeine, the older elderly perform worse on these tests in comparison with the 
younger elderly. Importantly there was no change in the placebo group. 
EF relies heavily on the frontal lobes and is crucial for the changing demands 
and situations experienced in daily living (Schroeter et al., 2012). The frontal 
lobes are highly sensitive to the aging process and experience a large decline in 
volume with age (Hedden and Gabrieli, 2004; Huag and Eggers, 1991; Resnick 
et al., 2003). The PFC also experiences alterations in neurotransmitter levels 
(Hedden and Gabrieli, 2004) and white matter tract integrity during aging.  This 
area is also affected in AD but not in the early stages of the disease (Hedden 
and Gabrieli, 2004).  It is, therefore, expected that increasing age would be 
associated with poorer EF performance, as can be observed in the present 
study but only in the caffeine subgroup again supporting the need to investigate 
the effect of caffeine further.   
EF is not a unitary component and consists of different sub domains (Miyake et 
al., 2000).  Some studies have noted impaired EF in the elderly (Carey et al., 
2008; Smith and Baltes, 1997) and specific impairments in EF sub domains 
have also been found including cognitive flexibility (Yang et al., 2006), which is 
the ability to switch between two stimuli or sets of information, decision making 
(Denburg et al., 2005) and attention (Verhaeghen and De Meersman, 1998).  
This chapter did not thoroughly assess all domains of EF, therefore, direct 
comparisons with these studies are not possible.  However, the studies 
mentioned above do not take into account the prior caffeine consumption of 
their participants which may have affected the data they have obtained.  
Few studies have directly compared EF in the younger elderly with the oldest 
old.  Bakos et al., (2008) investigated differences in EF in these two age groups.  
Their study comprised a small sample of 10 younger elderly participants aged 
60–67 years (mean age 62 years), and 10 ‘oldest old’ participants aged 75-84 
years, (mean age 79 years). The study specifically looked at performance on 
the Stroop test (a test of flexibility/inhibition), digit span (a test of working 
memory), vocabulary (a test of semantic knowledge) and the Iowa Gambling 
102 
 
Test (IGT) (a decision making task). Significant differences were only found for 
the measure of decision making and judgement, the IGT, whereby the oldest 
old performed significantly worse than the younger elderly. The current chapter 
did not utilise a problem solving based task and direct comparisons are not 
possible.  
 
5.5.3 EFs in MCI/AD 
Tasks which recruit EF have been suggested as useful in the prediction of 
whether MCI cases are likely to convert to AD (Tabert et al., 2006), as EF 
impairments are common in the neurodegenerative process (Schroeter et al., 
2012).  Clark et al., (2012) recruited 71 non-demented elderly participants and 
followed them longitudinally. Of these 71 participants, 15 showed a significant 
decline in performance after one year. For this subgroup there was significantly 
poorer performance at initial baseline testing on two measures of EF, the 
inhibition/switching component of the Colour–Word Interference Test (CWIT),  
which measures how quickly the participant is able to switch from reading words 
aloud to naming the colour of the ink the word is presented in, and the category 
switching condition of the Verbal Fluency test which assesses the participant’s 
ability to generate words fluently while simultaneously shifting between 
semantic concepts (Clark et al., 2012).  Other aspects of EF such as spatial 
planning, as measured by the Tower Test, and spatial fluency, measured by the 
Design Fluency switching condition of the Delis Kaplan Executive Function 
System (DKEFS), were spared.  These results highlight that EF tests utilising 
inhibition and task switching in particular may be useful in predicting cognitive 
decline.  Consequently if habitual levels of caffeine can have a significant effect 
with increasing age, as shown in the present study with 200mg of caffeine, on 
selected tests of EF, prior caffeine intake must be taken into account when 
using EF tests for the prediction of decline to AD. 
There is little literature specifically investigating the effect of caffeine on 
executive performance in the elderly. Cropley et al., (2012), using 39 healthy 
elderly participants revealed that caffeinated coffee (not pure caffeine) improved 
performance on tasks requiring attentional processes although there was no 
reported age interaction.  Hogervorst et al., (1998) reported that 225mg of 
103 
 
caffeine improved memory performance in the middle aged (age 50-65) but not 
in the older elderly (66-74) on an assessment of short-term memory and trial 
one of the Visual Verbal Learning Test with auditory distraction (VVLT-D).  A 
greater number of words were retained in those middle aged participants who 
had consumed caffeine. Hogervorst et al., (1998) do comment that their middle 
aged participants habitually consumed almost twice the amount of caffeine than 
both the elderly and young participants in their study which may have affected 
their results.   In the present study, in which habitual consumption was similar 
for all participants, we found no significant interaction between age and short-
term memory using a simple immediate word recall task which did not have a 
distraction component. 
Similar to the points of Hogervorst et al., (1998), Schmitt et al., (2003) 
highlighted the issue of possible interaction effects between caffeine, age and 
cognitive test scores.  The authors suggested that differences in habitual 
caffeine consumption between the younger elderly and the older elderly may 
cause reported differences in performance when participants are administered 
caffeine.  Higher caffeine intake in the younger elderly may make them more 
vulnerable to caffeine withdrawal effects when they are asked to abstain before 
taking part in experiments.  The results of their paper, however, failed to find 
any interaction effect of caffeine, age and assessments of digit span, word 
learning, the Stroop and memory scanning (Schmitt et al., 2003). The authors 
postulate that the lack of interaction effect with age may be due to the low dose 
of caffeine (100mg) administered.  This chapter used a higher dose of 200mg of 
caffeine and reported significant interaction effects of caffeine, age and 
assessments of EF and processing speed. 
 
5.5.4 Crossover points  
The significant interactions of caffeine/placebo with age and scores on 
assessments of EF and processing speed show crossover points at different 
ages.  For tests of EF (DT, DT T1-T2, SDMT total and Stroop Interference) the 
ages at crossover are 69, 64, 77 and 79 years respectively.    Differences in the 
crossover points for these tests may be because EF is not a single unitary 
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process and EF tasks actually draw upon multiple different strategies all of 
which may alter with different ages (Schroeter et al., 2012).   
For the two assessments of processing speed, PCS and LCS, which showed 
this significant interaction of caffeine/placebo with age, the crossover point is at 
an older age of 83 and 84 respectively.   The crossover points for the 
interactions in the Lesk et al., (2009) study were at similar ages to the current 
study (PCS - 82, LCS - 81, SDMT total - 82).  It is unclear as to what the exact 
underlying processes are which determine the age at which caffeine switches 
from enhancing to inhibiting performance in the elderly and this would require 
further, more detailed study. 
Yang et al., (2006), using a test re-test paradigm, reported evidence of 
continued cognitive plasticity in the oldest old even though this was reduced in 
comparison to the younger old.  Argimon and Stein (2005) investigated 
memory, attention and verbal fluency in a group of Brazilian elderly participants 
over the age of 80.  A higher preservation of cognitive ability was noted in those 
oldest old who had the highest education level.  The present study found no 
effect of education level on any of the assessments used. 
 
5.5.5 Gender 
The present study reported no effect of gender on any of the cognitive 
assessments administered. In Lesk et al., (2009) a main effect of gender was 
found on the GNT whereby males performed significantly better than females.  
No main effect of gender was found in this study for the GNT or any of the 
neuropsychological assessments used.  This may be due to the small numbers 
of males recruited in this study (n=9).  Previously Johnson-Kozlow et al., (2002) 
reported that for a sample of 890 females a higher lifetime coffee consumption, 
as measured by questionnaire, was associated with better performance on six 
out of the 12 assessments that the study employed.  There were no benefits of 
coffee consumption on any of the assessments for the male participants (n = 
638). A possible explanation for these effects was that caffeine may be 
metabolized differently in males and females (Relling et al., 1992).  The authors 
also imply that their results suggest that women are more susceptible to the 
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cholinergic properties of coffee compared to males (Johnson-Kozlow et al., 
2002). Likewise, Ritchie et al., (2007) reported beneficial effects of three or 
more cups of coffee on verbal memory in a group of women (mean age 73.8 
years) compared to women consuming one or fewer cups of coffee per day. 
There were no reported beneficial effects of coffee drinking in the male 
participants.  The FINE study reported that men who were drinking three or 
more cups of coffee a day showed the lowest decline in cognition (Eskelinen 
and Kivipelto, 2010).  These mixed findings may be in part due to the different 
methodologies, assessments and sample sizes used which make it difficult to 
directly compare the results.  Other confounding factors may also have affected 
the data even though most of these were controlled for, for example the use of 
HRT in women, use of statins for high cholesterol and use of anti-inflammatory 
drugs for conditions such as arthritis.  All of these have been investigated as 
possible factors which may affect cognitive performance during aging.  All of the 
studies mentioned have relied upon the self-report of caffeine consumption 
(predominantly in the form of coffee) over a set period of time.  In the present 
study which was more controlled, 200mg of pure caffeine was administered and 
no reported gender differences were found. 
 
5.5.6 Possible biological underpinnings 
Another speculative explanation for the decline in caffeine’s beneficial effects 
during aging may be due to alterations in adenosine receptor density with 
increasing age (Cunha et al., 1995). There is a consistent decrease in A1R 
receptor density during aging and animal studies have also confirmed a 
predominant increase in the density of A2AR receptors in aged animals (Cunha 
and Agostinho, 2010). Adenosine modulates the release of several 
neurotransmitters and adenosine binding in the cortex and hippocampal regions 
of the brain results in a decrease in the release of Ach (Cunha, 2001; Rahman, 
2009). Furthermore, a decrease in the adenosine A1R receptor subtype in the 
CA1 region of the hippocampus has also been reported in AD patients 
(Rahman, 2009).  A study using post-mortem samples revealed a 40-60% 
decrease in A1R adenosine receptors (Kalari et al., 1990). The highest reduction 
in expression was observed in the molecular layer of the dentate gyrus which 
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forms the major cortical input pathway to the hippocampus.  The present study 
found no interaction between caffeine and tests of memory although research 
has also confirmed that in early AD both A1R and A2AR receptors are also 
upregulated in the PFC, the area of the brain associated with executive 
performance. 
The potential role of adenosine in memory became apparent when adenosine 
agonists were shown to disrupt learning and memory in rodents (Corodimas 
and Tomita, 2001). The antagonism (blockade) of adenosine receptors by 
caffeine has the opposite effect and results in an increase in the amount of Ach 
released from synapses (Dall’Igna et al., 2004).  The changes in adenosine 
receptor expression, namely an up regulation, with increasing age is important 
for further study as this is a speculative explanation as to why the effects of 
caffeine alter with increasing age in this sample. An increase in receptor 
expression may decrease the degree of adenosine blockade that can be 
initiated by caffeine’s antagonism. This could result in a smaller effect both at 
the receptor site and via the downstream modulation of other neurotransmitter 
systems.  This may ultimately result in a lower performance enhancement from 
caffeine in the older elderly as demonstrated on some of the assessments used 
in the present study. 
 
5.6 Conclusion and implications 
The results of this preliminary study have shown that the older elderly who 
received 200mg of caffeine perform significantly worse than the younger elderly 
on tests of EF and processing speed.  Although there are some discrepancies 
between this study and the data obtained previously in Lesk et al., (2009), both 
studies have shown that when there is no caffeine in the system (i.e. no prior 
consumption of CCFS in Lesk et al (2009), and the placebo condition in the 
present chapter) the results are in agreement i.e. no significant effects of age 
and no main effects present in the regression analysis.  This is interesting and 
raises the question as to whether participants should be asked to abstain from 
caffeine and CCFS for at least four hours before being given any 
neuropsychological assessment to improve the accuracy of the data that is 
obtained. 
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Significant interactions with age were only present on tests of EF and 
processing speed which also has some implications for the diagnostic process 
of AD and a cognitive impairment. The results have shown that when controlling 
for caffeine the significant effects on tests that are especially sensitive to 
cognitive impairment such as the CANTAB PAL that were found in Lesk et al., 
(2009) are no longer seen.  This again highlights the need to control prior 
caffeine intake when interpreting scores on cognitive tests.  
The use of pure caffeine rather than coffee or reported CCFS intake reduced 
the possibility that the results obtained from this study may be due to other 
ingredients contained within caffeinated drinks.  The double blind nature also 
removed any subjective encouragement during testing from the researcher who 
was unaware which experimental condition each participant was assigned to.  
The specific inclusion criteria and checklist used by the researcher ensured that 
only those who were suitable to take part did so. Recruiting participants with a 
similar daily habitual consumption of CCFS (i.e between 1-3 cups of coffee per 
day) has minimised the likelihood that any interactions with age were due to 
differences in habitual consumption between participants.  This was previously 
highlighted as a potential issue in studies such as Hogervorst et al., (1998) and 
Schmitt et al., (2003) whereby the younger participants habitually consumed 
almost twice as much caffeine than the elderly participants.  Furthermore, the 
exclusion of excessive consumers (defined as >400mg or >4 cups of coffee per 
day) reduced the possibility that the results obtained may be attributed to a 
withdrawal affect of caffeine.  Using a specific amount of caffeine for each 
participant (200mg), and asking participants to abstain from caffeine for a set 
amount of time (12 hours), removed the possibility for variances in dose and 
also did not rely on the self-report of consumption by the participants which has 
the potential for errors and bias.  
It is important to consider the influence of potential outliers which may have 
skewed the data obtained and any interpretations made.  For example, in figure 
9b, one participant obtained a score of 46 on the DT T1-T2 interval. This 
participant’s score is elevated in relation to the rest of the cohort and may, 
therefore, be significantly influencing the data.  A repeat analysis, removing this 
participant’s score, did not affect the significance obtained, i.e there was still a 
signifciant interaction between age, caffeine and score on the DT T1-T2 score.  
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As a result this data point was not removed from the analysis but it is 
acknowledged that outliers may influence subsequent conclusions. 
The scores obtained from neuropsychological test batteries are used to give a 
diagnosis and discriminate between AD, MCI and other dementias.  Scores can 
also determine whether pharmacological treatment is commenced and what 
care plan is needed.  In addition, neuropsychological testing is used to 
determine if certain individuals are included in clinical trials and research 
studies.  Test scores must be as accurate and reliable as possible.  Although it 
is acknowledged that age can affect scores on some neuropsychological 
assessments (Overshott and Burns, 2004; Jacova et al., 2007; Salthouse, 
1996) the significant interactions with caffeine and age in this study warrant the 
control of this as an external variable. Issues with cognitive test batteries have 
highlighted that scores on these assessments are often compared to population 
norms and are, therefore, limited in their ability to diagnose (Lesk et al., 2009).  
Test accuracy and the ability to discriminate between AD and MCI and MCI and 
healthy cognitive aging are imperative particularly for early identification. 
Confounding factors should therefore be controlled. Such factors including 
caffeine should be identified and controlled for when creating normative data to 
ensure that these sets of data in particular are as accurate as possible, 
particularly as they will be used for comparison purposes (Lesk et al., 2009). 
 
5.7 Chapter summary of key points 
 The presence of caffeine may affect the accuracy of neuropsychological 
test scores. 
 Previously caffeine consumption in the form of CCFS such as tea and 
coffee longitudinally over decades has been associated with a lower risk 
of developing AD. 
 There has been little investigation into the immediate effects of prior 
caffeine at the time that tests are administered. 
 Previously Lesk et al., (2009) investigated the effect of CCFS 
consumption four hours prior to the neuropsychological assessment. 
 The results showed significant interactions between CCFS and age on 
some of the tests administered. 
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 This chapter explored the effects of 200mg of caffeine in the over 60s 
using a double blind experimental approach. 
 Participants who were suitable to take part were asked to abstain from 
CCFS for 12 hours prior to taking part and alcohol 24 hours prior. 
 Participants were randomly assigned to the caffeine or placebo condition 
and another researcher administered the participant their drink which 
may or may not have contained 200mg of caffeine. 40 minutes later a 
cognitive battery was administered. 
 The results of the chapter found no main effect of 200mg of caffeine on 
any of the tests used but there were significant interactions between 
caffeine, age and tests of EF and processing speed. 
 For these interactions the older elderly who had received caffeine 
performed significantly worse than the younger elderly. 
 This has important implications for the accurate interpretation of test 
scores and should be considered when scoring these tests. 
 The exact reasons as to why these particular cognitive domains were 
affected is unclear. EF is highly associated with frontal lobe functioning 
and these areas of the brain are highly susceptible to age related 
changes. 
 EF encompasses a number of cognitive processes and further study is 
needed to determine if particular sub domains are more affected over 
others. 
 The results of this chapter highlight the need to consider the participant’s 
prior caffeine consumption when scoring neuropsychological 
assessments. 
 This is particularly important if the scores obtained are compared to 
normative data or used for the inclusion/exclusion of individuals for 
research trials. 
 
Some of the information from this chapter can be found in Walters and Lesk (in 
prep - a) ‘The effect of prior caffeine consumption on neuropsychological 
testing’. 
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Chapter Six 
The effect of non-oily fish consumption on the MMSE 
 
6.1 Introduction 
Diet is a factor which can influence cognitive performance (Cole et al., 2009) 
and poor diet and malnutrition are risk factors for cognitive impairment in the 
elderly (Morris, 2009; von Arnim et al., 2010). Chapter five investigated the 
effect of caffeine on cognitive performance in the elderly.  This chapter will 
investigate another dietary factor, fish consumption, in order to determine any 
effect of this on neuropsychological test performance in the elderly.  
The chapter will extend upon findings by Walters et al., (2011) a study which 
originated from my MSc research project ‘Correlates of dietary patterns and 
lifestyle on cognitive performance in the over sixty fives’. This study utilised a 
dietary and lifestyle questionnaire (see appendix one) and a brief cognitive 
battery to investigate monthly fish consumption and cognitive performance in a 
group of elderly participants. The results revealed that participants’ consumption 
of non-oily fish, specifically cod and haddock was trending towards significance 
as a predictor of their score on the MMSE. Increased consumption of cod and 
haddock was associated with better performance on the MMSE.   
As the MMSE is a diagnostic tool used in the detection of cognitive impairment 
in the elderly and is recommended for use in the early detection of AD by the 
NICE dementia guidelines (NICE, 2011), it is important to investigate these 
preliminary findings in greater detail to determine whether non-oily fish intake is 
a factor which may influence cognitive performance.  Furthermore, there has 
been little investigation into the effects of non-oily fish intake on cognition in the 
elderly with most studies investigating total seafood consumption or specifically 
oily fish consumption (Cunnane et al., 2009).  Estimations of food intake 
provided by food frequency questionnaires (FFQs) may be subject to over and 
under reporting (Liu et al., 2013).  Likewise, portions can differ in size and 
weight therefore investigating people’s estimation of their grams of fish intake 
per month gives a more reliable indication of actual consumption.  
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Consequently, this chapter will extend upon the preliminary findings of Walters 
et al., (2011) by investigating the effect of monthly non-oily fish intake in grams 
on a more thorough battery of cognitive assessments in a different cohort of 
elderly participants via the use of a four week food diary. The first part of this 
chapter will review some of the existing literature which has investigated the 
effect of fish consumption on cognitive performance in the elderly and will 
provide further details of Walters et al., (2011). 
 
6.1.1 Fish consumption 
Marine fish are divided into oily and non-oily varieties.  Table six outlines some 
of the most commonly consumed types, however, there are many more.  Oily 
fish are referred to as fatty fish due to their higher fleshy fat content (approx 5-
20%) relative to non-oily fish (also referred to in the literature as white fish) 
which have a lower fat content (1-2%) and are known as lean fish (Scientific 
Advisory Committee on Nutrition, 2004).   
 
Table six: Commonly consumed oily and non-oily fish types 
Oily Fish Non-oily 
Sardines Cod 
Salmon Haddock 
Pilchards Plaice 
Mackerel Sole 
Herring Halibut 
Trout Hake 
Fresh Tuna Tinned Tuna 
 Whiting 
 Pollack 
 Seabass 
 Snapper 
 River Cobbler 
 White fish 
(Table adapted from the Scientific Advisory Committee on Nutrition, ‘Advice on 
fish consumption benefits and risks’, 2004, page 104 
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6.1.2 Fish oils 
Varieties of oily fish are a rich source of omega-3 polyunsaturated fatty acids (n-
3 PUFAS), known as ‘fish oils’ (Robinson et al., 2010), but these are also found 
in smaller amounts in non-oily fish. The two most biologically important n-3 
PUFAs are docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), 
both of which are crucial for the maintenance of brain structure and function 
(Devore et al., 2009; Dangour et al., 2010; Robinson et al., 2010; Cunnane et 
al., 2009).   Oily fish is a richer source of n-3 PUFAS comparative to non-oily 
varieties (Dangour et al., 2010; Danthiir et al., 2011) and smaller amounts of 
DHA and EPA can also be found in other foods such as meat, eggs, leeks and 
cereals (Robinson et al., 2010).  
DHA is the most abundant n-3 PUFA within the brain and is concentrated in 
membrane phospholipids (Hashimoto and Hossain, 2011).  Approximately 30-
40% of fatty acids within the cortical grey matter are composed of DHA 
(Robinson et al., 2010) which is predominantly derived from the diet and cannot 
be manufactured within the body (Devore et al., 2009; Robinson et al., 2010).   
Levels of DHA in the brain naturally decrease with age (Söderberg et al., 1991) 
and lower levels of plasma EPA and DHA have been reported in AD (Conquer 
et al., 2000; Hashimoto and Hossain, 2011).  The importance of DHA for brain 
structure and function lead to the investigation of the association between fish 
consumption (a rich source of DHA) and the risk of developing AD, as well as 
the effect of fish intake on cognitive function in general.  These areas will now 
be briefly reviewed.  
 
6.1.3 Fish consumption and cognitive function in the elderly 
Van de Rest et al., (2009) used a 126 item FFQ to investigate the effects of fish 
intake on cognition in a group of 1025 elderly male participants with a mean age 
of 68 years.  They investigated four fish items which included ‘dark-meat fish’, 
which consisted of mackerel, salmon and sardines, ‘canned tuna’, ‘other fish’ 
and ‘shrimp, lobster and scallops’. The total mean weekly fish consumption was 
calculated to be 2.4 servings, of which 1.3 servings constituted fatty (oily) fish.  
At baseline testing increased oily fish consumption was associated with 
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impaired memory and language.  Six hundred and seventy one participants 
were available at three year follow up and for these participants increased fish 
consumption was not associated with better cognitive ability.  Although the 
study used a large sample, a thorough cognitive battery and a well validated 
FFQ, the mean age of participants (68 years) was lower than in other studies.  
A protective effect of fish may occur only in advancing ages.   
Another study by van Gelder et al., (2007) investigated 210 elderly male 
participants aged between 70-89 years. The study employed experienced 
dieticians to carry out a dietary checklist with each participant in order to note 
which fish types were regularly consumed. They assessed general cognition 
using the MMSE.  The main findings indicated that men who did not consume 
fish experienced four times the decline in MMSE score than those participants 
who did consume fish after a five year follow up. The study did show that a 
higher intake of DHA and EPA (not fish portions) was associated with a lower 
decline in cognition. 
Kalmijn et al., (1997) also investigated elderly male participants’ fish 
consumption as a part of the Zutphen Elderly Study.  Fish intake was 
categorised into three groups according to the amount consumed and included 
0g per day, 1-20g per day and greater than 20g per day.  At baseline testing, for 
participants consuming greater than 20g of any fish type per day, there was an 
inverse association with cognitive impairment. After a three year follow up, 
although fish consumption was inversely associated with cognitive function, this 
association was not significant.  
 
6.1.4 Fish consumption and risk of dementia 
Morris et al., (2003) investigated 815 elderly participants aged between 65 and 
94 years, all of which were cognitively normal at baseline recruitment. Those 
participants who consumed higher amounts of DHA, as assessed by a dietary 
questionnaire, possessed a lower risk of developing AD compared with those 
individuals who ate lower amounts.  In this study a decreased risk of developing 
AD by approximately 60% was reported in those participants who consumed at 
least one fish meal per week compared to those eating fish rarely or never.  
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Similarly, Kalmijn et al., (1997) found increased dietary fish consumption over a 
two year period was beneficial at lowering risk of dementia (Kalmijn et al., 
1997).  A questionnaire based study by Barberger-Gateau et al., (2002) 
reported a lower risk of dementia in individuals who consumed at least one 
portion of seafood or fish per week.  Roberts et al., (2010) reported that in a 
cohort of elderly participants (over the age of 70 years), a higher intake of n-3 
PUFAs, as assessed by a 128 item FFQ was associated with a reduced 
likelihood of developing a MCI (Roberts et al., 2010).   
Devore et al., (2009) found no effect of high fish intake or n-3 PUFAs on 
dementia risk over a 10 year follow up in a large cohort of 5395 participants 
over the age of 55 years. This study used a meal based checklist where 
participants were asked to indicate foods that they had consumed at least two 
times per week for the past year. Although no significance was reported the 
authors did note that cod was the most abundant fish consumed in this cohort.  
In the Netherlands, where the study was conducted, cod tends to be prepared 
by frying and this may decrease the beneficial nutritional content of the fish 
which may help to explain the non significant results that were obtained (Devore 
et al., 2009). 
 
6.1.5 n-3 PUFA supplementation: AD and cognitive function 
Supplementation with DHA and EPA increases serum levels of these two fish 
oils (van de Rest et al., 2008).  Some studies have investigated whether fish oil 
supplements are able to change AD risk or prevent cognitive decline.  The 
majority of such studies have revealed negative findings and have concluded 
that increased n-3 PUFA consumption via supplementation methods had no 
relation with decreased AD risk (van de Rest et al., 2008; Englehart et al., 2004) 
or cognitive decline (Quinn et al., 2010; Dangour et al., 2010). These results do 
not concur with the findings of epidemiological studies which have associated 
high DHA intake with a reduced risk of AD (Cunnane et al., 2013).   
Dangour et al., (2010) investigated whether 700mg of n-3 PUFA 
supplementation for a period of 24 months relative to a placebo (olive oil 
capsule) could prevent cognitive decline in 867 individuals (mean age = 75 
115 
 
years) .  All of the participants were recruited from GP practices in the UK and 
had MMSE scores at baseline of ≥24 out of 30.  None of the participants were 
taking any fish oil supplements at recruitment.  Habitual baseline fish 
consumption was assessed using a dietary questionnaire.  After a period of 24 
months there was no change in cognitive function between the treatment and 
placebo groups.  There were, however, measurable biological changes in DHA 
in the treatment group.  Although no significance was reported in this study it is 
possible that those in the placebo arm continued to consume fish which may 
have naturally increased their intake of fish oils (Dangour et al., 2010).  
Likewise, the placebo was an olive oil capsule and olive oil has been shown, as 
a component of the Mediterranean diet, to be beneficial for cognition and 
healthy aging (Scarmeas et al., 2006).  Recently, Martínez-Lapiscina et al., 
(2013) showed that a diet supplemented with olive oil for a period of six and a 
half years was associated with significantly better performance on the MMSE 
and CDT.  
Other studies have investigated whether n-3 PUFAS can prevent further decline 
in diagnosed AD patients and these also revealed no beneficial association 
(Freund-Levi et al., 2006).  Chiu et al., (2008) implemented a double blind 
treatment vs placebo preliminary study to investigate whether 24 weeks of n-3 
PUFA treatment had an effect on cognition in a group of AD and MCI 
participants.  The study found that there was no change between the two 
groups on the cognitive section of the ADAS–COG.  The MCI participants who 
were administered the treatment showed a significant improvement on this test 
relative to the placebo group.  The short follow up period of 24 weeks may also 
have influenced the results and a longer follow up may have been needed.  
A more recent study by Yurko-Mauro et al., (2010) investigated whether a 24 
week supplementation study with 900mg/day of DHA could improve cognitive 
function as determined by fewer errors on the six pattern stage of the CANTAB 
PAL after 24 weeks of treatment.  The PAL has previously been shown to be 
sensitive to early cognitive impairment (as discussed in chapter four) (Swainson 
et al., 2001; Blackwell et al., 2004).  The results of the study revealed that there 
were significantly fewer errors made in the treatment group comparative to the 
performance of participants in the placebo condition. These beneficial findings 
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were noted after only a short follow up duration and it is possible that with 
longer follow up even larger improvements may be seen.   
 
6.1.6 Methods of collecting dietary information 
FFQs are frequently used to collect dietary information in a cross sectional 
manner and usually require participants to estimate their habitual consumption 
of certain food groups (Christensen et al., 2013; Liu et al., 2013).  In Walters et 
al., (2011) (see section 6.1.1) a lifestyle and dietary questionnaire was created 
to obtain information regarding participants’ intake of a variety of foods including 
a specific section on fish.  FFQs are quick and simple to complete but there are 
some criticisms of their use as a tool for the collection of dietary information.  
For example, the issue of self report, which relies on the participants’ self 
estimation of their fish consumption.  This creates the potential for errors due to 
over and under estimation of intake (Liu et al., 2013; Bowman et al., 2012; 
Arsenault et al., 2009; Cunnane et al., 2009).   
Food diaries on the other hand require participants to complete a record of their 
daily intake of all meals, including food and drinks.  By recording meals and 
snacks as they eat them there is less opportunity for participants to make errors 
due to estimation (Bowman et al., 2012; Arsenault et al., 2009). Food diaries 
are considered to be a more reliable method of assessing dietary intake (Legg 
et al., 2000).  Legg et al., (2000) do comment, however, that for any type of 
dietary data collection method (i.e. FFQs and food diaries) there is the potential 
for a response bias whereby a participant may provide estimates of intake 
based on what they believe the researcher is interested in.   
There are few studies which have specifically used food diaries as a method of 
comparing diet with cognitive function in the elderly.  To my knowledge the only 
food diary based study to compare fish intake with cognitive function in the 
elderly is Kesse-Guyot et al., (2013).  This study used a ‘food record’, which 
was the equivalent of a 24 hour food diary.  The study investgated whether 
adherence to a Mediterranean type diet in midlife had an effect on cognition 
after a follow up period of 13 years.  The Mediterranean diet includes a large 
intake of fish (Martínez-Lapiscina et al., 2013). Kesse-Guyot et al., (2013) 
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recruited 3083 participants with a mean age at baseline of 52 years.  
Participants were required to complete a 24 hour food record every two months 
resulting in a total of six records for a one year period across all seasons.  From 
these records the authors calculated a Mediterranean diet score (MDS) for each 
participant using an algorithm they created.  This was based upon the number 
of certain foods consumed.  After a period of 13 years participants were invited 
to attend a cognitive assessment.  At follow up the mean age of participants 
was 64 years.  
Overall there was no effect of a Mediterranean diet on cognitive performance, 
however, a higher MDS score was associated with better performance on an 
assessment of semantic fluency and a composite score of cognition.  In 
addition, MDS score correlated with n-3 PUFA intake.  A limitation of this study 
is the absence of baseline assessments of cognitive performance which makes 
it impossible to investigate whether those with a higher MDS score experienced 
lower levels of decline on some or all of the tests administered.  In addition, 24 
hour food diaries completed once every two months may not reflect general 
daily consumption.  Consequently, this method may not offer reliable dietary 
information although the day of the week that participants were asked to record 
intake was determined at random by the authors. 
 
6.1.7 Pilot Study: Walters et al., (2011) 
As a part of my MSc in Psychology in 2010 I investigated dietary correlates of 
cognition in the HE with the aim of determining whether certain foodstuffs 
and/or lifestyle habits were associated with cognitive performance. Using a 
separate cohort of participants Walters et al., (2011) further investigated 
preliminary findings from this study of an association between non-oily fish and 
MMSE score.  This showed that increased consumption was associated with 
improved performance on this test.  
Non-oily fish consumption was investigated in 70 participants with a mean age 
of 72.09 (SD ± 6.24) years and mean years spent in education of 15.57 (SD 
±4.86) years.  A FFQ was used to assess various aspects of lifestyle and diet 
and specifically asked participants about their medical history, current medical 
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conditions, medication use and lifestyle habits [including alcohol consumption, 
smoking status, levels of exercise and interests and hobbies].  The remainder of 
the questionnaire asked participants to estimate their daily, weekly or monthly 
consumption of a variety of different foods and drinks and included a small 
specific section on fish including non-oily and oily types.  A short cognitive 
battery consisting of the MMSE (Folstein et al., 1975), the Stroop Test (Trenerry 
et al., 1989), digit span (Wechsler et al., 1981) and immediate word recall was 
administered.  The results revealed that portions of non-oily fish intake was 
trending towards significance as a predictor of MMSE score (p = 0.08).  As 
consumption of non-oily fish increased MMSE score also increased.  There was 
no effect of any variety of oily fish on MMSE score (Walters et al., 2011).  
 
6.2 The present study: research aims 
This chapter will further investigate whether non-oily fish consumption is a 
dietary factor which may influence cognitive performance in the elderly using a 
more controlled method of collecting dietary information, a four week food diary. 
This will allow the investigation of whether the same effect as seen in Walters et 
al., (2011) is present in a different cohort of participants. 
 
6.3 Methods 
6.3.1 Participants 
All participants from the University of Bradford, Division of Psychology 
Participant Pool were invited to take part in the study and of these individuals 38 
participants were recruited to take part in the study.  The inclusion criteria 
specified that participants must be 60 years of age or older and must not 
possess an existing diagnosis of any neurological condition or a cognitive 
impairment.  A novel cohort was recruited for the purpose of this study and, 
therefore, none of the participants had taken part in the previous pilot studies 
which had investigated trends between non-oily fish and cognitive performance.  
Data from four participants could not be included in the study due to failure to 
correctly complete the food diary.  The final sample consisted of 11 males and 
23 females.  The mean age of participants was 72.59 (S.D ±6.09) years and the 
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mean years in education was 14.84 (S.D ±4.69).  Ethical approval was obtained 
from the University of Bradford Ethics Committee and all participants gave their 
informed written consent to take part. 
 
6.3.2 Materials 
6.3.2.1 Food diary 
A four week food diary was created to allow the recording of dietary information 
for a period of one month.  The diary consisted of a 17 page A4 landscape 
booklet which contained an information sheet, a detailed instruction section, an 
example of a completed diary sheet and a four week blank diary.  The diary was 
designed to be easy to complete and consisted of a tabular grid format which 
included a column for the day of the week and four columns for breakfast, 
lunch, dinner and snacks respectively.  
Participants were instructed to record any meal that they consumed which 
contained a fish item. They were also required to note the type of fish, the 
weight as stated on the packet or scales, the brand make or the location the fish 
was purchased from e.g. Morrisons fishmonger.  They were also required to 
note all foods eaten alongside the fish, condiments that were added and how 
the fish was prepared.   
 
6.3.2.2 Neuropsychological tests 
A neuropsychological assessment battery was used to assess cognition and 
this included the following tests.  Further details of each test can be found in 
Chapter four ‘Neuropsychological testing’. 
MoCA - an assessment of general cognitive function (Nasreddine et al., 2005). 
MMSE - an assessment of general cognitive ability (Folstein et al., 1975). 
DT - an assessment of EF (Baddeley et al., 1997). 
TMT - an assessment of EF (Reitan and Davison, 1974). 
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PCS and LCS - assessments of processing speed (Salthouse and Babcock, 
1991). 
Stroop Test - an assessment of processing speed and EF (Trenerry et al., 
1989). 
Digit span - an assessment of working memory (Wechsler, 1981). 
 
6.3.3 Procedure 
Participants were invited to take part in the study via a postal invitation letter.  
Those who accepted were invited to attend a brief meeting where they were 
given the opportunity to ask any questions, sign the consent form and were 
provided with a copy of the food diary to take home.  During this appointment 
the researcher explained how to complete the diary and what information was 
required.  Participants were asked to complete the diary for a period of four 
continuous weeks and it was specified that this must be a ‘’typical’’ four week 
period and must not be completed if the participant was going on holiday for 
example.  Another appointment was then arranged for the week after the diary 
had been completed where the cognitive assessment could be carried out.   
Participants were also instructed not to alter their habitual consumption of fish 
and provide an honest recall of their fish intake.  They were asked to note any 
supplements that they may take but were not specifically asked to record their 
medications.  A sample of a completed week was provided as a guide and 
participants were instructed to contact the researcher if they experienced any 
problems or required assistance in the completion of the food diary.  After they 
had completed the diary for a period of one month they were invited back to the 
university to complete a cognitive assessment (see section 6.3.2.2 for details).  
 
6.4 Results 
6.4.1 Main demographics 
The aim of the current chapter was to investigate the effect of monthly grams of 
non-oily fish intake on cognitive test scores in the HE in particular the MMSE. 
Table seven outlines the participants’ demographics, table eight shows the 
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types of fish consumed and the mean monthly consumption values and table 
nine shows computed values for total, oily and non-oily intake.  
Table seven: mean ± standard deviations for main patient demographics 
Demographic  
Age (mean years ±S.D) 72.59 (6.09) 
Education (mean years ± S.D) 14.84 (±4.69) 
Gender (M/F) 11/23 
 
 
Table eight: mean monthly consumption in grams of each fish type that participants 
consumed during the study 
 
 
Table nine: mean grams of non-oily, oily and total fish consumed during the study 
 Min (g) Max (g) Mean (g) ±SD (g) 
Total non-oily 0 1766.80 571.28 437.60 
Total oily 0 1431.00 377.85 378.04 
Total fish 289.30 1891.80 949.13 485.36 
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6.4.2 Neuropsychological tests 
6.4.2.1 Main effects of age and education 
There were significant main effects of age on the Stroop interference [F(1,32) = 
4.79, p< 0.05], the PCS [F(1,32) = 6.35, p< 0.05], the LCS, [F(1,32) = 6.64 p< 
0.05], TMT part A [F(1,32) = 9.54, p< 0.01] and TMT part B [F(1,32) = 10.06 p< 
0.01].  Regression analyses revealed that performance decreases with 
increasing age on all of these tests [Stroop interference - β = - 0.34, F(1,32) = 
4.79, p< 0.05, y-axis intercept = 50.94, regression correlation coefficient r = 
0.36, p<0.05; PCS – β = - 0.29, F(1,32) = 6.35, p< 0.05, y-axis intercept = 
45.67, regression correlation coefficient r = 0.41, p<0.05; LCS. β = .- 0.17, 
F(1,32) = 6.64, p< 0.05, y-axis intercept = 26.85, regression correlation 
coefficient r = 0.41, p<0.05; TMT part A – β = 1.04, F(1,32) = 9.54, p< 0.01, y-
axis intercept -41.03, regression correlation coefficient r = 0.48, p< 0.01; TMT 
part B – β = 1.66, F(1,32) = 10.06, p< 0.01, y-axis intercept = -51.67, regression 
correlation coefficient  r = 0.49, p < 0.01].  
There was a significant main effect of education on the Stroop Word [F (1, 32) = 
4.83, p<0.05]. A regression analysis revealed that increased education in years 
was associated with improved performance on this test [β=0.92, F (1, 32) = 
4.83, p< 0.05, y-axis intercept = 48.40, regression correlation coefficient r= 
0.36, p< 0.05].  
 
6.4.2.2 Main effects of gender 
Significant main effects of gender were noted on the LCS and MMSE [LCS - F 
(1, 32) = 4.31, p<0.05), MMSE - F (1, 32) = 7.97, p<0.01].  Independent sample 
t-tests revealed that the male participants performed significantly worse than 
female participants on both of these tests, [LCS - t (32) = -2.08, p<0.05, MMSE 
- t(32) = -2.44, p<0.05].  Independent t-tests revealed that there were no 
significant differences between males and females in terms of age or education. 
There were also no significant differences between males and females in their 
consumption of total, oily or non-oily fish as measured by independent t-tests 
(p>0.05).  
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6.4.3 Main effect of total grams of fish consumption 
Following the same analytical method as Walters et al., (2011), a MANCOVA 
with test scores as dependent variables and total grams of fish entered as a 
covariate, revealed a main effect of total monthly fish intake in grams on the 
MMSE [F(1,32) = 4.84, p<0.05].  A regression analysis showed that total grams 
of fish intake could significantly predict MMSE score [β = 0.36, F (1, 32) = 4.84, 
p<0.05, y-axis intercept = 27.62, r = 0.36].  See figure 11.  There was no effect 
of total grams of fish consumption on any of the other tests administered. 
 
 
 
Figure 11: total monthly fish consumption is a significant predictor of MMSE score. 
 
6.4.4 Main effects of oily and non-oily fish consumption 
In order to investigate the primary hypothesis and determine whether there 
were main effects of non-oily fish on any of the assessments used particularly 
the MMSE, as previously reported in Walters et al., (2011), a MANCOVA was 
carried out with all test scores entered as dependent variables and total non-oily 
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fish and total oily fish in grams entered into the model as covariates.  This 
revealed a significant main effect of non-oily fish on the MMSE [F (1, 31) = 4.09, 
p = 0.05].  A regression analysis for monthly non-oily fish and MMSE score was 
not significant, although, a scatter plot showed a positive association between 
MMSE score and non-oily fish intake in grams.  See figure 12.  
 
 
 
Figure 12: total monthly non-oily fish consumption is associated with an increased 
MMSE score 
 
6.4.5 Non-oily fish consumption and MMSE score 
The main effect of non-oily fish consumption and MMSE score was investigated 
in more detail to see the influence of any particular non-oily fish type.  A 
univariate analysis with MMSE score entered as the dependent variable and all 
the separate non-oily fish types in grams [pollock, sea bass, tinned tuna, 
haddock, white fish and cod] entered as covariates was carried out.  This 
revealed that there was a significant main effect of grams of monthly tinned tuna 
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consumption and MMSE score [F (1, 27) = 9.53, p<0.01].  There were no 
effects of any of the other non-oily fish types on MMSE score.  A regression 
analysis revealed that monthly tinned tuna consumption in grams was a 
significant predictor of MMSE score [β = 0.47, F (1,32) = 9.15, p<0.01, y-axis 
intercept = 28.19, regression correlation coefficient r = 0.47].  Increased 
consumption is associated with improved score on the MMSE.  A scatter plot of 
these results can be seen in figure 13.  There were no main effects of any oily 
fish type on MMSE score.  
 
 
 
Figure 13: increased monthly tinned tuna consumption is associated with increased 
MMSE score. 
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6.4.5.1 Interactions between tinned tuna, age and MMSE score 
In order to determine whether the effects of tinned tuna and general cognitive 
function changed during aging a MANCOVA was carried out and age and 
grams of tinned tuna consumption were entered into the model as covariates.  
An interaction term of age x grams of tinned tuna consumption was included.  
There was a significant interaction between tinned tuna, age and MMSE score 
[F (1, 32) = 9.50, p<0.01].  In order to graphically represent this interaction 
tinned tuna consumption was divided into low and high consumption using the 
median grams of tinned tuna intake.  Low tinned tuna consumption in older 
participants was associated with lower scores on the MMSE.  In contrast the 
older elderly who consumed ‘high intake’ of tinned tuna perform better on the 
MMSE.  See figure 14 for a scatter plot of this interaction. 
 
 
Figure 14: significant interaction between MMSE score, age and tinned tuna 
consumption. Participants with a low intake of tinned tuna experience a decline in 
MMSE performance with age whereas those with a high intake show a modest 
improvement with increasing age. 
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When the sample was divided based upon low and high tinned tuna 
consumption in those classified as ‘high intake’ age was not a significant 
predictor of MMSE performance (p>0.05).  For participants classed as low 
tinned tuna consumers a weak trend was observed for age as a predictor of 
MMSE performance (p=0.16). 
 
6.4.5.2 Effect of tinned tuna consumption on MMSE sub domains 
It is important to investigate the effect of tinned tuna consumption on the 
different sub sections of the MMSE to see if the effects are general or whether 
there is a specific effect given that the test is made up of general cognitive 
domains.  The points of the test were sub categorised according to the domain 
assessed into orientation (10 points), registration (3 points), attention, 
calculation and construction (6 points), recall (3 points) and language (8 points) 
respectively.  Table 10 shows the mean, minimum and maximum scores for 
each sub domain of the MMSE in this cohort of participants.  
 
Table 10: Participants’ mean and SD for scores on the sub domains of the MMSE 
MMSE sub domains Min Max Mean ±S.D 
Orientation 9 10 9.94 0.24 
Registration 3 3 3 0.00 
Recall 0 3 2.21 1.09 
Attention/Concentration 
and Calculation 
2 6 5.76 0.78 
Language 6 8 7.76 0.55 
 
In order to determine whether tinned tuna consumption could predict 
performance on a specific section of the MMSE a multivariate multiple 
regression analysis was carried out.  This showed that monthly grams of tinned 
tuna intake was a significant predictor of score on the recall portion only [β = 
0.002, F(1,32) = 4.00, p = 0.05, y-axis intercept = 1.95, regression correlation 
coefficient r = 0.33] revealing that increased tinned tuna consumption is 
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associated with a greater number of words recalled on the MMSE recall 
question.  See figure 15.  
 
 
 
Figure 15: monthly tinned tuna consumption is associated with the word recall portion 
of the MMSE.  Increased tinned tuna intake predicts better performance on this sub 
domain of the test. 
  
129 
 
6.5 Discussion 
6.5.1 Main findings 
In an earlier study Walters et al., (2011) used a FFQ to assess fish intake and a 
trend towards significance for portions of non-oily fish (cod and haddock) as a 
predictor of MMSE performance was found.  The aim of the current chapter was 
to extend upon these preliminary findings in a more controlled manor by 
examining the effects of monthly fish intake (particularly non-oily varieties, in 
grams, rather than portions) on a neuropsychological test battery in the HE via a 
more detailed method of data collection, a four week food diary.   
The main findings of the study were (1) total monthly fish intake in grams was a 
significant predictor of MMSE score. (2) a significant main effect of non-oily fish 
consumption in grams was found for the MMSE (3) of the non-oily fish types 
consumed, monthly tinned tuna consumption was the only significant predictor 
of MMSE score, (4) that score obtained on the word recall part of the MMSE 
was predicted by tinned tuna intake. 
 
6.5.2 Total grams of fish intake predicts MMSE score 
Total grams of fish intake (i.e. oily + non-oily varieties) was a significant 
predictor of MMSE score in this cohort.  The more fish consumed the better the 
participants’ performance on the MMSE.  There are few studies which have 
related current fish consumption to cognitive performance and most have 
focussed on whether fish consumption can predict cognitive decline or dementia 
and AD risk (e.g. Devore et al., 2009; van Gelder et al., 2007; Morris et al., 
2003; Kalmijn et al., 1997; Roberts et al., 2010).  Although some of these 
studies (e.g Van Gelder et al., 2007 and Kalmijn et al., 1997) have used the 
MMSE as a part of their cognitive assessment, none have specifically 
investigated which sub section of the test may be associated with fish intake.  
Nurk et al., (2007) reported in their cohort that fish eaters had significantly better 
performance on all of the neuropsychological tests administered (including the 
modified MMSE and TMT).   
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6.5.3 Tinned tuna as a predictor of MMSE score 
Increased monthly tinned tuna intake was associated with better performance 
on the MMSE.  Further investigation of the data revealed that tinned tuna 
consumption was a significant predictor of participants’ score on the word recall 
portion of the test which assesses short-term memory.  Increased intake was 
associated with a greater number of words recalled on this question. 
As an assessment of general cognitive function, the MMSE assesses a number 
of cognitive processes (Folstein et al., 1975).  As discussed in chapter four 
‘Neuropsychological testing’, section 4.2.1, the test consists of 12 items which 
include orientation, registration, recall, attention, concentration, calculation and  
language (Nasreddine et al., 2005; Markwick et al., 2012).   The test is weighted 
towards memory and orientation (Alzheimer’s Society, 2013) and devotes 16 of 
its 30 points to these domains.  Consequently the MMSE does not tax the full 
breadth of cognitive processes.  
The other tests which were administered as a part of the cognitive battery in this 
chapter assessed processing speed (specifically the PCS, LCS, TMT part A, 
Stroop Word), EF (specifically set switching in the TMT part B, inhibition in the 
Stroop interference and performing two tasks simultaneously in the DT), 
working memory (specifically the digit span task) and general cognitive function 
(the MoCA).  There was no effect of tinned tuna intake on any of these 
assessments.  The MMSE, which was associated with tinned tuna consumption, 
does not contain any questions within its 30 points which assess processing 
speed, working memory or EF.  Therefore, the lack of association between 
tinned tuna and score on the PCS and LCS, digit span, Stroop, DT and TMT 
concurs.  The finding that tinned tuna was a predictor of the number of words 
correctly recalled on the recall sub-section appears to suggest that tinned tuna 
is selectively associated with short-term memory performance in this cohort of 
participants.   
Like the MMSE the MoCA also assesses general cognitive performance but 
there was no association between tinned tuna consumption and MoCA scores 
in this cohort.  The MoCA was specifically designed to detect mild forms of 
cognitive impairment (Nasreddine et al., 2005) and the domains of cognition 
that the MoCA taxes differ slightly from the MMSE (Jacova et al., 2007; 
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Markwick et al., 2012).  For example, the MoCA contains a more complex 
assessment of visuospatial skills whereas the MMSE asks participants to copy 
two interlinked pentagons, which assesses visual construction (Guerrero-Berroa 
et al., 2009).  The MoCA requires the participant to correctly join a series of 
circles containing numbers and letters (similar to the TMT part B), copy a 3D 
cube and draw the face of clock inserting all of the correct numbers and setting 
the time (a version of the CDT).  The MoCA also incorporates questions 
assessing working memory (digit span) and abstraction (Markwick et al., 2012).  
It is worth noting that, regarding word recall, unlike the MMSE the MoCA’s 
assessment of this domain requires participants to remember five words, 
instead of the three words in the MMSE (Nasreddine et al. 2005).  The MoCA 
also allows participants two attempts to repeat these words in the learning 
phase which differs from the MMSE where they are only asked to repeat each 
word once.  Recall of words in the MoCA occurs after a longer delay of five 
minutes; therefore, it is argued that the MoCA incorporates a more rigorous 
assessment of memory (Markwick et al., 2012).  Delayed recall has been shown 
to be a sensitive domain for the prediction of future cognitive decline (Jacova et 
al., 2007; Chodosh et al., 2002; Albert et al., 2011).  
Given the significant differences between the MMSE and MoCA in terms of their 
structure and testing domains it is difficult to compare the two with regards to 
tuna’s effect on word recall.  Further study utilising a thorough assessment of 
episodic memory using alterative tests will be required to investigate the effect 
of tinned tuna on short term recall in more detail.  
Tinned tuna, unlike fresh tuna, is classified as a ‘non-oily’ fish (Scientific 
Advisory Committee, 2004 page 104; British Heart Foundation, 2012).  To my 
knowledge there have been no previous studies which have specifically 
reported an effect of tuna consumption on MMSE performance or cognitive 
performance in general.  The interactions between tinned tuna, age and MMSE 
score showed that those participants classified as consuming larger amounts of 
tuna per month did not experience a decline in MMSE performance with 
increasing age.  The exact reasons for this cannot be determined from the 
present data and longitudinal follow up of this cohort will investigate whether 
tinned tuna consumption is associated with any cognitive decline with aging. 
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6.5.4 MMSE score and Walters et al., (2011) 
The results of this chapter were not able to replicate the trend towards 
significance for cod and haddock portions as a predictor of MMSE score 
reported in Walters et al., (2011).  This is likely to be due to less reliable 
methods of measuring dietary intake (i.e the FFQ) and the fact that a different 
cohort of participants were recruited and therefore differences in MMSE scores 
were obtained.    
 
6.5.5 Methodological considerations 
Creating a detailed four week food diary for the dietary recollection of fish intake 
has removed some of the potential for errors associated with FFQs such as the 
reliance upon self estimation of intake (Liu et al., 2013; Bowman et al., 2012). 
Using a battery of cognitive tests allowed the investigation of whether non-oily 
fish consumption had a domain specific effect on cognitive performance. 
Assessing dietary fish intake over a period of four weeks may not represent 
general consumption and intake may vary depending on the time of year.  
Likewise, current intake may not reflect the individuals’ life time intake (Gillette-
Guyonnet et al., 2013) and participants may have increased their consumption 
of fish in midlife because they were aware of the potential health benefits 
associated with increased fish consumption (Morris et al., 2009).  For example, 
consumption of fish has been recommended for those with heart disease and is 
associated with a decreased risk of heart attack and coronary disease (NHS, 
2013; Morris, 2009; Kalmijn et al., 1997).  
Tinned tuna was one of the most commonly consumed fish by this cohort.  
Participants also consumed larger amounts of salmon and haddock relative to 
the other varieties but there was no effect of these types of fish on MMSE 
score.  Increased consumption of the other varieties of fish consumed by this 
cohort may lead to an effect of these fish types on cognitive performance 
although this cannot be determined by the present data.  
The participants in this cohort volunteered to take part in the study.  As a result 
they may not be a true representation of the general population.  It is possible 
that those participants who consumed a greater amount of fish per month were 
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more likely to possess a healthier diet over all.  Wennberg et al., (2012) 
commented that fish consumption in general seems to be associated with a 
healthy lifestyle.  Cunnane et al., (2009) noted that fish consumers tend to be 
consumers of other healthy foodstuffs such as fruits and vegetables which are 
also rich sources of antioxidants.  Fish is a major component of the 
Mediterranean diet (Cunnane et al., 2009; Martínez-Lapiscina et al., 2013), 
which has in some previous research been associated with a lower risk of 
developing AD (Scarmeas et al. 2006; von Arnim et al, 2010; Cunnane et al., 
2009).  Fish is commonly thought of as a healthier dietary option by the general 
public (Cunnane et al. 2009) and individuals consuming fish, in the case of this 
chapter, tinned tuna, may be more likely to be aware of other healthier dietary 
options.  This type of diet is likely to protect against other age associated 
conditions such as diabetes, hypertension and high cholesterol and promote 
healthy aging overall (Cunnane et al., 2009).   
As a non-oily fish, tinned tuna contains lower amounts of fish oils than fresh 
tuna and other oily fish varieties as the process of ‘tinning’ reduces the fish oil 
content to that of other non-oily varieties (NHS, 2011).  It is possible that any 
potential benefits of increased consumption maybe due to other nutrients aside 
from DHA and EPA within non-oily fish.  For example, their high protein content 
(Cunnane et al., 2009), selenium levels (Cunnane et al., 2009; Mehdi et al., 
2013; Gao et al., 2007) vitamin content (Cunnane et al., 2009) or low fat content 
(Scientific Advisory Committee on Nutrition, 2004).   
 
6.5.6 Implications  
The results of this food diary study have shown that a diet which includes a 
larger amount of non-oily fish, specifically tinned tuna, is associated with 
improved performance on the MMSE with the significance lying in the MMSE’s 
assessment of short-term recall.  The MMSE is recommended as a test of 
choice for the diagnosis of cognitive impairment by the recently reviewed NICE 
dementia guidelines (NICE, 2011) and is still used in the early assessment of 
cognitive impairment (Alzheimer’s Association, 2012).  The participant’s score 
on the MMSE can be considered when determining diagnosis, treatment and 
research inclusion.  Performance may also be compared with normative data 
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sets.  It is acknowledged that the MMSE has received some criticisms for being 
insufficiently sensitive to mild forms of cognitive impairment (Mitchell, 2009, 
Tombaugh and McIntyre, 1994) and the occurrence of ceiling and floor affects 
are common which creates clusters of scores at the test’s maximum and 
minimum range (Crum et al., 1993).  Despite this the MMSE is still widely used 
by clinicians and researchers to determine overall global cognitive function and 
detect early cognitive symptoms.  
The fact that tinned tuna intake was able to predict MMSE score, specifically the 
word recall portion of the task, in a sample of older HE adults may have 
implications for cognitive testing.  The findings also add to the current literature 
investigating dietary factors and cognitive performance in the elderly.  The 
Alzheimer’s Association comment that GPs will often ask patients about their 
dietary intake.  Should a strong effect remain with further study this may have 
implications for the promotion of fish as a modifiable dietary factor which may 
aid cognitive aging.  This is relatively inexpensive and is a method that the 
individual themselves can implement in the home without the need for 
consultation with clinicians which is time consuming and expensive.    There 
has been very little literature which has incorporated food diaries as a method of 
measuring fish intake. The use of the food diary in the present chapter has 
demonstrated that diaries can be useful tools to collect dietary information from 
elderly participants when conducting research within the field of cognitive 
neuropsychology.   
 
6.6 Conclusion and summary 
The results of this chapter have shown that a greater monthly intake of tinned 
tuna is associated with better performance on the MMSE.  Furthermore, tinned 
tuna consumption was a significant predictor of participants’ scores on the recall 
item of the MMSE which assesses short term memory. There was no effect of 
tinned tuna intake on any of the other assessments administered. 
The results have novelly suggested that tinned tuna consumption may be 
important for both general cognitive performance and short-term memory.  This 
has implications for cognitive research, cognitive aging and the diagnosis of 
cognitive impairments. The fact that total tinned tuna consumption is associated 
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with better performance on the MMSE’s recall item and none of the other 
cognitive processes assessed in the battery administered is important.  Future 
study will need to investigate this further via the administration of other cognitive 
assessments assessing short term memory and word recall.  
 
6.7 Chapter summary of key points 
 Fish consumption is a dietary factor which may influence cognitive 
function and neuropsychological test performance in the elderly.  
 Previously, Walters et al., (2011) reported via a FFQ, a trend towards 
significance for non-oily fish consumption (specifically cod and haddock) 
as a predictor of MMSE performance in the HE. 
 Fish is a rich source of fish oils and non-oily varieties also contain other 
nutrients which may be associated with brain health.  
 A four week food diary was created to enable participants to record all 
meals containing a fish item as well as specifically recording the grams of 
each portion. Gram information is likely to provide a more accurate 
representation of intake in comparison to portions which may differ in 
size.  
 Participants completed the food diary and a cognitive battery in order to 
extend upon the findings of Walters et al., (2011) and investigate the 
trend towards non-oily fish intake and MMSE score in a more controlled 
manor. 
 A MANCOVA revealed there was a significant association between non-
oily fish consumption and MMSE score. 
 Of all the non-oily fish varieties consumed a regression analysis showed 
that grams of monthly tinned tuna intake was a significant predictor of 
MMSE score in this cohort. 
 Multivariate multiple regression analysis of the MMSE’s sub domains 
showed that tinned tuna consumption was a significant predictor of 
participants’ performance on the word recall portion of the test which 
assesses short-term memory. 
 These preliminary findings are worth future study. 
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Chapter 7  
The effect of time of day on neuropsychological test 
scores in the elderly 
 
7.1 Introduction 
As previously stated in the introductory chapters of this thesis 
neuropsychological testing forms a part of the diagnostic process for the 
detection of AD and MCI (Chapman et al., 2010).  As the incidence of AD 
continues to increase it is vital that the diagnostic process is as accurate and 
reliable as possible if mild alterations in cognition are to be detected at the 
earliest possible time.   
One current issue is that many of the neuropsychological assessments used 
are influenced by a number of external factors, which if not controlled for or 
taken into consideration, may have the ability to affect the accuracy of the 
scores obtained (Overshott and Burns, 2004; Jacova et al., 2007; Forlenza et 
al., 2010; Ashford et al., 2006). Even subtle external variables may have the 
ability to affect any data obtained which may have consequences for the 
interpretation of test scores.  So far chapter five of this thesis has explored 
whether prior consumption of pure caffeine can affect cognitive performance in 
the elderly (Walters and Lesk, in prep - a; Lesk and Walters, 2012) and chapter 
six has investigated whether non oily fish, a dietary component can influence 
cognition.  There are many other variables to consider such as the participant’s 
mood (Jacova et al., 2007), their prior consumption of CCFS (i.e. tea, coffee, 
soft drinks or chocolate) (Lesk et al., 2009), and possibly any medications which 
they are prescribed (Gray et al., 1999).  This chapter will explore the effect of 
time of day (TOD) on cognitive performance in the elderly.  If the time that 
cognitive tests are administered can affect the score obtained then this has 
implications for the interpretation of data and ultimately the accuracy of a 
potential diagnosis. In addition, this chapter will also investigate whether 200mg 
of caffeine can influence the presence of TOD effects in the elderly, using the 
data from chapter five. 
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7.1.1 Peak arousal 
Across the 24 hour day there are fluctuations in cognitive performance and this 
has been linked to the influence of underlying biological circadian rhythms 
(Froy, 2011).  Circadian peak efficiency refers to the TOD that the individual is 
at their optimal arousal and this alters with age (Hasher et al., 2005) which 
impacts on the sleep-wake cycle. The elderly often report a decline in their night 
time sleep quality and quantity (Schmidt et al., 2012), a decreased sleep depth 
(Bliwise, 2005), increased reports of napping in day light hours (Blatter and 
Cajochen, 2007) and earlier sleep onset and offset times (Farajnia et al., 2013).  
These changes result in 75% of older individuals subjectively reporting that they 
would classify themselves as morning types in comparison to only 7% of 
younger adults (Yoon et al., 1999).  This tendency to prefer mornings is 
reflected in daily living tasks, for example, Yoon et al., (1999) used a simple 
questionnaire to evaluate daily living habits in both young and older adults in 
order to determine whether TOD effects were present.  They found that over 
80% of the older participants reported that they read newspapers in the morning 
compared to only 14% of the younger adults.  Likewise, over 50% of older 
adults went shopping during the morning when they were at their optimal 
arousal. Leirer et al., (1994) also reported that the elderly were more likely to 
arrange appointments and take their medications in the morning when they 
believe that they are at their most alert.   
 
7.1.2 Implications for cognitive performance 
The preference for morningness seems to begin at approximately age 50 
(Schmidt et al., 2007) and has implications for cognitive performance.  For 
example, young adults show improvements in performance during the day with 
a peak efficiency in the afternoon whereas the opposite pattern is observed in 
the elderly who experience a marked deterioration in their performance as time 
spans into the afternoon and evening (Yoon et al., 1999; May et al., 1993; May 
and Hasher, 1998; Schmidt et al., 2007; Yang et al., 2007).  The Morningess-
Eveningness Questionnaire (MEQ) (Horne and Ostberg, 1976) is a 
psychometric index of circadian rhythmicity and scores on this questionnaire 
typically correlate with the participant’s cognitive performance (Winocur and 
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Hasher, 2004).  The questionnaire consists of 19 questions and participants 
receive a score of between 19 and 86 points.  Scores are divided into five 
potential categorical outcomes which include ‘definite evening’, ‘moderate 
evening’, ‘intermediate’, ‘moderate morning’ and ‘definite morning’.  High scores 
are associated with morning types and lower scores with evening types. The 
scores obtained on this questionnaire correlate well with biological measures of 
circadian rhythmicity including body temperature (temperature increases during 
mental activity (Weinert, 2010)), sleep cycle and levels of alertness (Hasher et 
al., 2005; Tankova et al., 1994). 
May et al., (1993) administered the MEQ to 210 young adults aged between 18 
and 22 years.  They reported that only 6% of the sample were classified as 
‘moderately morning types’ and that none of the young participants were 
defined as ‘definitely morning types’.  When the authors administered the 
questionnaire to a sample of older adults, aged between 66 and 78 years, less 
than 2% of these participants were categorised as ‘evening’ types.  These 
findings suggest that there appears to be substantial shifts in arousal times 
during aging. 
Hasher et al., (1999) suggest that when the individual is able to choose at what 
time to take part in an assessment their performance is optimised; hence age 
related deficits will be more pronounced when older participants are tested at 
their non-preferred time which for the majority of these individuals is the 
afternoon (Hasher et al., 1999; Blatter and Cajochen, 2007).  Under normal 
sleep-wake patterns the young outperform the old on most cognitive domains, 
however, this is not as pronounced when the older adults are assessed at their 
chosen optimal time i.e. the morning (May and Hasher, 1998). This effect has 
been noted on assessments of word span (Yoon et al., 1999), sentence 
recognition (May et al., 1993), cued recall (May et al., 2005), story recall 
(Winocur and Hasher, 2002) and a false memory paradigm (Intons-Peterson et 
al., 1999).  The elderly tested in the morning do not perform significantly 
different from young adults also tested in the morning. For participants of any 
age, cognitive performance will be maximised when testing occurs during the 
individual’s optimal arousal period. This effect has been termed ‘the synchrony 
effect’ (Hasher et al., 2002; May et al., 1993; May and Hasher, 1998) and as 
mentioned earlier, for the majority of young adults peak arousal occurs during 
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the late afternoon and evening whereas for older adults peak arousal occurs in 
the morning (Schmidt et al., 2007). 
This synchrony effect is also seen on assessments of EF. Whilst younger adults 
generally outperform older adults at executive tasks, (Ohsugi et al., 2013; Goh 
et al., 2012) including those with an inhibitory component, (Zacks and 
Hasher,1994) these age differences can be reduced when older adults are 
tested at their preferred TOD, the morning. These findings have implications for 
neuropsychological testing and May et al., (1993) suggested that variations in 
cognitive test scores may be exaggerated if participants are tested at their non-
optimal time.  This is a consideration for the interpretation of scores on cognitive 
tests and the comparison of scores with normative data. 
The forced desynchrony paradigm has also been used to investigate TOD 
effects on cognition (Blatter and Cajochen, 2007).  This involves disrupting the 
synchrony between the sleep–wake cycle and the circadian rhythms which 
control various physiological processes within the body over a 24 hour natural 
light-dark cycle (Blatter and Cajochen, 2007; Schmidt et al., 2007). In humans 
these two processes interact so that typically individuals are awake during ‘light’ 
conditions (i.e. during the day) and asleep during the night when light levels 
decrease. Forced desynchrony of these processes can, therefore, be 
implemented by exposing an individual to an artificial sleep-wake cycle which 
can be achieved by shortening or lengthening the typical 24 hour period (Silva 
et al., 2010; Blatter and Cajochen, 2007).  Although such experiments can be 
time consuming they are useful for investigating and determining the effects of 
circadian mis-alignment on cognitive performance during aging, particularly 
whether alterations to sleep and peak arousal times affect TOD effects. Results 
from forced desynchrony experiments have shown that younger adults seem to 
be more affected by sleep loss than older adults and that sleep disturbance in 
the elderly seems to have less of an effect on cognitive performance (Silva et 
al., 2010).  
Silva et al., (2010) investigated a small sample of 10 younger and 10 older 
adults who took part in a 20 hour forced desynchrony study.  Three weeks prior 
to the study all subjects were asked to follow sleep-wake schedules consisting 
of eight hours of sleep (at their habitual times) and 16 hours of time spent 
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awake.  In the third week participants were instructed to abstain from caffeine, 
nicotine and alcohol and their compliance was checked using toxicological 
analysis.  During the study phase, after three baseline days following the 
schedule mentioned above, 20 hour forced desynchrony schedules were 
implemented.  Participants were required to spend 13.33 hours awake and 6.67 
hours asleep, resulting in ‘waking’ periods which were four hours earlier than 
normal.  This was completed for a minimum of 18 consecutive days.  For the 
duration of the study younger and older adults resided in private study rooms at 
the testing location.  The results showed that the younger adults reported 
greater feelings of sleepiness, had longer reaction times and exhibited more 
moments of lapsed attention during waking hours than the older adults. The 
authors speculate that the ability of older adults to maintain reaction times and 
sustained attention comparative to younger adults after desynchrony may be 
due to alterations in the circadian cycle with age. For example, circadian signals 
become weaker with increasing age and older adults may, therefore, be better 
able to cope with periods of sleep deprivation (Silva et al., 2010).  
 
7.1.3 TOD and cognitive domains 
Studies investigating TOD effects on cognitive performance in the elderly have 
revealed that not all cognitive processes are equally affected (Schmidt et al., 
2007). Tasks which assess EF seem to be especially vulnerable to TOD effects 
with significance reported for tasks engaging attentional and inhibitory 
processes (Hasher et al., 2007; Yang et al., 2007; Winocur and Hasher, 2004).  
The frontal lobes experience the largest decline in brain volume with age and 
are also vulnerable to fatigue (Hedden and Gabrielli, 2004; Schmidt et al., 2012; 
Blatter and Cajochen, 2007).  There are, however, substantial individual 
differences in the rates and patterns of normal brain aging which may explain to 
some extent the differences in performance seen on some tasks (Bugg et al., 
2006; Hasher et al., 2005). 
Miyake et al., (2000) suggested that EF incorporates three main processes, 
working memory, task switching and inhibitory control.  Inhibitory control links 
with attentional control and the ability to ignore distracting stimuli (Yoon et al., 
1999). Older adults often complain that they are unable to focus and maintain 
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attention for long periods of time (Brumback-Peltz et al., 2011).  Furthermore, 
they report feelings of being unable to suppress or ignore distracting stimuli 
(Hasher and Zacks, 1988).  EF tasks tend to be complex and, therefore, are 
more likely to be sensitive to sleep loss and tiredness (Blatter and Cajochen, 
2007). 
Deficits of inhibitory control are present in the elderly and in patients with AD 
(May and Hasher, 1998; Weintraub et al., 2012; Festa et al., 2010). Age related 
deterioration has been shown to be more severe when older adults were 
assessed at their non-optimal time on assessments of inhibitory efficiency 
(Yoon et al., 1999; May and Hasher, 1998). For example, West et al., (2002) 
investigated 20 young adults and 20 older adults. Ten participants from each 
age group were tested in the morning (mean age of younger adults – 25.10 
years, mean age of older adults – 72.6 years) and the remaining 10 participants 
from each group were assessed in the evening (mean age of younger adults – 
23.70 years, mean age of older adults – 72.9 years).  Performance was 
compared on a working memory task (the Four-box task) which included an 
inhibitory component.  The first portion of the task requires the participant to 
observe which of the four boxes presented on screen a stimulus (smiley face) 
will appear in.  Once the stimulus appears the participant must press the 
corresponding box on their response key pad as quickly and accurately as 
possible.  In the second part of the task an inhibitory component is introduced. 
The participant must still press which box the stimulus appears in but must also 
simultaneously ignore the box which will contain a distracter shape. The third 
stage requires the participant to remember which box the stimulus appeared in 
the previous trial (i.e. 1-back) and the fourth stage requires the 1-back 
identification of the stimulus but again a distracter is present.  
The study also used the MEQ (Horne and Ostberg, 1976) to assess 
participants’ TOD preference and measured their body temperature at varying 
intervals. Body temperature is decreased at rest and elevated when the subject 
is mentally active thereby indicating the participants level of arousal (Weinert, 
2010). Subjective alertness levels were also noted.  Consistent with previous 
research, the older adults reported a preference for mornings and this was 
matched by higher subjective ratings of alertness in the morning.  As expected 
older adults performed worse on the inhibitory portion of the task, which 
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involved ignoring a distracter and focussing on correctly determining the 
location of the visual target (i.e. the smiley face) as compared to the first stage 
of the task when no distracter shape was present, when tested in the afternoon 
(West et al., 2002).  
The investigation of TOD effects on other cognitive domains has not been 
widely investigated, however, TOD does not appear to affect tasks which utilise 
well established knowledge such as sentence completion or vocabulary (Borella 
et al., 2011; Yoon et al., 1999). Yoon et al., (1999) noted that vocabulary test 
scores in both young and older adults did not change considerably across the 
day.  This implies that retrieval of information from semantic long term stores 
seems to be spared at non-optimal times.  Yoon et al., (1999) hypothesise that 
well learned familiar items of information are not likely to be affected by TOD 
fluctuations in arousal. The characteristics of the task employed show different 
vulnerabilities to TOD effects.  For example, tasks which are longer in duration, 
have a high cognitive load and take longer to complete are more likely to be 
affected by the TOD at which they are carried out (Schmidt et al., 2007; Blatter 
and Cajochen, 2007).  The order in which tests are administered to participants 
may also influence whether TOD effects are found.  For example, participants 
may perform at their maximum on tests which are administered at the start of a 
cognitive battery but performance may decline on tests completed at the end of 
the battery due to increased mental fatigue from sustained attention on previous 
tests (van der Heijden et al., 2010). 
 
7.1.4 Caffeine and TOD effects 
Chapter five investigated whether the consumption of 200mg of pure caffeine 
consumed 40 minutes before the neuropsychological assessment could affect 
cognitive test scores in the elderly. Caffeine is a widely consumed stimulant 
found in many food stuffs such as tea, coffee, chocolate and sweets (Nehlig, 
2010). Consumers often report increased subjective energy levels and alertness 
following caffeine consumption (Lorist and Tops, 2003; Addicott and Laurienti, 
2009; Sagaspe et al., 2007).  In addition, caffeine is often used purposely to 
modulate the sleep cycle, for example, by individuals who complete shift work 
and who are required to stay awake during night time hours (Lorist and Tops, 
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2003; Samuels and Szabadi, 2008; Sagaspe et al., 2007).  Chemically caffeine 
is a methylxanthine and an antagonist for adenosine receptors in the brain 
(Cunha, 2001).  During prolonged periods of wakefulness levels of cerebral 
adenosine increase, particularly in the basal forebrain regions (Basheer et al., 
2004), until a threshold is reached and sleep is initiated.  During sleep 
adenosine levels begin to fall back to baseline and are at their lowest when the 
individual awakens (Porkka-Heiskanen and Kalinchuk, 2011). Caffeine’s ability 
to antagonise adenosine receptors prolongs wakefulness and decreases 
subjective tiredness (Cunha, 2001).  At habitual levels, (i.e. at amounts which 
are commonly consumed during a typical day, but that can vary depending on 
location and culture (Nawrot et al., 2003)) caffeine administration in humans 
acts as a neurostimulant (Addicott and Laurienti, 2009) and can antagonise the 
rise in adenosine levels seen during prolonged periods of wakefulness,.  This is 
particularly apparent in the BF and hypothalamus and counteracts sleep 
induction, prolonging the time spent awake (Basheer et al., 2004).  Tiredness in 
the afternoon may, therefore, be influenced by the administration of caffeine 
and may result in a decrease in the TOD effects noted on cognitive 
performance in the elderly.   
Previous research in the elderly has demonstrated that the prior consumption of 
varying doses of caffeine can impact on neuropsychological test performance 
(Walters and Lesk in prep - a (see chapter five of this thesis); Lesk and Walters, 
2012; Lesk et al., 2009).  Lesk et al., (2009) investigated the effects of CCFS on 
cognitive performance in a group of elderly participants.  In those participants 
who had consumed CCFS up to four hours prior to testing there were significant 
interaction effects between age and tests of processing speed, semantic 
memory, visuospatial associative memory and EF.  This was not seen for 
participants that had not consumed CCFS prior to testing.    Chapter five of this 
thesis (Walters and Lesk in prep - a) extended these findings and found 
significant interaction effects for 200mg of pure caffeine and age on tests of EF 
and processing speed, whereby the older elderly performed significantly worse 
than the younger elderly.  This effect was not seen in the placebo group.  These 
results highlighted the need to consider prior caffeine consumption when 
scoring neuropsychological tests or comparing results to normative data. With 
regards to the present chapter, because CCFS are commonly consumed to 
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relieve tiredness (Carrier et al., 2009), it is important to investigate whether 
200mg of pure caffeine, (equivalent to one strong cup of coffee as stated in 
chapter five), can interact with the TOD that tests are administered and 
subsequently affect test scores.  Should there be a significant effect, this has 
implications for the diagnosis of AD and/or MCI. This is particularly important as 
scores can determine treatment and/or inclusion/exclusion in research and 
treatment trials. 
 
7.2 The present study: research aims 
There has been a large focus on the effects of TOD on tasks of EF and 
inhibition with little literature investigating TOD effects across all cognitive 
domains or on assessments which are commonly used at the primary 
consultation such as the MMSE or the MoCA. The MMSE is currently 
recommended by NICE as one of the brief cognitive assessments to be used in 
the diagnosis of dementia (NICE, 2011). Furthermore, the score obtained on 
this assessment can be used to determine whether or not a patient is 
prescribed medication (NICE, 2011). An earlier version of the NICE dementia 
guidelines published in 2006 had recommended that treatment with AchEIs be 
discontinued if the patient’s MMSE score fell below a certain cut off point 
(<10/30 points). After heavy criticism this was amended in the latest revised 
version, published in 2011, to state that clinicians should continue to prescribe 
medication as long as the drugs were still having a benefit on the patient’s 
cognition, behaviour or quality of life (NICE, 2011). Despite these criticisms the 
MMSE remains the most widely used brief test of general cognitive ability and it 
is important to investigate the effects of external factors such as TOD on MMSE 
performance. 
This chapter will investigate TOD effects on two data sets obtained from studies 
carried out during this PhD which administered a battery of assessments taxing 
a variety of cognitive domains.  One of the data sets is that of chapter five ‘the 
effect of caffeine consumption on neuropsychological testing in the elderly’ 
which allows investigation of low doses of pure caffeine and TOD effects on the 
neuropsychological assessments administered. The second data set is that of 
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chapter six which investigated the effect of non-oily fish consumption on 
cognitive performance in the elderly via the use of a food diary. 
 
7.3 Methods 
Two data sets were investigated for TOD effects. Participants were recruited 
from the University of Bradford over-60s participant pool and gave full informed 
written consent to take part. 
Data set one (data from chapter six of this thesis) – the aim of this study was to 
determine whether monthly non-oily fish consumption, as assessed by the 
completion of a food diary influenced neuropsychological test performance in 
the elderly. The mean age of participants was 72.53 (S.D ±6.09) years and the 
mean years spent in education was 14.76 (S.D ±4.60).  The sample comprised 
11 males and 25 females. Inclusion criteria for this study specified that 
participants must be aged 60 years or over, must be cognitively healthy, i.e. 
must not possess a current diagnosis of any neurological disorder or memory 
impairment. The neuropsychological battery administered consisted of the 
MoCA, digit span forwards, Stroop test, PCS, LCS, DT, TMT and the MMSE. 
Data set two (data from chapter five of this thesis) – the aim of this study was to 
investigate the effect of 200mg of pure caffeine on neuropsychological test 
performance in the elderly using a double blind treatment vs. placebo design.  
The mean age of participants was 73.35 (S.D ±6.56) years and the mean years 
in education was 15.53 (S.D ±3.93). The sample comprised nine males and 31 
females. Inclusion criteria for this study specified that participants must be aged 
60 years or over, must not have an existing diagnosis of a memory impairment 
or neurological disease, must be regular consumers of caffeine (but not have 
more than 400mg per day). Participants must not have been advised by a 
health care professional to avoid consuming caffeine.  All participants were 
required to have abstained from CCFS 12 hours prior to attending their 
appointment and alcohol for 24 hours prior.  See chapter five for more details on 
the methodology. Neuropsychological tests administered included the MMSE, 
SDMT, Stroop Test, Word Recall, PCS, LCS, PAL, GNT, digit span and the  DT. 
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7.3.1 Materials 
Assessments 
Detailed descriptions of each cognitive assessment that was administered can 
be found in chapter four ‘Neuropsychological Testing’.  A list of the tests and the 
domains they assess are given below for reference. 
 MMSE - an assessment of general cognitive function (Folstein et al., 
1975).  
 MoCA - an assessment of general cognitive function (Nasreddine et al., 
2005). 
 Immediate Word Recall - an assessment of short-term memory created 
by the researcher.  
 CANTAB PAL - an assessment of visuo spatial associative memory 
(Égérhazi et al., 2007).  
 CANTAB GNT - an assessment of semantic memory (McKenna and 
Warrington, 1980). 
 SDMT - a timed assessment of EF (Smith, 1968). 
 Stroop Test - an assessment of EF and processing speed (Trenerry et 
al., 1989).  
 PCS and LCS - assessments of processing speed (Salthouse and 
Babcock, 1991).   
 Digit Span and Digit Score - assessments of working memory 
(Wechsler, 1981).   
 DT - a test of EF, (Baddeley et al., 1997).  
 TMT - a two part test assessing visual attention and EF (Reitan and 
Davison, 1974).  Part A assesses visual attention and Part B assesses 
EF, specifically flexibility (Ashendorf et al., 2008).    
 
7.3.2 Procedure 
Data sets from two studies were analysed for TOD effects.  TOD was not 
controlled for.  All participants completed the full battery of neuropsychological 
tests in the same order. The cognitive batteries differed slightly between data 
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sets. For data set two it must be noted that participants had abstained from 
caffeine for 12 hours prior to testing and alcohol for 24 hours prior to testing and 
were randomly divided into two groups, one group received 200mg of caffeine 
prior to the neuropsychological assessment and the second group a placebo. 
 
7.4 Results 
The aim of the study was to investigate the effect of TOD on two batteries of 
neuropsychological assessments administered to elderly participants.  
 
7.4.1 Main effects of TOD on cognitive test scores 
Data set one: 
To formally assess any influence of TOD on test scores a multivariate analysis 
of covariance (MANCOVA) with test scores as the dependent variables and 
TOD as a covariate was carried out.  Significant main effects of TOD were 
present for the PCS [F(1,33) = 4.72, p<0.05], LCS [F(1,33) = 13.51, p<0.01] and 
part A of the TMT [F(1,33) = 4.29, p<0.05].  A regression analysis revealed a 
linear decrease in performance on all of these assessments as TOD progresses 
into the afternoon.  PCS - [β = -0·35, (F(1,34) = 4·77, p <0·05), y-axis intercept  
= 32·55 with regression correlation coefficient r = 0·35, p <0·05], LCS, [β = -
0·54, (F(1,34) = 13·67, p <0·01), y-axis intercept  = 21·94 with regression 
correlation coefficient r = 0·54, p <0·01] and TMT part A, [β = 0·33, (F(1,34) = 
4·23, p <0·05), y-axis intercept  = 10·28 with regression correlation coefficient r 
= 0·33, p <0·05].  Scatter plots of these tests can be seen in figure 16.  In 
addition, a trend towards significance was found for TOD and MoCA score, p = 
0·08. 
  
148 
 
 
 
 
 
 
 
 
B 
A 
149 
 
 
 
 
Figure 16: data set one - a linear decrease in performance as time spans into the afternoon on 
assessments of A - PCS, B - LCS and C - TMT part A. Negative correlations are present for the 
PCS and LCS signifying a lower number of patterns (PCS) or letter strings (LCS) were correctly 
compared as TOD progresses.  A positive correlation is presented in part A of the TMT 
signifying that as TOD increases subjects take longer to complete the task. 
 
Data set two:  
Following the same analysis method as mentioned in the previous section, data 
set two revealed significant main effects of TOD on the MMSE [F(1,38) = 9.01, 
p<0.01] and the GNT [F(1,38) = 7.69, p<0.01]. Regression analysis revealed 
that TOD was a significant predictor of MMSE score [ β = -0.24, F(1,38) = 9·01, 
p <0·01, y-axis intercept - 31·55, with regression coefficient r = 0·44 p <0·01] 
and GNT score [ β = -0.58, F(1,38) = 7·69, p<0·01) y-axis intercept = 33·18, 
with regression coefficient r = 0·41, p <0·01] revealing a linear decrease in test 
score as TOD increases for both of these tests. See figure 17 for scatter plots of 
these results. 
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Figure 17: data set two - a linear decrease in performance as time spans into the afternoon for 
A - the MMSE and B - the GNT. Negative correlations are present signifying that scores on both 
assessments decrease as TOD progresses. 
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7.4.2 Data set two: main effects of caffeine vs. placebo and interactions 
between caffeine and cognitive test scores 
There was no significant difference in performance between the caffeine or 
placebo group on any of the assessments administered (see chapter five for 
details). To assess prior caffeine consumption and any interaction with TOD all 
cognitive tests were submitted to a MANCOVA with drug group (caffeine or 
placebo) entered as a fixed factor and TOD as a covariate. An interaction term 
was included in the model. Significant interactions between drug group, TOD 
and both MMSE [F (2, 37) = 4·78, p<0·05] and GNT [F (2, 37) = 3·96, p < 0·05] 
score were found.  Scatter plots of these interactions can be seen in figure 18. 
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Figure 18: significant interactions between caffeine/placebo, TOD and scores from data set two 
for A - the MMSE and B - the GNT.  There is a significant linear decrease in performance for 
both the caffeine and placebo group as time spans into the afternoon for both tests.  For the 
MMSE caffeine improves performance in the morning hours however a decline in performance 
is observed in the afternoon. For the GNT participants who received caffeine perform 
significantly better than those receiving placebo throughout the morning and afternoon. 
 
7.4.3 Effect of age x TOD x cognitive test scores 
Given the age x CCFS interaction effect found in Lesk et al., (2009) and the 
drug group x age interaction effects found in chapter five of this thesis, this 
section will now investigate any interaction effects of TOD and age (data set 
one) and any three-way interactions between caffeine/placebo, age and TOD 
(data set two).  
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7.4.3.1 Data set one: age x TOD interactions 
A MANCOVA with age and TOD entered as covariates and cognitive test 
scores as dependent variables was carried out.  Significant interactions with 
age, TOD and scores on the PCS [F (1, 33) = 8·22, p <0·01)], LCS [F (1, 33) = 
18.79, p <0·001] and TMT part A [F (1, 33) = 9·05, p< 0·01] were found.  A 
trend towards significance was obtained for the MoCA (p =0·07), TMT part B (p 
=0·06) and the Stroop word (p = 0·07). For all of these tests the older elderly 
perform worse than the younger elderly as TOD increases.  Interestingly, it is 
the younger elderly who experience the steepest decline in performance across 
the time of day variable in comparison with the older elderly. To graphically 
represent these interactions the median age of the participants (73.5 years) was 
used to divide the sample into ‘younger’ and ‘older’ elderly participants. See 
figure 19 for scatter plots.  
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Figure 19 – data set one - significant interactions between TOD, age and A - PCS, B - LCS and 
C – TMT part A scores.  In the PCS and LCS negative correlations are present, the younger 
elderly perform better than the older elderly as TOD progresse, however, the younger elderly 
experience a steeper decline in performance as TOD increases.  For the TMT part A a positive 
correlation is seen, the younger and elderly take longer to complete the task as TOD 
progresses however the younger elderly perform better throughout the day in comparison to the 
older elderly.  
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7.4.3.2 Data set two: age x TOD interactions 
Using the same method as mentioned previously for data set one, significant 
interactions with age, TOD and scores on the MMSE [F(1,38) = 9.97, p< 0.01], 
SDMT total responses [F(1,38) = 7.88, p<0.01], SDMT total correct responses 
[F(1,38) = 7.96, p<0.01] and GNT [F(1,38) = 10.95, p< 0.01] were found in data 
set two.  A trend towards significance was obtained for the Stroop word 
(p=0.07), Stroop Interference (p=0.07) and the DTR (p=0.08). For the MMSE 
and GNT the younger elderly perform better than the older elderly during the 
morning, however, a steeper decline in performance is seen for these 
participants in the afternoon.  For the SDMT the younger elderly perform 
significantly better than the older elderly throughout the day. To graphically 
represent these interactions the median age of the participants (73 years) was 
used to divide the sample into ‘younger’ and ‘older’ elderly participants. See 
figure 20 for scatter plots.  
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Figure 20 – data set two - significant interactions between TOD, age and A - MMSE, B - SDMT 
total responses, C - SDMT total correct responses and D - GNT.  For all these tests negative 
correlations are present whereby the younger elderly perform better than the older elderly as 
TOD progresses however both the younger and older elderly experience a decline in 
performance as TOD increases.  For the MMSE and GNT a steeper decline in performance 
occurs for the younger elderly in the afternoon.   
 
7.4.3.3 Data set two: age x TOD x caffeine/placebo 
In order to examine any interactions between caffeine/placebo, age and TOD 
on neuropsychological test scores all of the tests were submitted to a 
MANCOVA with caffeine/placebo as a fixed factor, age and TOD as covariates 
and test scores as the dependent variables.  Significant three-way interactions 
between drug group (caffeine/placebo), age and TOD were found on the MMSE 
[F(2,37)= 5·26, p <0·05], SDMT total responses [F(2,37)= 3·92, p <0·05)], 
SDMT total correct responses (i.e. total responses – errors) [F(2,37)= 3·90, p 
<0·05], LCS [F(2,37)= 3.42, p <0·05), and GNT [F(2,37)= 5·43, p < 0·01] 
revealing that the older elderly who had received caffeine, perform worse than 
D 
158 
 
the younger elderly receiving caffeine, however, caffeine in the older elderly 
maintains performance in the afternoon. Trends towards significance were 
reported for the PCS (p=0·06) and the DTR (p=0·06). In order to graphically 
represent these interactions the median age of the sample (73 years) was used 
to divide the sample into ‘younger’ and ‘older’ elderly participants. Separate 
scatter plots for each test which showed an interaction were then created and 
markers of ‘younger elderly caffeine’, ‘older elderly caffeine’, ‘younger elderly 
placebo’ and ‘older elderly placebo’ were plotted. See figure 21 for scatter plots 
of these interactions.  
 
 
 
A 
159 
 
 
 
 
 
 
B 
C 
160 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21 – data set two, significant interactions between caffeine/placebo x TOD x age and score on A – 
MMSE, B – SDMT total responses, C – SDMT total correct responses, D – LCS and E – GNT. For A – 
MMSE, in the morning older elderly participants in the caffeine condition perform worse than the younger 
elderly.  In the afternoon the younger elderly participants (caffeine condition) experience a sharp decline in 
performance whereas the older elderly exhibit only a slight decline. For B - SDMT total responses, C - total 
correct responses and E - GNT the older elderly participants who received caffeine perform significantly 
worse than the younger elderly in the caffeine condition throughout the morning and afternoon but do not 
show as steep a decline in the afternoon.  For E LCS, the older elderly (caffeine condition) perform 
significantly worse than the younger elderly in the caffeine condition throughout the morning and the 
afternoon.  
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7.5 Discussion  
7.5.1 Main findings 
The aim of this chapter was to investigate whether the TOD that elderly 
participants completed a series of neuropsychological assessments had an 
effect on the scores obtained.  Two data sets were reviewed. Analysis of data 
set one (data from chapter six of this thesis) showed a significant effect of TOD 
on two assessments of processing speed, the PCS and LCS, and one 
assessment of visual attention, the TMT part A.  A trend was observed for TOD 
and performance on the MoCA. Analysis of data set two (data from chapter five 
of this thesis) showed a significant effect of TOD for one assessment of general 
cognitive function, the MMSE, and one test of semantic memory, the GNT.  All 
of these assessments, over both data sets, showed a decrease in performance 
as TOD spanned into the afternoon.   
Regarding age, data set one revealed significant interactions between TOD, 
age and scores on the PCS, LCS and TMT part A, the same tests which 
showed an effect with TOD alone. The younger elderly experience a larger 
decline in performance as TOD progresses relative to the older elderly.  
Although there is a decline in the older elderly’s performance as TOD increases 
this is not as marked relative to the younger elderly. In data set two there were 
significant interactions between age, TOD and scores on the MMSE, SDMT and 
GNT. Furthermore, there were significant interactions between TOD, 
caffeine/placebo, and test scores for the MMSE and GNT in data set two. 
Significant three way interactions between TOD, age and caffeine/placebo were 
also found in data set two for the MMSE, SDMT total responses and total 
correct responses, LCS and GNT.  These interactions revealed that the older 
elderly who had received 200mg of caffeine, performed significantly worse than 
the younger elderly participants in the caffeine condition but that caffeine did 
seem to influence the performance of the older elderly in the afternoon.  
Furthermore, the younger elderly in the caffeine condition experienced a sharp 
decline in performance on the MMSE and GNT as time spanned into the 
afternoon, an effect which was not seen for the older elderly 
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7.5.2 TOD and general cognitive ability 
For data set two participants completing the MMSE in the afternoon performed 
significantly worse than those participants taking the assessment in the 
morning. The mean MMSE score for participants completing the test in the 
morning was 28.89 whereas the mean MMSE score for participants taking the 
test in the afternoon was 28.29.  Although this is only a small difference this 
may be of significant consequence for participants who score on the borderline 
of an abnormal score.  A thorough literature review has shown, that to my 
knowledge, there are no previous studies which have specifically investigated 
TOD effects for brief tests of general cognitive ability such as the MMSE and 
the MoCA. As stated in chapter four the MMSE is comprised of 11 questions 
and was designed to tax a variety of cognitive domains including orientation, 
naming, short term memory, sentence generation, instruction and spatial 
copying (Folstein et al., 1975).  The MMSE is currently one of the 
recommended brief cognitive tests by the NICE dementia guidelines which were 
updated in 2011 (NICE, 2011).  The MMSE is, therefore, widely used in the GP 
and hospital setting as a tool for dementia diagnosis and the score obtained on 
this test is considered when determining whether pharmacological intervention 
with AchEI drugs is to be initiated (NICE, 2011).  The test is no longer used to 
provide  cut off scores for the withdrawal of drug treatment.  
It is important that MMSE score is accurate and reliable.  Previous research has  
highlighted potential problems with this test as it is not sensitive for the 
detection of mild degrees of cognitive impairment (Mitchell, 2009; Tombaugh 
and McIntyre, 1992, Markwick et al., 2012; Jacova et al., 2007) and should not 
be used alone to diagnose MCI (Tombaugh and McIntyre, 1992).  For example, 
in a group of patients who converted to AD within a 30 month follow up period 
baseline MMSE scores showed large variations of between 23-28/30 (Blackwell 
et al., 2004).  This creates a conflict between measurable cognitive ability and 
underlying evidence of disease.  Participants who obtained high scores i.e. 
28/30 would have been classified as ‘no impairment’ and this ‘label’ would not 
have correlated with underlying pathological signs of disease. As a 
consequence it has been suggested that the MMSE should be used to rule out 
suspected dementia and AD (Mitchell, 2009).  
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In data set one a trend towards significance was noted for TOD and the MoCA 
whereby there was a linear decrease in performance as time spanned into the 
afternoon (p=0.08). The mean score on the MoCA for participants completing 
the test in the morning was 28.08 whereas the mean score for participants 
taking the MoCA in the afternoon was 27.26.  The MoCA was not administered 
to participants in data set two. The MoCA, like the MMSE, is a brief test of 
general cognitive ability taxing multiple cognitive domains on a 30 point scale 
(Nasreddine et al., 2005; Jacova et al., 2007). Previously the MoCA has shown 
good internal consistency, test retest reliability and was able to correctly identify 
90% of a sample of 94 MCI participants (Nasreddine et al., 2005). The MoCA is 
considered to be a superior choice to the MMSE for its ability to detect mild 
degrees of cognitive impairment (Nasreddine et al., 2005, Jacova et al., 2007; 
Dong et al., 2012; Larner, 2012).  Further study should employ the MoCA with a 
larger sample of participants to potentially obtain significance with TOD. 
 
7.5.3 TOD and semantic knowledge 
In the present paper, for data set two, a significant effect of TOD was noted on 
the GNT whereby participants who completed the assessment in the afternoon 
scored lower than those completing the test in the morning.  The mean score for 
participants completing the GNT in the morning was 27.21 whereas the mean 
score for those completing the test in the afternoon was 24.86.  Previous 
research has failed to find significant effects of TOD on assessments of 
semantic knowledge (May and Hasher, 1998), however, the findings of the 
present chapter contradict this. This may be because all of the participants in 
this data set had abstained from CCFS for twelve hours prior to testing and 
some of the participants had then consumed 200mg of prior caffeine which may 
have influenced TOD affects on GNT performance.   
The GNT has previously been shown to be sensitive to the detection of mild 
degrees of cognitive impairment and early AD (Blackwell et al., 2004, Lonie et 
al., 2008).  As previously mentioned earlier in this thesis, Blackwell et al., (2004) 
used GNT score in an algorithm created from their data.  Using a regression 
analysis the number of errors made at the six pattern stage of the CANTAB 
PAL, the score obtained on the GNT and the participant’s age at the time of 
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testing could identify converters to AD with 100% accuracy within a 32 month 
period using a sample of 40 patients. The significant effect of TOD on GNT 
score in the present chapter demonstrates that caution should be applied when 
using such algorithms which have not considered additional external factors 
such as TOD or prior caffeine consumption.  The GNT was not administered to 
participants in data set one and, therefore, comparisons between the two data 
sets are not possible.   
 
7.5.4 TOD and processing speed 
Data set one revealed significant TOD effects for two assessments of 
processing speed, the PCS and LCS. The mean PCS and LCS scores for 
participants tested in the morning were 25.77 and 15.92 respectively and for 
participants completing the tests in the afternoon the mean scores were PCS - 
22.83 and LCS - 13.70.  A linear decrease in performance was noted for both 
assessments as TOD spanned into the afternoon. As far as I am aware there 
are no other studies which have specifically investigated the effects of TOD on 
these cognitive tests in the elderly.  
Processing speed relies on attention mechanisms and frontal functioning, 
therefore, it would be expected that this domain would be susceptible to 
tiredness and TOD effects.  Previous research has shown that sleep loss and 
tiredness have a negative effect on performance for tasks which recruit the PFC 
(Blatter and Cajochen, 2007; Drummond et al., 2001). When completing these 
two assessments the participant must actively ignore the patterns (PCS) and 
letter strings (LCS) above and below the item they are answering in order to 
complete as many pairs as possible (Lustig et al., 2006).  Lustig et al., (2006) 
investigated this consideration by creating a computerized version of the LCS.  
Older and younger adults who took part were randomly assigned to two 
experimental conditions, high distractibility or low distractibility.  In the high 
distraction condition participants viewed two columns of 12 letter strings on a 
standard PC monitor; in the low distraction condition participants viewed each 
letter string separately as it appeared alone in the centre of the screen.  The 
authors reported over a 15% reduction in processing speed in the high 
distraction condition which they attribute to the inability of the older adults to 
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ignore distracting irrelevant information (i.e. the letters above and below) which 
slows their processing speed. Those tested in the afternoon may find this 
inhibition difficult if they are experiencing feelings of tiredness.  Inhibition is a 
component of EF and previous studies have noted TOD effects on inhibitory 
tasks in the elderly (Schmidt et al., 2007) which  is discussed further in the next 
section. 
 
7.5.5 TOD and EF 
Much of the previous literature investigating TOD effects in the elderly has 
noted significant effects for tasks of EF.  The elderly perform significantly worse 
on these types of assessments in the afternoon and evening relative to when 
tested in the morning (Zacks and Hasher, 1994; Hasher et al., 2007). For 
example, May et al., (1993) reported a significant deterioration in the afternoon 
for older adults completing a simple problem solving task.  TOD effects have 
mostly been found for those EF tasks which have an inhibitory component, i.e. 
those tests which require the participant to ignore or tune out distracting or 
irrelevant stimuli (Winocur and Hasher, 2004).  Intons-Peterson et al., (1999) 
and West et al., (2002) have also reported TOD effects on inhibitory tasks in the 
elderly. The present chapter failed to find TOD effects on assessments of EF in 
either data set one or two. Specifically, there were no effects of TOD on the DT, 
Stroop interference or TMT part B in data set one or the SDMT, Stroop 
Interference and DT in data set two. The discrepancy between the present 
study and the previous literature regarding TOD effects on EF tasks is 
interesting.  In data set two participants had abstained from caffeine for 12 
hours prior to testing and may then have randomly been allocated to the 
caffeine condition where they then received a further 200mg of caffeine.  The 
absence of TOD effects on EF tasks in data set two may, therefore, be due to 
the presence of caffeine.  Caffeine may influence inhibition and other 
components of EF during fatigue in the afternoon.  The absence of TOD effects 
in data set one where caffeine was not controlled for may also be due to the 
consumption of CCFS prior to the participant’s arrival at the University.   
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7.5.6 Interactions between TOD and age on test scores 
The interactions between age, TOD and scores on the PCS, LCS, and TMT part 
A in data set one and the MMSE, SDMT and GNT in data set two, revealed that 
the older elderly performed significantly worse than the younger elderly as TOD 
increases.  Importantly the younger elderly experience a steeper decline in 
performance as TOD increases, however, the exaxt reasons as to why this 
occurs are not known.  With increasing age there is likely to be a larger effect of 
TOD due to circadian alterations in the hypothalamic supra chiasmatic nuclei 
(SCN) and other brain areas expressing clock genes (Schmidt et al., 2007; 
2012) (see section 7.4.7 of this discussion for more detail). During healthy aging 
there is a large variability in the rate at which brain tissue degenerates (Bugg 
and Head, 2011) and this may explain some of the intra individual variation in 
cognitive performance with age. For example, alterations in brain volume during 
normal aging are dependent on a number of factors such as educational level 
(Ho et al., 2011), physical activity (Bugg and Head, 2011), smoking status 
(Durazzo et al., 2012), HCy levels (Jochemsen et al., 2013), high cholesterol 
(Enzinger et al., 2005), alcohol consumption (Enzinger et al., 2005) the 
presence of co-morbid medical conditions including depression (Geerlings et 
al., 2012) or diabetes (Enzinger et al., 2005), cognitive activity (Ruthirakuhen et 
al., 2012) and genetics (e.g APOE allele, Honea et al., 2009).  All of these 
factors could, therefore, subsequently affect the rate at which brain volume 
declines with increasing age and potentially create slight variations in cognitive 
performance in the HE at different times of day.   
 
7.5.7 Caffeine and TOD interactions 
The second aim of this chapter was to investigate whether caffeine, a 
commonly consumed stimulant present in a variety of foods (Nehlig, 2010), 
interacted with the TOD that assessments were delivered to affect overall test 
scores. Caffeine consumption (e.g. in the form of CCFS) is often used to relieve 
feelings of tiredness and increase levels of alertness (Sharwood et al., 2013; 
Salín-Pascual et al., 2006; Wright et al., 2013).  Caffeine could, therefore, have 
the potential to influence TOD affects on cognitive performance and perhaps 
affect performance in the afternoon.  In data set two (data from chapter five of 
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this thesis), significant interactions were found between TOD, caffeine, and 
participants’ MMSE and GNT scores. 
Those participants who had consumed 200mg of pure caffeine 40 minutes prior 
to the completion of the MMSE in the morning performed better than those who 
received placebo.  In the afternoon a linear decrease in performance was 
observed for both subgroups.  However, those participants who received 
caffeine performed worse as time spanned later into the afternoon (at 
approximately time 14.00 hours). The fact that the presence of 200mg of 
caffeine (which is the equivalent to one medium filter coffee (Starbucks, 2011)) 
was able to affect performance and interact with the time that tests were 
completed further indicates the importance of controlling for, or at least noting, 
the presence of external variables such as CCFS and TOD. For the GNT, an 
assessment of semantic memory (McKenna and Warrington,1980), both the 
caffeine and placebo group show a linear decrease in performance with time.  
However, the caffeine sub-group perform significantly better suggesting that 
caffeine may decrease TOD effects on certain tests depending on the testing 
domain.   
Chemically caffeine is a methyxanthine (Cunha, 2001) and these compounds 
are known to alter the circadian rhythm resulting in a phase shift or delaying 
effect which then impacts on the sleep-wake cycle (Miller et al., 1995).  Mitchell 
and Redman (1992) noted that caffeine was able to improve performance on a 
visual serial search task but only for participants completing the assessment in 
the morning.  Although the data sets analysed in the current chapter did not use 
a visual search assessment as a part of the cognitive battery delivered, 
participants in the caffeine condition did perform better on the MMSE and GNT 
in the morning. Another consideration is that there may be circadian variations 
in the rate of absorption of pharmacological substances, such as caffeine, and 
that this may alter at different times of the day (Miller et al., 1995; De Giorgi et 
al., 2013). Should this be the case, participants who received caffeine in the 
afternoon may show a differential effect from those who received caffeine in the 
morning but it remains unclear how this would impact on the results obtained in 
this chapter.   
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Three way interactions between caffeine, age and TOD were investigated and 
plotted in figure 21.  Due to the small sample size of this cohort and the 
subsequent division of participants into categories to graphically represent the 
interactions, firm conclusions of the effect of caffeine and age across the time of 
day variable can not be accurately determined. Interestingly, the younger 
elderly experience a performance enhancement from caffeine in the morning 
hours on the MMSE and GNT.  However, a steep decline in their performance is 
noted in the afternoon, an effect which is not seen for the older elderly in the 
caffeine condition.  A speculative reason as to the interactions between age and 
caffeine may be due to alterations in adenosine receptor expression with age 
(Cunha, 2001), whereby there may be changes in the degree of adenosine 
antagonism that caffeine can induce. This is speculative and more research is 
needed to clarify this. Given that the consumption of caffeine, even at low doses 
can influence feelings of tiredness and levels of alertness (Wright et al., 2013, 
Nehlig, 2010) it would be expected that caffeine consumption in the afternoon 
may influence the individuals susceptibility to TOD effects.  Further study will 
aim to extend upon these preliminary findings. The recruitment of additional 
participants will allow a more thorough investigation of these three way 
interactions and will increase the number of participants present in each 
category. 
 
7.5.8 Underlying cerebral mechanisms: circadian rhythms and TOD 
As mentioned briefly in the introduction of this chapter, TOD effects on cognitive 
performance can be linked to underlying biological circadian rhythms (Froy, 
2011). Circadian rhythms are 24 hour cyclical processes (Hasher et al., 2005) 
controlled by complex cellular mechanisms originating in the SCN (Froy, 2011; 
van der Heijden et al., 2010), commonly referred to as the central ‘pacemaker’ 
(Gritton et al., 2013).  A number of other brain areas have also been found to 
express ‘clock’ genes which are protein transcripts that are activated by 
downstream messengers of the master clock (the SCN) and are linked to 
functions associated with timing e.g. body temperature, hormone secretion, 
sleep cycle amongst others (Froy et al., 2011). Clock gene expression has been 
found in the PFC, amygdala, ventral tegmental area, hippocampus and striatum 
(Wright et al., 2012) suggesting that functions associated with timing and 
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alertness involve a coordinated response from multiple brain areas. Whilst 
circadian rhythms have been found to influence numerous bodily processes 
such as temperature (Schmidt et al., 2007), eating behaviours (Froy, 2007), 
cardiovascular activity (Yang, 2010), sleep (Schmidt et al., 2007) and hormonal 
secretions (e.g. Kennaway et al., 2012), they are also present in human 
cognitive functioning (Schmidt et al., 2007; Froy, 2011; van der Heijden et al., 
2010; Wright et al., 2012). This creates variations in cognitive performance 
depending on the TOD that cognitive assessments are administered (Hasher et 
al., 2007). Disruptions to the circadian clock are common during aging (Froy, 
2011; Tranah et al., 2011) and circadian disturbances and SCN alterations are 
seen in AD patients (Volicer et al., 2001) leading to disturbances in the sleep-
wake cycle.  This is often a common reason for the decision to move the patient 
to nursing home facilities (Satlin et al., 1995, Tranah et al., 2011).   
Increasing age is associated with neuronal changes in the SCN (Hofman and 
Swaab, 2006; Farajnia et al., 2013) as well as alterations in the 
electrophysiology and neurochemical activity of neurons within this area (Froy, 
2011). This results in a decreased number of neuronal projections to the frontal 
cortex and hippocampal areas (Samuels and Szabadi, 2008) and alters 
synaptic density, affecting overall cognitive performance (Usher et al., 1999). 
Disruptions between the SCN and other areas of the brain involved in circadian 
rhythms may, therefore, contribute to alterations in cognitive function and may 
explain the larger TOD effects noted on the performance of older adults and the 
cognitive difficulties of AD patients (Cermakian et al., 2011).  
Melatonin is a hormone produced by the pineal gland during darkness and 
influences the time of sleep onset (Wu and Swaab, 2007). Alterations in 
melatonin secretion occur during aging and recently a decrease in CSF 
melatonin levels have been found in AD patients (Pandi-Perumal et al., 2012) 
and in individuals with MCI (Cardinali et al., 2012). This suggests that early 
circadian disruption may be an important marker for evidence of cognitive 
impairment (Cardinali et al., 2012).  Furthermore, melatonin decreases have 
been recorded before cognitive symptoms manifest but it is still unclear whether 
this decline in production is a result of, or a cause of, the neurodegeneration 
seen in AD (Zhou et al., 2003).  
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Cardinali et al., (2012) administered 3-24mg of fast release melatonin to 61 MCI 
participants in combination with their other medication (this varied between 
participants but consisted of AchEIs and antidepressant drugs). Melatonin was 
administered prior to bed time for a period of 15-60 months. A further 35 MCI 
participants acted as controls and did not receive melatonin treatment.  After the 
follow up period, those participants in the treatment group exhibited better 
performance on all tests within a neuropsychological battery which included the 
MMSE and TMT, suggesting that melatonin may be useful as an add on 
treatment for cognitive impairment. Concentrations of melatonin may influence 
sleep quality and quantity in the elderly which may then subsequently influence 
peak arousal times and the individuals susceptibility to TOD affects on cognitive 
tasks. In the HE weakened circadian activity is also linked to a higher risk of 
mortality (Paudel et al., 2010).  Tranah et al., (2011) showed that in a large 
sample of 1282 women, alterations to the circadian clock, specifically a 
weakened circadian rhythm, were consistently related to the subsequent 
development of MCI and dementia after 2-4 years of follow up. Even though this 
is beyond the scope of this thesis it highlights potential neurobiological 
underpinnings that in the future may lead to potential explanations of the results 
central to this chapter.  
Although melatonin is a factor which contributes to the elderly having earlier 
habitual sleep onset times and the tendency to be easily disturbed during their 
sleep (Froy, 2011) there are other factors which may influence sleep patterns 
and arousal levels in older adults.  These may include levels of exercise, diet, 
stress, presence of co-morbid disorders such as depression, amongst others 
which may be important considerations when calculating and determining peak 
arousal times and the individual’s likelihood of demonstrating a change in 
performance with TOD.  
 
7.5.9 Methodological considerations 
This chapter has only investigated the effect of TOD on cognitive test scores.  
Participants were not asked about their TOD preference, level of subjective 
tiredness, sleep patterns or the number of hours of sleep they obtained the 
night before testing.  The study did not, therefore, take into consideration 
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participants’ peak arousal time and this is important for future study.  Although 
significant TOD effects have been noted it is important to consider other 
variables which impact on an individual’s need for sleep or their levels of 
tiredness.  For example, amounts of daily exercise (Bugg et al., 2006), dietary 
patterns (Peuhkuri et al., 2012), medication use (Pagel, 2013), caffeine 
consumption (Porkka-Heiskanen and Kalinchuk, 2011) and stress levels 
(Meerlo et al., 2008). All of these factors have the ability to alter or mask the 
underlying circadian variations in cognitive performance and should ideally be 
controlled for to determine true TOD effects.  Physical activity has been shown 
to maintain performance on tasks of EF in the elderly (Bugg et al., 2006).  
Improved cardiovascular fitness is able to increase the amount of blood flow to 
the frontal and prefrontal cortices, delaying age related deficits seen on 
executive tasks.  Previously, physical activity has been shown to delay or 
prevent cognitive decline (Albert et al., 1995; Yaffe et al., 2001; Laurin et al., 
2001).  TOD effects may be modulated by mental fatigue, and Bugg et al., 
(2006) hypothesised that mental fatigue in the afternoon may be modulated by 
cardiovascular fitness.  In their study the sedentary elderly experienced a 
significant decline in working memory in the afternoon hours relative to the more 
active elderly who performed similarly throughout the day (Bugg et al., 2006).  
Analysis of the two data sets in this chapter did not show consistent TOD 
effects for certain tests.  For example, TOD effects on the MMSE were only 
noted in data set two and not data set one.  Likewise, significant TOD effects 
were noted for the PCS and LCS in data set one and not data in set two.    This 
is most likely because in data set two participants had been asked to abstain 
from CCFS 12 hours prior to the assessment, this was not the case for 
participants in data set one.  This is also why the data sets were analysed 
separately, i.e. that caffeine is known to have a striking influence on tiredness 
(Basheer et al., 2004) and also highlights the importance of taking self report 
measurements of tiredness/alertness into account.  
 
7.6 Conclusion and summary 
From the present data within this chapter and the previous literature in this area 
it is apparent that there are TOD effects on some neuropsychological test 
172 
 
scores depending on the nature of the task and the type of cognitive domain it 
assesses.  This is an important consideration for the accuracy of cognitive test 
scores which, as mentioned in previous chapters have the potential to be 
affected by external factors. Despite this scores are often used to decide 
diagnosis, treatment, care, research inclusion and comparisons with normative 
data.  Furthermore, the significant interactions between TOD, caffeine and 
MMSE and GNT score in the present study also highlight the need to take 
participants prior caffeine consumption and its interaction with TOD into 
consideration.   
The data sets reviewed in this chapter did not ask participants about their sleep 
patterns or subjective feelings of tiredness, therefore, peak arousal times were 
not calculated.  Significant TOD effects for assessments of general cognitive 
function, i.e. the MMSE and the MoCA (trending) have implications for the 
diagnosis of dementia in the UK as the MMSE is one of the most widely used 
instruments recommended by the NICE dementia guidelines (NICE, 2011).   
The TOD effects obtained in this chapter have practical and theoretical 
considerations for clinicians and neuropsychologists who may use cognitive 
assessments as a part of their diagnostic outcomes or research along with the 
wider field of experimental psychology and cognitive neuroscience.  This is 
important if scores are compared to population norms which may not have 
considered TOD.  Likewise, for those scores which are to be used to determine 
whether an individual is to be included in a research trial or treatment 
intervention.  Wherever possible clinicians and neuropsychologists should aim 
to deliver cognitive assessments at the individual’s peak arousal time to avoid 
or minimise any effects of TOD. For the majority of elderly individuals this 
typically occurs during the morning.  
 
7.7 Chapter summary of key points 
 The time that cognitive tests are delivered may influence the participant’s 
performance. 
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 Circadian rhythms control multiple bodily processes across the 24 hour 
day and give rise to peak efficiency periods. This is the time when the 
individual is maximally aroused and this alters with age. 
 For older adults peak arousal occurs in the morning, as a result older 
adults tested in the afternoon may perform differently as to when 
assessed in the morning. 
 Caffeine may also influence the presence of TOD affects as it is 
commonly used to relieve feelings of tiredness. 
 This chapter explored two sets of data obtained from this thesis to 
determine the presence of TOD effects. The chapter also aimed to 
investigate any interactions between caffeine and TOD from the data 
obtained in chapter five of this thesis.  
 Main effects of TOD day were found in data set one (data from chapter 
seven) on the PCS, LCS and TMT part A.  
 Main effects of TOD were found for the MMSE and GNT in data set two 
(data from chapter five).  
 Across both data sets performance on these tests decreased as TOD 
progressed.  
 In data set two there were significant interactions between caffeine, TOD 
and performance on the GNT and MMSE.  Significant three way 
interactions were also noted in data set two for age x TOD x caffeine x 
score on the MMSE, SDMT, LCS and GNT.  
 The findings have shown that TOD is a factor which influences 
performance on some cognitive tests depending on the cognitive domain 
assessed. 
 Significant interactions between caffeine and TOD highlight the need to 
control prior caffeine intake when interpreting neuropsychological data.  
 The results of this chapter have implications for psychological research 
which may use scores to determine outcomes or further research 
inclusion. 
Some of the information within this chapter can be found in Walters and Lesk (in 
prep - b) ‘The effect of TOD on cognitive performance in the over 60s’. 
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Chapter 8 
Evaluating a new virtual reality based test of spatial 
route learning for the early detection of cognitive 
impairment 
 
8.1 Introduction 
The previous experimental chapters of this thesis have explored factors which 
may affect neuropsychological testing in the elderly and in particular whether 
these factors can influence the scores obtained.  This is important as cognitive 
test scores may be used to detect early cognitive impairment and may, 
therefore, have implications for the early detection of AD.  In order for an early 
diagnosis to be possible the assessments and tools used by clinicians must be 
sensitive to the earliest of cognitive changes (Mapstone et al., 2003).  The 
cognitive domain the task targets is an important factor to consider when 
detecting such alterations in cognitive function as certain areas of the brain 
experience larger volumetric declines and increased AD related pathology in the 
earliest stages of the disease‘s trajectory.  
Tests which stimulate these areas are more likely to identify early impairments if 
the underlying area is already compromised.  Any assessments that are used 
must also be able to accurately discriminate between participant sub-groups i.e. 
whether the participant has AD, MCI, another form of dementia or whether they 
are cognitively ‘normal’.  The symptoms the patient presents with often involve a 
number of cognitive, behavioural and social complaints.  This, accompanied by 
the fact that many other forms of dementia such as vascular dementia, 
frontotemporal dementia and semantic dementia, present with similar initial 
symptoms makes an accurate diagnosis challenging in the early stages 
(Karantzoulis and Galvin, 2011).  This chapter investigates and evaluates a 
newly created assessment of spatial route learning as a possible novel tool for 
the accurate, early detection of AD.   
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8.1.1 Spatial memory 
Research studies sampling participants with MCI (i.e. those who do not fully 
meet the criteria for AD) have revealed an elevated volumetric decline in the EC 
of the hippocampus (Blackwell et al., 2004).  This area is crucial for memory 
function (Feczko et al., 2009) and navigation (Laczó et al., 2009) and has been 
implicated in early AD in a number of research studies including Shen et al., 
(2011) and Gómez-Isla et al., (1996).  Developments and improvements in 
imaging techniques have improved the accuracy of imaging MTL structures and 
as a result these volumetric data can identify anatomical change in the earliest 
stages of AD (Pruessner et al., 2002).  In addition to a decline in EC volume the 
earliest signs of the presence of pathological markers are also found in this area 
in the form of NFTs (Braak and Braak, 1991; de Calignon et al., 2012).  As 
mentioned in chapter two the fact that these individuals present with 
pathological biological markers which are hallmarks of AD suggests they are, in 
fact, in a prodromal early stage of the disease.   
Lesion studies and imaging studies carried out in combination have found the 
EC to be highly sensitive to tests stimulating visuospatial associative memory 
(Smith and Milner, 1981; Owen et al., 1996).  This type of memory typically 
involves learning the association between a visual stimulus and a distinct spatial 
location and is recruited in navigational tasks such as remembering routes 
(Tippett et al., 2009).  An example of an existing test which recruits this type of 
memory is the CANTAB PAL (Blackwell et al., 2004) which requires the 
participant to learn an association between a visual stimulus and a spatial 
location (Égérhazi et al., 2007) (see chapter four ‘Neuropsychological Testing’).  
The number of errors made at the six pattern stage of the PAL has been shown 
to be highly sensitive to MCI and early AD (Blackwell et al., 2004).  
Performance at this level significantly correlates with the subsequent 
deterioration in global cognitive function over the following eight months 
(Swainson et al., 2001).  This suggests that spatial associative tasks may be 
sensitive to the earliest degeneration occurring in AD (Laczó et al., 2009).   
Some of the earliest studies of spatial memory were investigated using rodents.  
The Morris Water task (MWT) (Morris et al., 1982) is one of the most influential 
and will be discussed as it is a useful model applicable to AD. The MWT was 
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developed by Morris and colleagues in 1982 as a task which relates 
hippocampal functioning, aging and spatial learning (Morris et al., 1982, Lithfous 
et al., 2013).  The task requires the animal to successfully locate a raised 
escape platform in an opaque water pool.  Once the animal has learnt the 
location of the platform they are then much faster at reaching the platform on 
their subsequent applications to the tank.  Aged rats are impaired at this task 
(Foster, 2012; D’Hooge and De Deyn, 2001) and animals with a hippocampal 
lesion show an even greater impairment (Foster, 1999).  Aged rats took longer 
to locate the escape platform, travelled longer distances before finding the 
platform and required a greater number of trials to successfully complete the 
task (Lithfous et al., 2013). 
Genetic AD mouse models have also demonstrated deficits in spatial memory 
and navigational ability on these types of task (Foster, 2012).  The TgCRND8 
mice, which possess amyloid induced synaptic dysfunction resulting in the 
expression of an APP variant linked to AD and plaque deposition (Chishti et al., 
2001), perform poorly in comparison to control mice on the Barnes maze (an 
alternative to the MWT) (Lithfous et al., 2013).  The Barnes maze, like the 
MWT, assesses spatial learning and memory (Barnes et al., 1980).  The animal 
is required to locate a lower darkened chamber beneath a bright open platform 
via one of 18 holes (Sunyer et al., 2007).  These findings have suggested that 
the presence of AD pathology impairs the animals’ ability to learn new spatial 
scenarios. 
 
8.1.2 Brain structures involved in spatial memory and navigation 
The hippocampus is crucial for visuo associative spatial memory and successful 
navigation through the environment (Burgess et al., 2002; Lithfous et al., 2013).  
The cognitive map theory by O’Keefe and Nadel (1978) proposed that in 
rodents the hippocampus is composed of specific ‘place cells’ which collate to 
form a cognitive map.  Landmarks or environmental cues caused the activation 
of certain ‘place cells’ within the cognitive map and a similar system is believed 
to be present in humans (Knierim et al., 1995; Laczó et al., 2009).  
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The processing of spatial stimuli is further sub-divided into allocentric and 
egocentric processing (Burgess et al., 2002).  Egocentric processing occurs 
when spatial information is collated with the individual at the centre and this 
type of processing involves the parietal cortex (O’Keefe and Nadel, 1978). 
Allocentric processing on the other hand occurs via an environment driven 
framework supported by the hippocampus (Burgess et al., 2002).  An important 
consideration of spatial processing, which appears to affect the specific brain 
structures recruited, is the difference between 2-dimensional (2D) and 3-
dimensional (3D) images or environments (Burgess et al., 2002).  This has 
implications for carrying out spatial tasks.  For example, a participant with a 
spatial impairment, who may be disorientated when taking a novel route, may 
still perform normally on an assessment of table top object locations (Burgess et 
al., 2002).  2D spatial assessments activate the right parahippocampal gyrus 
and lesions to this area impair performance (Bohbot et al., 1998), whereas 3D 
environments activate a separate region of the hippocampus (Burgess et al., 
2002). 
In order to specifically investigate which brain areas and pathways are involved 
during spatial route learning tasks Maguire et al., (1998) created a 3D virtual 
environment of a town and asked the participant to manoeuvre along several 
routes whilst undergoing PET imaging.  During successful navigation of the 
area there was significant right parahippocampal and hippocampal activation. 
The participant’s accuracy correlated with right hippocampal and right 
inferiopareital cortex activation.  The speed at which the participant navigated 
through the virtual town correlated with the degree of caudate activation and 
PFC activation occurred when participants took a ‘detour’ which the authors 
suggest helped with the planning and organising of a new unfamiliar route 
(Maguire et al., 1998).   
When the same experiment was performed by brain damaged patients, those 
with right temporal lobectomy were significantly impaired whereas those with a 
left temporal lobectomy performed intermediately between controls and right 
lobectomy patients (Spiers et al., 2001).  The results of these experiments 
support the role of the right hippocampus and parahippocampus in successful 
navigation and route learning. 
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8.1.3 Aging and spatial navigation 
Alterations to the brain structures involved in route learning occur during aging 
and this may impair successful navigation (Raz et al., 2004). Data from previous 
research has shown that the elderly report self-perceived deficits in their 
navigational abilities (Cushman et al., 2008) which may lead to this cohort 
avoiding new routes or places which are unfamiliar to them.  A review of studies 
which have recruited HE participants by Klencklen et al., (2012) revealed that 
older adults are significantly worse in comparison to younger adults at 
navigational tasks.  Jansen et al., (2010) and Rodgers et al., (2010). Jansen et 
al., (2010) investigated spatial knowledge acquisition in young (20-30 years), 
middle aged (40-50 years) and older (60-70 years) adults via the use of a virtual 
reality (VR) environment.  Participants were required to learn a specified route, 
recall the presence of certain landmarks and were then asked to draw the route 
using a pen and paper.  The results revealed that the elderly participants took 
longer to learn the route, were worse at recalling landmarks and made more 
errors when attempting to draw the specified route. 
Rodgers et al., (2010) evaluated a new spatial test based on the Barnes maze 
which was initially designed to test spatial ability in mice (Barnes et al., 1980) 
(see section 8.1.1 for more detail).  Their sample included 45 community 
dwelling older adults aged between 55-85 years and 54 younger adults aged 
18-35 years.  They reported that the older adults were slower at completing the 
task and used a different strategy to the younger adults, whereby they preferred 
to rely upon on egocentric route learning which relies upon route cues.  
Navigational deficits become particularly striking when the elderly are tested in 
new unfamiliar environments (Devlin, 2001).  Clinically relevant deficits in 
spatial memory and route learning have been implicated in the early stages of 
dementia (Klein et al., 1999) leading to reports of wandering in these patients 
(McShane et al., 1998).   
 
8.1.4 Navigation in AD and MCI 
Navigational deficits are more pronounced in AD patients (Lithfous et al., 2013) 
but similar deficits are also present in individuals with a MCI (Cushman et al., 
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2008). Since navigational and spatial deficits are present in MCI, which is 
believed to be a prodromal state of AD (Petersen et al., 1999), testing this 
particular memory domain could improve the earlier diagnosis of AD.  
Furthermore, those MCI participants with navigational difficulties seem to be at 
an elevated risk of conversion to an AD diagnosis (Laczó et al., 2011) 
compared with MCI participants with intact spatial memory. This has important 
implications for the treatment and subsequent monitoring of these individuals.   
Topographical disorientation (TD) refers to problems orientating oneself to the 
surrounding environment (Barrash et al., 2000) and produces difficulties 
navigating to specific locations and recalling routes (Barrash et al., 2000). TD is 
a common problem in AD resulting in many patients becoming lost or unsure of 
their surroundings (Cherrier et al, 2001; Lithfous et al., 2013; Serino and Riva, 
2013). TD may be due to a failure of the brain areas involved in the encoding of 
spatial layouts or may reflect a more general deficit in spatial processing 
(Cherrier et al., 2001).   Barrash et al., (2000) comment that TD results when 
the integrity of the inferior medial occipital, occipitotemporal cortices or the right 
medial temporal areas are compromised either by lesions or the aging process.  
Research studies using AD patients have linked TD with other measures of 
neuropsychological assessment suggesting that numerous brain areas 
contribute to the manifestation of TD symptoms.  For example, Henderson et 
al., (1989) investigated a group of 28 probable AD patients whose carers had 
stated that they became lost on a regular basis.  Using a regression analysis 
this study showed that memory performance but not attention, language or 
disease severity was a significant predictor of spatial disorientation. 
Passini et al., (1995) investigated navigational ability in a large hospital setting 
with 14 mild to moderate AD patients and 28 HE controls.  All of the AD patients 
failed to navigate to a set location without making errors, the participants were 
recorded along their route and AD patients showed impaired problem solving 
abilities. 
TD could also be linked to problems with optic flow.  Optic flow provides a 
moving individual with information on the stimuli surrounding them.  It also aids 
their navigation and orientation through their environment (Duffy, 2009). 
Tetewsky and Duffy (1999) and Duffy (2009) report that there is significant 
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impairment in measurements of optic flow in AD patients. This implys that there 
may be deficits in visuospatial processing contributing to the TD experienced in 
these patients.  
TD is one of the earliest symptoms of AD (Lithfous et al., 2013; Cherrier et al., 
2001; Morris, 1993; Serino and Riva, 2013). Approximately 25% of AD patients 
present with initial TD and this increases to 50% within the first three years of 
the disease being diagnosed (Pengas et al., 2010).  These figures are likely to 
be under represented as some patients often attempt to hide their TD by using 
new strategies and avoiding new routes or places (Serino and Riva, 2013). As a 
result, carers often only become aware of spatial difficulties when the patient is 
away from their home setting such as on holiday, when they fail to remember or 
learn new places and routes (Pengas et al., 2010).   
Whilst some of the HE may experience TD in new surroundings; AD patients 
are often disorientated in familiar environments such as their home (Cherrier et 
al., 2001; Cushman et al., 2008; Serino and Riva, 2013). This restricts daily 
living tasks and results in patients becoming lost when out and about, 
wandering, and taking the wrong direction on journeys (Head and Isom, 2010).  
This has the potential for serious consequences and causes anxiety for the 
carers and families of such individuals. 
In Cherrier et al’s., (2001) paper, mild to moderate AD patients (with a mean 
Dementia Rating Scale score of 107) and a group of elderly control participants 
learnt an outdoor route whilst accompanied by a researcher.  The purpose of 
this study was to determine whether AD patients experienced problems with 
spatial memory and orientation rather than simply having an inability to 
recognise landmarks along the chosen route.  AD patients were significantly 
worse at the route learning test. As the authors predicted, the results confirmed 
that there were clear deficits in spatial orientation and processing. Strong 
associations between their route learning test scores and scores on an 
established route learning task (the Money Road Map test) were noted.   These 
findings were consistent with previous work which has linked TD to the impaired 
optic flow seen in AD (Tetwesky and Duffy, 1999).  All of the AD patients in this 
sample were impaired at recognising the route, however, they performed almost 
as well as the control participants in their ability to recall the presence of 
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landmarks (Cherrier et al., 2001). These results support the suggestion that 
spatial orientation is impaired in the disease. 
Duffy (2009) suggests that visual information processing is impaired in AD and 
a number of studies have shown that both AD and MCI populations have 
problems in visual motion processing, which are thought to underlie their 
navigational difficulties (Mapstone et al., 2003; Tetewsky and Duffy, 1999; 
O’Brien et al., 2001; Dubinsky et al., 2000; Uc et al., 2004). Testing navigational 
deficits using 'real-world' methods can be difficult and requires long 
administration times (Duffy, 2009).  Sheehan et al., (2006) investigated 
navigational deficits using a real world situation.  These authors recruited mild 
AD patients and healthy controls and accompanied them on a short 30 minute 
walk close to where they reside.  The participants were then asked to complete 
the route again, the researcher accompanied them but did not correct any 
wrong turns or errors.  Clear deficits were seen for the AD patients and this 
group experienced significant way finding difficulties leading them to become 
lost.  The results of the study demonstrated the reliance on external cues as 
many of the patients stated that they knew to look out for certain signs or 
landmarks to help them return home.  This implies that rather than reliance on 
visuospatial memory, memory for familiar objects seems to play a significant 
role in route planning and spatial orientation.  The authors recognise the 
limitations to this approach such as the use of subjective recordings by a 
researcher and the fact that environmental cues may change on a daily basis, 
Such cues may include the weather, external traffic noise and/or the presence 
of others and may affect the ability of the participant to remember their route 
(Sheehan et al., 2006).  This technique relies upon the participant being mobile 
and the experience itself could become stressful and tiresome particularly if the 
patient becomes disorientated or lost.  
 
8.1.5 Virtual reality environments 
In recent years the use of computer technology has increased and virtual 
environments are now used to replicate real-world tasks (Tippett et al., 2009). 
VR has been recognized as a technology in a variety of domains including 
phobias (Garcia-Palacios et al., 2002), fear of flying (Banos et al., 2002), 
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acrophobia (Coelho et al., 2009), fear of public speaking (Slater et al., 2006) 
and motor rehabilitation (Holden, 2005).  
Previously, Werner et al., (2009) examined the feasibility and the validity of a 
virtual action planning supermarket (VAP-S) for the diagnosis of individuals with 
a MCI. The study investigated deficits in EF rather than route learning, and 
recruited 30 MCI and 30 control participants.  Participants were instructed to 
purchase seven items from a list and told to pay for these items at the virtual 
counter. When using the virtual supermarket those with a MCI made more 
pauses and took longer trajectories through the supermarket.  They also 
performed a greater number of incorrect actions than the controls and the 
authors explain this is likely to be due to impaired EF skills such as planning 
ability and the employment of a task strategy.   Score on the VAP-S alone was 
unable to accurately discriminate the MCI participants from the controls, 
although using one of the VAP-S scores (trajectory duration) in combination 
with the participant’s MMSE score identified 93% of the controls and 80% of the 
MCI participants.  The authors suggest that the small sample size may have 
contributed to the inability of the VAP-S to accurately discriminate all of the 
participants in each clinical group. 
Pengas et al., (2010) also used a virtual environment with the aim of accurately 
discriminating between AD patients and controls. This was assessed using 
three tasks, one of which was the Virtual Route Learning Test (VRLT), a virtual 
town consisting of four routes. The study recruited 69 participants which 
included 32 with a MCI, 22 with mild to moderate AD, 15 with semantic 
dementia and 35 controls.  The authors also further split the MCI participants 
into different subtypes consisting of 14 aMCI, 15 multi-domain MCI and three 
naMCI.  The results revealed that the VRLT achieved 95% sensitivity and 94% 
specificity in discriminating AD patients from control participants.   Tippet et al., 
(2009) examined performance on the ‘Sunnybrook city VE’ in a group of 18 
elderly controls (mean age 69 years) and eight MCI individuals (mean age 72 
years). The VR task consisted of a fictional city block which the participants 
were required to navigate through and the authors also administered a 
neuropsychological test battery. Scores on the virtual route task were unable to 
discriminate between the MCI and control participants.  The authors suggested 
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that the task may not have been challenging enough and those with a MCI may 
have found the task too easy.  
Cushman et al., (2008) investigated the efficacy of using a VR environment 
when assessing navigational performance in participants with early AD and MCI 
as well as young adults and HE controls.  The authors used a real world 
navigational task where the participant was taken on a wheel chair route around 
a hospital lobby by an experimenter.  They were instructed to attend to the 
environment and completed a series of questions at the end of the tour.  The 
participants also completed a virtual version of the same lobby route, and were 
assessed again.  The results showed correlations between real-world 
navigational deficits and those from the VR environment across all groups, 
highlighting the potential efficacy of using VR as a test for dementia and AD.  
None of the measures were able to predict which clinical group the individual 
belonged to. 
The results of these studies confirm that AD patients perform significantly worse 
than MCI participants and aged matched controls on these types of task 
(Tippett et al., 2009; Cushman et al., 2008; Pengas et al., 2010; Werner et al., 
2009).  Some studies have also demonstrated that MCI participants take longer 
to complete VR tasks, make more errors and revisit locations many times when 
learning a new route in comparison to the HE (Werner et al., 2009).  Currently 
none of the existing research which has used VR has been able to discriminate 
with 100% accuracy between participant sub-groups; for example, whether the 
participant completing the task is HE, MCI, or AD.  As mentioned previously it is 
vitally important for a test to be 100% accurate at identifying the participant’s 
clinical group if it is to be considered for an early diagnostic tool.   
Some studies, for example Werner et al., (2009) and Pengas et al., (2010), 
confirmed deficits in MCI individuals but were unable to correctly identify which 
clinical group they belonged to based on their score on the VR test only.  The 
test required participants’ scores on an additional test to correctly identify them.  
This creates a more time consuming, complex scenario for clinicians to 
interpret.  Furthermore, Pengas et al., (2010) revealed that 70% of their MCI 
participants were impaired at the VR assessment.  If the remaining 30% of this 
cohort were able to successfully pass the test and perform with no significant 
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difference from the HE their assessment is not sensitive to the early deficits 
seen in AD. 
 
8.1.6 Advantages and disadvantages of using a virtual environment 
There have been some criticisms that VR does not sufficiently mimic real world 
situations (Burgess et al., 2002), however, it does offer some advantages over 
standard pen and paper assessments.  For example, VR gives the 
experimenter control over the number and the type of stimuli the environment 
contains as well as control over the complexity which allows them to observe 
the participants response in more detail.  Using a computerized system allows 
for the accurate recording of data and the number of errors made without the 
reliance of subjective assessments and note taking from a researcher.  
Pen and paper tests of spatial navigation have been criticised as they lack 
ecological validity which limits their reliability for comparisons to real world 
navigational difficulties (Werner et al., 2009).  Virtual environments provide the 
user with a high level of immersion and subjects often report that they felt as 
though they were actually within the ‘game’ or ‘scene’ which can cover a much 
larger spatial area than standard tests (Duffy, 2009; Weniger et al., 2011).  
Virtual tasks are also more useful than real world navigational tasks which, 
although may be better than standard pen and paper tasks, can be impractical 
as they often rely on public areas such as a hospital lobby, or the floor of a 
building.  These places are likely to change on a daily basis in terms of the 
number and presence of others, level of noise, smell and sound (Pengas et al., 
2010).   
Another advantage of virtual assessments is their potential to be used across 
multiple centres allowing for the direct comparison of results at different clinical 
settings.  Virtual tests may also be useful tools for the differentiation between 
dementia subtypes, for example, patients with semantic dementia are often 
misdiagnosed as having AD (Dubois et al., 2007).  Topographical memory is 
usually preserved in semantic dementia compared to AD, therefore, these types 
of tests may be useful at confirming/ruling out other types of dementia (Pengas 
et al., 2010).  The mis-diagnosis of semantic dementia can lead to the inclusion 
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of these individuals in AD research trials and studies which has the potential to 
affect the results obtained. 
When recruiting elderly participants for VR tasks there is often a concern 
regarding their level of previous computer experience.  A study by Moffat et al., 
(2001) showed that prior computer experience only impacted on the fluency of 
manoeuvres through a virtual world.   These same researchers gave their HE 
community dwelling sample (mean age 57.8 years) extensive training and 
practise sessions to ensure that all participants were comfortable and 
competent at the task before they commenced.   
A limitation of using a virtual environment for this type of assessment is that it 
does not allow the participant to recruit cues from the external environment 
which they may use in real world tasks.  For example, audio stimuli or sensory 
information via perceived touch, as there is no actual movement through space 
(Moffat et al., 2001).  This also restricts their visual field and the richness of 
sensory input available.  Despite this, researchers are still obtaining significant 
and important results when using VR in a variety of different fields such as 
dementia research (Man et al., 2011), stroke rehabilitation (Laver et al., 2011 
and Cikajlo et al.,2012), depression (Meyerbröker et al., 2011) and rehabilitation 
following head trauma (Levac et al., 2011). 
 
8.2 The present study: research aims 
This chapter will preliminary evaluate the use of a newly developed VR test, 
Virtual reality of early detection of dementia (VREAD), which was created in 
collaboration with the University of Bradford, School of Computing, Informatics 
and Media in a small sample of HE participants.  The study will examine 
whether score on this novel task of spatial route learning correlates with existing 
neuropsychological tests used in the diagnosis of early cognitive impairments 
seen in AD.  A second aim is to investigate whether the test can discriminate 
accurately between the HE and people with a suspected MCI.  
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8.3 Methods 
8.3.1 Participants 
Thirty one participants (10 males and 21 females) were recruited to take part in 
the piloting of VREAD.  Inclusion criteria specified that participants must be 
aged 60 years or over and should not possess an existing neurological disorder 
or clinically diagnosed memory impairment. Prior computer experience was not 
essential.  None of the participants had an uncorrectable visual impairment. All 
participants were recruited from the University of Bradford, Division of 
Psychology over-60s participant pool, and the study was approved by the 
University of Bradford Ethics Committee. All participants gave their informed 
written consent before taking part.  Of the 31 subjects recruited, nine were 
classified as having a MCI. In this study MCI was defined as a score of 27 or 
less on the MMSE and/or a probability of 80% or more on the algorithm created 
by Blackwell et al., (2004) and/or a score of greater than 11 errors on the 
CANTAB PAL 6 pattern stage.  
 
8.3.2 Materials 
8.3.2.1 Virtual reality of early detection of dementia (VREAD) 
The virtual task, VREAD consisted of three modules: VR Practice, VR Park and 
VR Games. VR Park and VR Games both contain five different levels.  Each 
level is progressively harder.  VREAD was administered on a standard PC and 
participants were required to use the cursor keys on a standard key board to 
manoeuvre through each level. Participants were seated throughout the 
experiment.  There was no time limit for each level. 
8.3.2.2 Neuropsychological tests 
In addition to VREAD a short battery of neuropsychological tests was 
administered to each participant to obtain a profile of their cognitive function.  A 
detailed description of each of these assessments can be found in chapter four 
‘Neuropsychological testing’ and a brief explanation of each is given. 
GNT -  a test of semantic memory (McKenna and Warrington, 1980).  
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CANTAB PAL - an assessment of visuospatial associative memory (Égerházi 
et al., 2007).  
MMSE - an assessment of general cognitive ability (Folstein et al., 1975)  
Immediate word recall - an assessment of short-term memory and  
8.3.2.3 Questionnaires 
Participants were requested to complete a VREAD feedback questionnaire 
following their participation.  The questionnaire was specifically designed by 
colleagues in the Informatics Department and aimed to gain information about 
the participants’ acceptance and satisfaction of the virtual environment.  The 
questionnaire assessed the participants (i) ease of learning the controls, (ii) 
ease of movement, (iii) ability to understand the instructions and (iv) freedom of 
movement.  See appendix two for a copy of this questionnaire. 
 
8.3.3 Procedure 
Participants were invited to take part in the study via a postal invitation letter 
and those who were willing to participate were invited to attend a testing 
session at the University.  A unique user ID was given to each participant to 
anonymise the data collected.  This number was entered into the VREAD 
system at the start of the testing session. Each participant was trained to use 
the arrow keys on a standard keyboard during the VREAD practice module 
(these are the keys needed to carry out the test).  When participants were 
comfortable at using these keys the experiment commenced.  Participants were 
assigned to see one of the two modules: VR Park or VR Games.  In each level 
of the VREAD participants repeated the exercise of reaching a target 
destination three times by following a thick red line attached to the path. The 
VREAD consisted of five different levels of difficulty ranging from easy to 
complex.  Level one was considered to be the easiest with each level becoming 
progressively harder requiring more complex navigation.  The levels of difficulty 
were defined based on the number of junctions, paths and target destinations in 
each route which users had to achieve in the testing phase.  Extra destinations 
were added as a ‘dummy’ to make the path more complex and difficult.  VR 
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Park had the target destinations of a typical park layout and included a 
playground, picnic area, art gallery, park square and a mini garden. For the 
second module, VR Games, target destinations were typical outdoor games 
such as a giant chessboard, giant board games, lawn bowls, mini golf and a 
picnic area. Both modules had the same number of levels and landmarks and 
the VR Parks path was mirrored to the VR Game path. Pilot testing showed that 
the VR scores were significantly worse on VR Park and so it was decided to 
continue with just this version. 
Each participant was given three attempts at locating the destination using a red 
line present on the path as a guide.  There was no time limit for this, after the 
third attempt with the line present, the line was removed and the participant was 
tested on their ability to recollect the given path.  All data were collected and 
recorded during this phase.  Lastly the data was exported to the information 
system to be analysed.  See figure 22 for screenshots of the VR environment.  
After completing the VREAD each participant was then administered the 
accompanying neuropsychological test battery in the same order. 
 
 
Figure 22: screen shots taken from one of the VREAD levels.  On the left the presence 
of a red line used to guide the user to a set location can be seen.  On the right there is 
no red line present and the user must remember the route from memory. 
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8.3.4 Analysis of VREAD data 
Movement measures in VREAD were based on underlying path squares, which 
consisted of underlying grids unknown to users along each route. These path 
squares were systematically numbered and were used to calculate the 
participants’ overall scores at each level.  During the testing phase, data were 
collected automatically in real time comprising the following five attributes: (i) 
correct path, (ii) incorrect path, (iii) correct sequences, (iv) incorrect sequences 
and (v) time. An overall percentage score was calculated based on path 
sequences and path squares for each participant. The higher the overall 
percentage score the more accurate the participant was at locating the target 
destination and following the correct route of underlying path squares. 
 
8.4 Results 
The aim of the present study was to evaluate a newly developed VR 
environment, VREAD, as a novel test of spatial navigation for the potential use 
in early detection of AD. Each participant completed a battery of 
neuropsychological assessments as well as all five levels of VREAD. The 
descriptive statistics for the participants can be seen in table 11 and the 
descriptives for each neuropsychological test and VREAD levels are shown in 
tables 12 and 13 respectively. 
Table 11: Demographics for those classified as HE and MCI 
Characterisitics HE (n = 22) MCI (n = 9) 
Age, years (mean ± S.D) 
 
69.77 (4.60) 72.67 (6.56) 
Gender (M:F) 
 
5:17 5:4 
Education, years (mean 
± S.D) 
15.50 (6.04) 20.07 (6.26) 
Possessed previous 
computer experience 
6 2 
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Independent t tests revealed that there were no significant differences between 
the HE or MCI participants in terms of age or years in education (p>0.05).  A chi 
square test showed that there was no significant difference in the gender 
distribution between the two diagnostic categories (p>0.05).  
 
Table 12: mean and S.D for each neuropsychological assessment 
Test MIN MAX Mean ±S.D 
MMSE 26 30 28.84 1.21 
Word Recall 3 10 5.55 1.84 
PAL 6 Errors 0 49 10.13 11.14 
GNT 19 30 25.9 3.14 
 
Table 13: mean and SDs for each level of the VREAD 
VREAD 
Level 
MIN (%) MAX (%) Mean (%) ±S.D. 
1 60 100 97.90 8.34 
2 6.41 100 93.00 23.42 
3 41.67 100 95.06 12.98 
4 19.35 100 94.60 16.92 
5 56 100 89.80 13.56 
 
The results of all the VREAD levels and all the neuropsychological tests 
(MMSE, CANTAB PAL 6 error score, GNT and word recall) were submitted to a 
correlational analysis using SPSS.  Of the five levels of VREAD, level four (VR 
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4) significantly correlated with participants’ scores on both the CANTAB PAL six 
pattern stage and the GNT, r = -0.45 p < 0.02 and r = 0.43, p < 0.02 
respectively.  There was a trend towards significance for the word recall test 
(p=0.069).   No significant correlation was seen for VR4 and the participant’s 
MMSE score. No other level of VREAD significantly correlated with any of the 
neuropsychological test scores. Scatter plots for these significant associations 
are shown in figures 23 and 24. 
 
 
Figure 23: scatter plot of the participants’ number of errors made on the six pattern stage of the 
CANTAB PAL and the overall percentage score on level four of VREAD.  As the number of 
errors on the PAL increased performance on VR4 decreases demonstrating a negative 
correlation. 
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Figure 24: scatter plot of GNT score out of a maximum of 30 against VR4 score. As VR4 score 
increases so does performance on the GNT. 
Given the importance of VR 4, a general linear model (GLM) univariate analysis 
of variance, was used to investigate the effects of age, gender and education on 
the scores of VR 4.  There were no significant main effects noted.  A 
multivariate analysis was used to investigate age, gender and education on the 
neuropsychological tests and again no significance was reported. 
 
8.4.1 Discrimination between groups 
In total there were 22 HE participants and nine MCI.  Figure 25 shows that the 
mean score for VR 4 was lower in the MCI group compared with the HE group.  
An independent-samples t-test showed that this difference was significant t (29) 
= 3.17, p < 0.01, suggesting that VR 4 was able to discriminate between the two 
groups. 
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Figure 25: histogram of mean VR4 scores for the two diagnostic groups of participants, HE – 
healthy elderly and MCI – Mild Cognitive Impairment. 
 
8.4.2 Previous computer experience 
Eight participants reported that they possessed previous VR experience (of 
these individuals, two were classified as MCI).  An independent samples t-test 
of VR4 score carried out between those that had previous VR experience and 
those that had not was non-significant t(29) = 0.29, p>0.05. 
 
8.4.3 Sensitivity and Specificity of VR4 to MCI 
In order to examine the ability of VR4 to discriminate between a diagnosis of HE 
vs MCI a Receiver Operating Characterics (ROC) curve was created in SPSS.  
The area under the curve was trending towards significance, p=0.06, see figure 
26.  
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Figure 26: ROC curve for the sensitivity and specificity of VR4 
A selected cut off score which gave the highest sensitivity and specificity was 
chosen which was the equivalent to a value of 94% on VR4.  Logistic regression 
analysis using the optimal cut off value as the dependent variable (re coded as 
below ‘0’ and equal or above ‘1’ the cut off score of 94%) was then carried out.  
In this stepwise backward regression analysis potential confouding variables 
such as age, gender, education and previous computer experience were 
included along with diagnosis.  This determined whether the cut off needed to 
be modified as a function of one or more of these variables. The model revealed 
that none of these variables were predicitive of VR4 performance.  
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8.5 Discussion 
8.5.1 Main findings 
The aim of the present study was to evaluate whether a new VR environment, 
VREAD, could be used as a novel test of spatial memory useful for investigating 
cognition in the elderly.  A secondary aim explored how VREAD scores 
correlate with established neuropsychological tests of cognitive function for this 
age group, particularly the CANTAB PAL and GNT which are sensitive to early 
cognitive dysfunction.  The overarching aim is to use this test as a method for 
quick, early, accurate diagnosis of a cognitive impairment.  VR is becoming a 
useful method for assessing participants on a wide range of tasks particularly in 
the health care domain (Tippett et al., 2009; Broeren et al., 2002; Boejen and 
Grau, 2011; Greenleaf and Tovar, 1994; Khalifa et al., 2006). This chapter 
evaluated the use of a novel VR based assessment, VREAD, as a potential tool 
for the accurate, early detection of AD.  Each participant carried out five levels 
of the VREAD and the results obtained demonstrate that the percentage correct 
scores on VR 4 significantly correlated with the CANTAB PAL 6 pattern error 
score and the GNT score.  There was also a trend towards significance for the 
word recall task (p=0.069).  Score on VR 4 did not correlate with participants’ 
MMSE score which is important as the MMSE has previously been noted not to 
be sensitive to mild degrees of cognitive impairment (Pasquier, 1999; Cullum et 
al., 2000; de Jager et al., 2008) which is problematic as it is widely used in the 
GP setting.  In addition, the mean score on VR 4 was significantly lower in the 
MCI group suggesting that in its preliminary format VR 4 is able to successfully 
discriminate between participants (according to whether they were classified as 
HE or MCI). 
Blackwell et al., (2004) used a combination of CANTAB PAL 6 pattern error 
score, GNT score and the subjects’ age at the time of testing and incorporated 
these into a regression analysis in order to create an algorithm to predict the 
likelihood of a decline to a diagnosis of AD.  Using these variables the algorithm 
was able to accurately predict with 100% which participants converted to AD 
and those that stayed as questionable dementia over a 32 month period.  In the 
present study, VR 4 score significantly correlated with these two well 
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established tests but showed no effect of age suggesting that it could be used 
as a more straightforward method of testing cognition and cognitive decline. 
Like the results of this chapter other studies using MCI participants have also 
demonstrated impairments in route learning (Klein et al., 1999), although, the 
criteria for MCI may differ across studies. MCI participants have, on imaging 
scans, presented with an elevated volumetric decline in the EC of the 
hippocampus in the MTL, an area responsible for visuo spatial associative 
memory (Dubois et al., 2007).  Imaging techniques and lesion studies have 
shown that this deterioration occurs early in the disease pathway and therefore 
tests which are sensitive to visuo spatial associative memory and route learning 
should show deficiencies in performance if this area is affected.  
Tombaugh and McIntyre (1992) commented that poor performance on 
neuropsychological tests may simply be due to increasing age within the 
sample. The results of this study demonstrate that age was not significantly 
associated with score on VR 4.  Likewise, participants’ scores at this level 
revealed no association with MMSE score.  Baseline score on the MMSE can 
vary immensely.  Blackwell et al., (2004) found that in a group of AD convertors 
baseline score varied from between 23 and 28 out of a possible 30. Individuals 
scoring 28 would have been classified as normal and this is problematic as their 
score does not correlate with underlying changes in brain pathology. The NICE 
dementia guidelines currently recommend the MMSE as a tool for the detection 
of suspected cognitive impairment and the score obtained can be used to 
determine whether a patient receives pharmacological treatment (Dening, 
2009).  Previously NICE stated that drugs should only be given to those 
individuals with a moderate form of dementia which meant that a patient with a 
mild impairment would not be treated until they continued to decline further. 
After a review in 2011, NICE now recommend treatment is administered to 
patients with a mild form of the disease if the clinician believes it will prove 
beneficial.   Furthermore, patients who did receive drug treatment would have 
their medication removed when they declined past a score of 10/30 even if they 
found the treatment beneficial.  The accuracy and reliability of scores obtained 
on the MMSE can be affected by external factors such as the participant’s 
mood, education level and age (Jacova et al., 2007). 
197 
 
Although some previous studies have reported gender effects on navigational 
ability, with males performing better than females, (Galea and Kimura, 1992; 
Ward et al., 1986; Astur et al., 1998; Maguire et al., 1999) there were no main 
effects of gender in this study.  This may be due to the small numbers of males 
recruited (n = 10) and this is a factor which requires further investigation. 
Sandstrom et al., (1998) suggest that gender differences in performance on 
route learning tasks are likely to be due to the different strategies employed by 
males and females.  For example, males seem to be better at encoding 
geometrical information whereas females place a heavier reliance on landmark 
cues (Sandstrom et al., 1998; Galea and Kimura, 1992).  Future study using 
VREAD could incorporate a recognition memory task to specifically investigate 
whether participants recall the presence of landmarks along the route. Widmann 
et al., (2012) incorporated a similar approach and found that AD participants 
were impaired at landmark recall compared with the HE controls. 
An important quality of neuropsychological tests should be their ability to 
correctly identify a participant’s clinical group.  The score obtained on VR 4 was 
significantly worse in those participants with a MCI in comparison with the HE 
suggesting that this novel assessment can discriminate reliably between the two 
groups. Although the area under the ROC curve in figure 26 showed a trend 
towards significance, stepwise backward logistic regression analysis revealed 
that neither age, gender, education, prior computer experience nor diagnosis 
could significantly predict performance on VR4.  This result is likely to be 
influenced in part by the small sample size of the cohort which resulted in a 
small number of individuals classified as MCI.  This is likely to have limited the 
statisitical power.  Future studies using the VREAD test, particularly VR4, need 
to recruit larger samples to investigate the specificity and sensitivity of the test 
in further detail and should control for age across both diagnositic categories.  It 
is clear from the results of this study that a number of participants scored 100% 
which could potentially be obscuring participants that have a more subtle 
impairment.  The results do still successfully show a difference in performance 
between the two experimental groups but future study making the VR test 
harder and more challenging would be needed to avoid this. 
It remains unclear why VR 4 was the level of the VREAD which correlated with 
the scores on the neuropsychological tests.  VR 5 was more complex although 
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no significance was obtained for this level.  Each level of VREAD became 
progressively harder based on the number of turns and the number of objects 
such as trees, benches, street lights, fences and buildings.  The overarching 
aim is to have a simple test with one level which can be administered quickly in 
clinical settings and this will require further study.   
In some previous investigations researchers have raised concerns about the 
possible side effects of using a virtual task.  This included participants reporting 
feelings of disorientation or nausea during the task (Moffat et al., 2001).  In their 
sample of 133 individuals Moffat et al., (2001) reported that 13 participants 
withdrew due to feelings of nausea and dizziness during their VR test.  This 
prior knowledge could affect willingness to participate and may make subjects 
anxious should they be made aware of this which needs to be an important 
consideration.  However, this particular issue was not problematic in this study 
and there were no reports of illness, headaches or nausea as assessed by the 
usability questionnaire (Wan Shamsuddin et al., 2011a; Wan Shamsuddin et al., 
2011b).   
Previous criticisms of virtual environments have included the issue of 
extrapolation to the real world and whether or not a false ‘world’ can be thought 
of as a reliable way to learn and encode newly formed routes or cognitive maps 
(Werner et al., 2009).  Some participants reported that they found the VREAD 
test too easy and stated that they did not feel they required three practice 
attempts at each trial. None of the participants commented that they were 
unable to use the apparatus and each individual was allowed a practice session 
prior to commencing the actual assessment so as to familiarise themselves with 
the keyboard and virtual environment.  Although it is often assumed that the 
elderly possess low levels of computer experience (Head and Isom, 2010) in 
this sample, those who possessed prior use of games consoles or computer 
gaming devices, may have moved more fluently through the test but this did not 
contribute to their ability to memorise and learn each route (p>0.05). This may 
change should a more difficult version be used and again is an important 
consideration which will need to be checked. 
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8.5.2 Ability of VREAD to predict cognitive decline 
The ability of a neuropsychological test to predict cognitive decline is important 
to identify individuals who may need closer monitoring and intervention.  MMSE 
scores (but not CANTAB PAL scores due to financial restrictions) were obtained 
one year after baseline testing.  None of the participants classified as HE in this 
chapter had declined to an abnormal MMSE score and as a result it has not 
been possible to assess whether level 4 of the test could predict cognitive 
decline although this is something which deserves further study and longitudinal 
follow up will take place. 
 
8.6 Conclusion and summary 
The self report of navigational deficits is common in the elderly and the ability to 
encode and remember new routes is impaired in those individuals who have a 
cognitive impairment.  The fact that deficits in route learning are common in the 
early stages of AD and in participants with a MCI makes tests of navigation 
interesting tools for earlier detection. The results of this chapter which has 
preliminary tested a newly developed VR based assessment, VREAD, have 
shown that this task could have the potential to be used as a possible method 
for the detection of an early cognitive impairment after some further 
modifications are addressed.  Significant correlations were found between level 
four of this test, the CANTAB PAL 6 pattern error score and the GNT.  There 
was no association with the MMSE which has previously been criticised for its 
inability to detect mild changes in cognition (Tombaugh and McIntyre, 1992). 
VR 4 was also significantly lower in those participants classified as MCI 
compared to the HE sub group.  The ability to accurately discriminate between 
participant sub groups is vital for the accurate diagnosis of AD and MCI.   
Future study following on from these preliminary findings is needed and should 
focus on investigations into whether the VR test can predict future cognitive 
decline. This will require detailed longitudinal follow up of these participants. 
Furthermore, the sample size of 31 participants with nine of these having MCI is 
too small, along with the high ceiling effect of the current version, to verify the 
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utility of the test in a clinical setting at present but given these promising 
preliminary results then further study will aim to achieve this. 
 
8.7 Chapter summary of key points 
 
 The domain a task assesses is a factor which can affect the overall 
accuracy of detecting an early impairment. 
 Visuospatial associative memory and route learning activate the EC, one 
of the earliest brain regions to be affected by AD pathology. 
 Impairments in route learning are common in the elderly but are more 
pronounced in AD and MCI. 
 VR assessments are useful for the testing of route learning. 
 A novel virtual environment VREAD was evaluated in a sample of HE 
participants who were >60 years of age with no pre diagnosed cognitive 
impairment or neurological condition. 
 Scores on level 4 of VREAD significantly correlated with CANTAB PAL 
and GNT scores. 
 There were no associations between VR 4 and MMSE score or age, 
education or gender. 
 VR4 was able to discriminate between HE and MCI participants. 
 VR4 may be useful for early detection of cognitive impairments. 
 Future experiments need to investigate how the task can be made more 
complex, for example, by decreasing the number of practice levels and 
determining why VR4 and not the other levels seems to be the most 
sensitive to navigational difficulties. 
  
Some of the information within this chapter can be found in Wan Shamsuddin et 
al., (in prep) ‘Using a virtual environment to assess cognition in the elderly’ 
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Chapter Nine 
General discussion and summary 
 
9.1 Introduction 
This thesis has presented experiments which have aimed to investigate some 
subtle external factors which may affect performance on neuropsychological 
test batteries during typical testing conditions in the healthy elderly.  In addition 
a newly developed virtual reality based test was evaluated as a possible novel 
tool for the early detection of AD.  All of the experimental chapters followed an 
experimental quantitative methodology which utilised cognitive batteries 
consisting of a variety of neuropsychological tests, chosen to specifically tax 
different cognitive domains and which are commonly used assessments in 
research settings.  All of the experiments within the thesis recruited HE 
participants; however, the findings may have implications for the use of 
neuropsychological testing in AD and MCI research. The thesis has illustrated 
that external factors such as prior caffeine consumption (chapter five), tinned 
tuna consumption (chapter six), and time of day (TOD) (chapter seven) can 
influence the scores obtained on some neuropsychological tests.  The thesis 
has also presented preliminary findings that VREAD, a novel virtual assessment 
of spatial route learning, could be useful as a tool to detect early cognitive 
impairment in the future (chapter eight).  This final chapter collates the main 
findings from the experimental chapters and discusses the implications these 
may have. The chapter will also provide a summary of the thesis as a whole 
and will address some methodological considerations and possible ideas for 
future research.   
 
9.2 Motivation 
In recent years there has been a prominent focus to try to diagnose and treat 
AD as early as possible.  Signs of the disease including pathological markers 
and changes in underlying cerebral systems can be detected years, possibly 
even decades before cognitive symptoms first become noticeable (Forlenza et 
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al., 2010; Dickerson et al., 2011; Petersen, 2009; Sperling et al., 2011). 
Neuropsychological testing is one method by which early detection can be 
implemented and it is commonly used in the diagnosis of a cognitive impairment 
associated with AD or MCI (Chapman et al., 2010). It is crucial that the scores 
obtained on neuropsychological tests are accurate.  It is important, therefore, 
that external factors which may influence performance are controlled for or at 
least considered when interpreting participants’ performance.  
A number of demographic factors have been investigated previously, such as 
education, age and ethnicity (Fields et al., 2011), and are now usually taken into 
consideration when evaluating neuropsychological performance.  There are still 
many other variables which may affect the participant’s performance.  It is 
useful to determine the effects of these especially when test scores are used in 
research studies and to determine diagnosis, treatment and care.  Furthermore, 
normative data which is commonly referred to for comparison purposes may not 
have controlled for such factors (Lesk et al., 2009). 
 
9.3 Main findings 
Caffeine, TOD and diet (non-oily fish consumption) are all common lifestyle 
factors which have the potential to influence and skew data obtained on 
psychological assessments. These factors are routinely prevalent in the daily 
life of most individuals attending a cognitive assessment and were, therefore, 
investigated as factors which may affect neuropsychological testing in the HE.  
Chapter five showed that 200mg of prior caffeine interacted with age and scores 
on assessments of EF and processing speed.  This revealed that the older 
elderly who had received caffeine showed a steeper decline in performance 
with increasing age, an effect which was not present on any of the assessments 
for participants in the placebo condition (Walters and Lesk in prep - a; Lesk and 
Walters, 2012). These findings were not attributed to an alertness effect of 
caffeine as there was no main effect of caffeine compared to placebo on any of 
the assessments and caffeine did not improve performance in the older elderly.  
Chapter six investigated a dietary factor, monthly non-oily fish consumption.  
Although this was not an immediate prior factor which can be controlled for in 
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experimental situations it is important to determine the effects of dietary factors 
on cognitive performance in the elderly.  Grams of monthly tinned tuna 
consumption was a significant predictor of MMSE score, specifically the word 
recall item of the task which assesses short-term memory. Chapter seven 
demonstrated that the TOD that some neuropsychological tests are delivered 
can affect the participants performance. TOD also interacted with the 
participants’ age and prior caffeine consumption on certain assessments 
(Walters and Lesk, in prep - b). 
Chapter eight’s evaluation of the newly created virtual reality based 
assessment, VREAD, created in collaboration with the University of Bradford, 
School of Computing, Informatics and Media, showed that scores on level four 
of the test were associated with the participant’s performance on the PAL and 
GNT.  Both of these tests been shown to be sensitive to early cognitive 
impairments (Blackwell et al., 2004; de Rover et al., 2011).  Score on level four 
was also significantly lower in those participants classified as MCI compared to 
the HE suggesting that in its preliminary form VREAD could distinguish between 
clinical groups. 
Previous research which has investigated dietary factors such as caffeine and 
fish consumption in the elderly has taken a longitudinal approach and has 
investigated participants’ habitual consumption of CCFS and fish intake on their 
risk of developing AD or likelihood of cognitive decline (for example Ritchie et 
al., 2007; Eskelinen et al., 2009; Lindsay et al., 2002; van Gelder et al., 2007; 
Santos et al., 2010 and Morris et al., 2003; Devore et al., 2009; Kalmijn et al., 
1997; van Gelder et al., 2007).  Studies investigating the effects of caffeine 
have relied upon the self report of CCFS consumption and these substances 
(such as tea, coffee, chocolate and soft drinks) may contain other active 
compounds which may also be able to influence cognitive performance. For 
example, polyphenols are found in tea (Lindsay et al., 2002) and chlorogenic 
acid, cafestol and kaweaol are active ingredients present within coffee 
(Eskelinen and Kivipelto, 2010). The administration of pure caffeine 40 minutes 
prior to the neuropsychological assessment in chapter five has reduced the 
possibility that any findings were due to other ingredients contained within 
CCFS and has allowed the immediate effects of caffeine on cognition in the 
elderly to be studied. Due to financial restrictions it was not possible to measure 
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participants’ salivary caffeine concentrations prior to testing and Hogervorst et 
al., (1998) excluded three participants from analysis because their prior caffeine 
salivary levels were slightly greater than 2.0mg/l suggesting that these 
individuals had not adhered to the abstinence protocol. This should be 
considered in future research.  
In all of the experimental chapters participants’ TOD preference and peak 
arousal time was not pre determined.  Chapter seven reviewed data sets from 
chapters five and six.  The hypothesis of these chapters was not to investigate 
peak arousal or time of day effects on performance and, therefore, testing time 
was not controlled for. The participants were given some choice as to when to 
attend the neuropsychological assessment and so it is reasonable to assume 
that at least some of these individuals took part at their preferred TOD even 
though this may not have been their optimal arousal period.  Likewise, for all of 
the experimental chapters of the thesis TOD preference and peak arousal may 
have been important factors to consider. 
The creation of a food diary to obtain details of participants’ monthly fish 
consumption in chapter six was constructed to reduce the possibility of errors in 
self-estimation which often arise when using FFQs (Bowman et al., 2012).  
Food diaries as far as I am aware have not been used previously in research 
specifically investigating fish consumption and their use in cognitive research in 
the elderly is also limited.  Food diaries are considered to be a more reliable 
method for obtaining dietary information in comparison to FFQs (Legg et al., 
2000) and, therefore, it is likely that a more accurate account of monthly fish 
consumption was obtained.  The use of gram information rather than portion 
numbers further strengthened the participants’ accounts of their actual intake.  
The preliminary findings of chapter eight revealed that some participants found 
the VREAD test too easy (Wan Shamsuddin et al., 2011b) and this is 
concurrent with the high ceiling effect obtained in the early levels of the test. 
This suggests that VREAD needs to be adjusted and made more challenging 
and complex.  The majority of the HE participants were able to perform at 
ceiling and this currently limits the application of VREAD as an early detection 
tool.  
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9.4 Future work 
This thesis has established that some external factors can influence 
neuropsychological scores.  As discussed throughout this thesis it is important 
to consider subtle external factors when scoring psychological assessments 
and making comparisons with normative data.  The results obtained have 
provided a solid basis for future work.  
The findings of chapter five, i.e. the significant interaction effects between 
caffeine/placebo, age and assessments of EF and processing speed, could be 
extended upon to confirm these findings using more rigorous tests of each 
domain.  Caffeine is often deliberately consumed to improve attention and 
maintain alertness (Sharwood et al., 2013; Wright et al., 2013) both of which are 
components of EF.   EF encompasses a number of sub functions including, 
attention, inhibition, problem solving, task switching, dual tasks, reasoning and 
the ability to plan and devise strategies (Goh et al., 2012) which were not 
investigated in chapter five.  Previous research has demonstrated that some of 
these processes are affected by age more than others (Goh et al., 2012).  For 
example, Hasher et al., (2007) demonstrated that older participants show a 
reduced ability to inhibit or ignore distracting stimuli.  This thesis found 
significant affects of caffeine and age on the DT and the SDMT.  The DT 
specifically assesses participants’ ability to process two tasks simultaneously 
(Baddelely et al., 1997) and the SDMT assesses attention, visual search and 
concentration (González et al., 2007).   It is important to establish whether 
similar interactions with caffeine and age are found on other tests assessing 
different EF domains to determine whether caffeine’s affects are indeed 
selective. Examples of tests which could be investigated may include the TMT 
[specifically the difference between TMT part A and TMT part B which would 
assess task switching ability (Reitan and Davison, 1974)], the Tower of London 
test which assesses planning and decision making (Shallice, 1982) and the 
Wisconsin card sorting test which assesses goal switching and decision making 
(Berg, 1948).  
Likewise, further study is needed to extend upon the effect of caffeine on 
processing speed.  The LCS and PCS are classified as tests of processing 
speed (Salthouse and Babcock, 1991) but the pen and paper versions of both 
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tests have high levels of distractibility.  Whilst confirming whether two patterns 
or strings of letters are the same or different the participant must also ignore the 
patterns and strings above and below and it could be argued that a certain 
degree of inhibition (a sub domain of EF) is also required when completing 
these tasks (Lustig et al., 2006).  In chapter five one other test of processing 
speed, the Stroop Word, did not show the same interaction suggesting that the 
effects of caffeine are selectively dependent on executive processes only.  
The cross over point for each test which showed a significant interaction 
between caffeine, age and test score occurred at a different age depending on 
the cognitive test used. For example, the PCS and LCS had older cross over 
ages of 83 and 84 years respectively, however, for the assessments of EF, the 
DTR, DT T1-T2, SDMT and Stroop Interference had ages at cross over of 69, 
64, 77 and 79 years respectively.  Furthermore, there is little literature which 
has specifically investigated the effect of prior caffeine on the cognitive 
performance of those with a MCI and this too could be important.  
A preliminary analysis (data of chapter five) was carried out and classified 
participants as high or low performers based upon their total z-scores for overall 
performance. In the tests that showed the significant interactions with caffeine 
and age in chapter five an interesting differential pattern of results was 
observed, whereby those classified as low performers showed poorer 
performance on caffeine whereas those classified as high performers scored 
better on caffeine.  This was partly expected as the majority of younger 
participants were classified as high performers.  This does deserve further work 
in a larger sample and will be the topic of future study. 
The finding that tinned tuna consumption was a predictor of MMSE performance 
in chapter six, specifically the recall item of the test, also requires further study 
to determine the effect of tinned tuna intake on other assessments of short-term 
memory and recall.  None of the other assessments administered in chapter six 
tested episodic, short-term memory or word recall and it is possible that the 
benefits of increased tuna intake are selective to memory processes. This 
needs to be further investigated and confirmed using more rigorous testing of 
these domains with appropriate neuropsychological tests and a larger sample.  
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Although food diaries provide more reliable data than FFQs which rely on self 
estimation (Bowman et al., 2012; Arsenault et al., 2009), the diary in chapter six 
was only completed for a period of four weeks and previous researchers have 
commented that fish consumption may vary depending on the time of year and 
season (Cunnane et al., 2009).  Consequently, the study could be continued 
over a longer period of time to confirm if the current findings are still present.  A 
thorough investigation into memory and tuna intake should now be implemented 
based upon these initial findings. It is possible that similar findings may be 
present in a cohort of participants who eat larger amounts of other types of fish, 
of which only smaller amounts were consumed in the cohort recruited in chapter 
six.  Recruiting participants with a MCI would also determine any effects of 
tinned tuna consumption in individuals with impaired cognitive performance.  
Although some previous studies have investigated whether total fish 
consumption is associated with the subsequent level of cognitive decline over 
follow up, it would also be useful to further investigate whether non-oily fish 
consumption (and/or tinned tuna consumption specifically) is able to predict 
cognitive decline in those with lower monthly intakes.  This will be the focus of 
ongoing study which will utilise the longitudinal follow up of this cohort. 
There are many other external factors which may affect performance on 
neuropsychological tests in the elderly prior to their administration aside from 
those studied in this thesis.  Prior caffeine, smoking and alcohol were controlled 
for in chapter five by asking participants to abstain for a set amount of time 
before attending the assessment and only non smokers were recruited.  Other 
factors to consider include the participants prior intake of any medications (Gray 
et al., 1999), water (which may influence hydration level) (Sécher and Ritz, 
2012), mood and emotional state (Jacova et al., 2007), prior food intake (Maisto 
et al., 2011), particularly glucose (Gorby et al., 2010), stress and cortisol levels 
(Shansky and Lipps, 2013); homocysteine and B12 (Smith et al., 2010; de 
Jager et al., 2012) and their overall general health.  Future study investigating 
the effects these may have on cognitive performance at the time that tests are 
administered is needed. 
The findings of chapter eight were preliminary and further research is needed 
for the test to be used as a tool for the detection of cognitive impairment.  The 
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results suggested that VREAD does have the potential to be used as a tool for 
the detection of a cognitive impairment after some changes in the administration 
and design of the task are made (Wan Shamsuddin et al., 2011a).  The high 
ceiling effect which was found suggests that VREAD is currently too easy and, 
therefore, not sufficiently challenging enough for the HE.  This has meant that 
the majority of participants were able to score close to the tests maximum score 
implying that the tasks difficulty and complexity requires some alterations and 
adjustment.  Ideally VREAD should consist of one level which would reduce the 
administration time and make the test more suitable for clinical use where time 
constraints are present for each appointment.  Although the use of a single 
cognitive test score should not be used to determine overall outcome, if the 
assessment assesses a cognitive domain which is known to be affected by 
early underlying brain alterations concurrent with AD (i.e. the EC which is 
recruited during visuo associative memory testing), and also an area which 
sees the earliest deposition of AD related pathology (i.e. the presence of tau 
tangles (Blackwell et al., 2004)) this would improve the validity and reliability of 
such results and the administration of long test batteries would not be 
necessary. Test re test reliability is also needed for VREAD. Continued use of 
VREAD addressing these points is warranted.  However, there are few tests 
using VR in early diagnosis and this is an important preliminary investigation.  
Some participants noted in the VREAD feedback questionnaire that they found 
three practice attempts at each level unnecessary (Wan Shamsuddin et al., 
2011b) and the task could be repeated with only one practice at each level to 
determine whether this would affect performance.  Task difficulty could also be 
evaluated by making each route longer with more complex paths to remember.  
Similarly additional parameters could be assessed, for example, the recall of 
landmarks or the participants’ capability to draw the followed route on paper.  
The time taken to complete each level was not factored into the overall score on 
VREAD and this could be important.  For example, two participants who scored 
the same may have taken significantly different lengths of time to complete 
each level and this should be considered in future continuations of this 
research. The ability of VREAD to predict later cognitive decline has also not yet 
been determined and this would be important should the task be modified and 
applied to a larger cohort.   
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9.5 Neuropsychological implications 
Small habitual amounts of caffeine (200mg), which is the equivalent to a 
medium filter coffee (Starbucks, 2011) and is a commonly consumed amount, 
had the ability to affect cognitive performance on a number of 
neuropsychological assessments in the over 60s in chapter five (Walters and 
Lesk in prep - a; Lesk and Walters, 2012). Caffeine impaired performance in the 
older elderly compared to the younger elderly.  The older elderly participants 
who received caffeine may have scored lower than on an occasion when they 
had not been administered caffeine.  For example, those participants over the 
age of 80 years who scored 27 and 32 respectively on the SDMT in chapter five 
may have scored closer to 40 if they had received placebo.  Even a small 
difference in the points awarded may affect the interpretation of the results 
which is particularly important on assessments such as the MMSE where the 
borderline between normal cognition, mild impairment and AD only spans over 
a six point difference (Tombaugh, 2005).   
These findings have implications for the interpretation of test scores and the 
accuracy of neuropsychological data and are applicable to any experiment 
which utilises cognitive tests. For the placebo condition there was no main 
effect or age interaction and this finding was similar to the results of Lesk et al., 
(2009) who also reported no significant effect of placebo (i.e. CCFS absent) on 
any of the assessments using a similar cognitive battery to that of chapter five.  
Together these results signify that researchers should ask their participants to 
abstain from caffeine for a set period of time or at least take note of any prior 
consumption before they take part in a neuropsychological assessment to 
ensure that the results obtained are the most controlled. This is not just 
applicable to aging research but to any cohort undergoing a cognitive 
assessment. Hogervorst et al., (1998) comment that usually cross sectional 
studies do not control for the participant’s caffeine consumption. This is 
problematic particularly for aging research where age effects may be 
exacerbated by caffeine administration. The results of chapter five are also 
important in terms of the use of and creation of normative data which often 
serves as a comparison and may not have considered participants’ prior 
caffeine consumption (Lesk et al., 2009). The results of chapter five are 
consistent with Lesk and Womble (2004) and Lesk et al., (2007) who also found 
210 
 
striking effects of 200mg of prior caffeine in young participants on two studies 
using phonological priming of the tip-of-the tongue-state, one in young 
participants and one investigating an anomic aphasic patient. 
The finding that monthly tinned tuna consumption (classified as a non-oily fish 
(NHS, 2013)) can predict general cognitive performance as measured by the 
MMSE, and can specifically predict the number of words recalled on the recall 
sub-domain in chapter six has important implications for the consideration of the 
effects of dietary factors on cognitive performance.  Tinned tuna is classified as 
a non-oily fish because the ‘canning/tinning’ process removes the majority of its 
fish oil content (NHS, 2013).  Previous research has failed to report an effect of 
white fish or non-oily fish intake on cognitive performance in the elderly or 
associated this type of fish with a reduced risk of developing a cognitive 
impairment.  The NHS and British Heart Foundation recommend that adults 
consume two portions of fish per week, one of which must be oily, although they 
clearly state that tinned tuna does not classify as a portion of oily fish (NHS, 
2011; British Heart Foundation, 2012).  The findings of this thesis may have 
implications for how tinned tuna is indeed classified regarding advice given to 
the general public.  Whether or not non-oily fish intake, specifically tinned tuna, 
can predict future cognitive decline is yet to be determined.  
Like previous work on circadian rhythms and TOD effects, chapter seven 
confirmed that TOD can affect performance on some cognitive domains in the 
elderly. The significant TOD effects noted on the MMSE are important for AD 
related research as this test is currently recommended as a diagnostic tool for 
the detection of AD and dementia in the UK (Ballard et al., 2011).  TOD is, 
therefore, an important factor which affects the neuropsychological testing 
process and should be considered in studies related to cognitive aging if elderly 
participants are assessed later in the afternoon at their ‘off peak’ arousal time.  
TOD effects were also noted on the GNT, an assessment of semantic memory 
(McKenna and Warrington, 1980), which has been recognised as a useful tool 
for detecting mild cognitive alterations (Blackwell et al., 2004).  Blackwell et al., 
(2004) entered GNT score as one component of an algorithm created from their 
data.  If participants were assessed at their ‘off peak’ arousal period their score 
may not reflect their actual semantic ability and as a result the accuracy and 
reliability of the algorithm may have been affected.  
211 
 
If researchers and clinicians are aware that TOD effects in cognition do exist 
(Schmidt et al., 2007; Wright et al., 2012; Froy, 2011) and that cognition is 
optimal at peak arousal times (Froy, 2011; Hasher et al., 2005), wherever 
possible efforts should be made to ensure that participants are assessed at 
their preferred TOD.  For the majority of the elderly this is in the morning 
(Schmidt et al., 2007).  This is important to avoid exaggerated age differences 
particularly if test scores are to be used to determine research 
inclusion/exclusion and or diagnosis. Although it may not be possible for 
researchers or clinicians to administer assessments in the morning for every 
participant, they could at least note the time the examination takes place and 
consider this. 
TOD effects on cognitive performance should be considered in any study within 
the fields of experimental psychology, cognitive neuroscience or cognitive 
psychology which tests human brain function and performance. The findings of 
this thesis are not only relevant to research which recruits elderly participants 
but are applicable to participants of any age range. The same issues should be 
considered when cognitively assessing children and younger adults. Teenagers 
and young adults should be assessed at their peak arousal time which for the 
majority of these individuals is in the afternoon or evening and not the early 
morning (Schmidt et al., 2007; Hasher et al., 2005).  Likewise, young children 
have peak arousal times in the early morning (Schmidt et al., 2007; Hasher et 
al., 2005). Hasher et al., (2005) commented that currently the majority of 
examinations for younger adults and the teaching of critical subjects such as 
mathematics take place in the early morning at approximately 9.00am due to 
the common belief that performance is maximal after waking. This 
misconception could disadvantage the performance of children and teenagers 
and highlights that TOD affects have important considerations for not only 
cognitive psychology but also for other fields of research and the education 
systems.  
The results of chapter eight have shown that VR based assessments are useful 
tools in the elderly with positive feedback being received in the feedback 
questionnaire (Wan Shamsuddin et al., 2011a; Wan Shamsuddin et al., 2011b).  
Deficits in route learning do occur in early AD (Lithfous et al., 2013; Cherrier et 
al., 2001; Morris, 1993; Serino and Riva, 2013) and, therefore, assessments of 
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this type of ability may be useful in the earlier detection of cognitive impairment.  
The preliminary findings of chapter eight have shown that score on level four of 
VREAD is significantly correlated with performance on other tests which have 
previously been shown to be sensitive to early cognitive symptoms.  This implys 
that VREAD may be suitable as a clinical tool, however, it is acknowledged that 
improvements and alterations to this preliminary version would be required 
before this can be considered further.  This is important particularly as some 
participants classified as MCI were able to score maximally on this level. 
Improvements to the tests sensitivity and specificity are therefore needed and 
this will be the focus of future study. 
 
9.6 Wider implications of the thesis 
There is a prominent focus to try to detect and treat AD as early as possible, as 
signs of the disease including pathological markers and changes in underlying 
cerebral systems can be detected years, possibly even decades before the first 
cognitive symptoms become noticeable (Forlenza et al., 2010; Dickerson et al., 
2011; Petersen, 2009; Sperling et al., 2011). Neuropsychological testing is one 
method by which early detection may be implemented and it is commonly used 
in the diagnosis of a cognitive impairment (Chapman et al., 2010) and the 
mapping of the impairments trajectory over time.  Neuropsychological testing is 
used in the diagnosis and research of other medical conditions such as 
Parkinson’s disease (O’Claassen and Wylie, 2012), stroke (Suzuki et al., 2013), 
other dementias (Fields et al., 2011) e.g Lewy Body Dementia, semantic 
dementia and FTD (Lambon Ralph et al., 2001), schizophrenia (Schaub et al., 
2013), autism (Losh et al., 2009), Huntington’s disease (Paulsen, 2011), TBI 
(Dean and Sterr, 2013) and child development amongst others.    
This thesis has investigated subtle external factors which are prevalent during a 
typical testing condition and which may have the ability to influence 
neuropsychological test scores with significant consequences.  Although the 
thesis has focussed on the implications for AD and MCI related research and 
has studied elderly cohorts using high level neuropsychological testing used in 
research settings, the findings are important for any type of study which uses 
cognitive testing as a part of its methodology.  
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Clinicians and researchers may use neuropsychological test scores to aid their 
interpretation of the participant’s general cognitive ability and performance may 
be considered when making a diagnosis or determining whether more in-depth 
cognitive testing is required (Jacova et al., 2007). The outcome of 
neuropsychological testing may influence the decision to initiate treatments (e.g. 
MMSE score and AchEIs, Ballard et al., 2011), recommend social interventions 
and/or lifestyle changes or select participants for research trials (Zamrini et al., 
2004).  It is crucial that the scores obtained on these tests are as accurate as 
possible and represent the participant’s actual level of cognitive function 
particularly for the early detection of AD.  The findings of an effect of caffeine 
and TOD have implications for the collection and interpretation of population 
norms, which are often referred to during the clinical interpretation of a 
participant’s performance (Lesk et al., 2009; Fields et al., 2011) but may not 
have considered or taken into account external variables such as caffeine and 
tiredness. Subsequently this may limit their use as a comparison.  Current 
policy, including the NICE dementia guidelines, has stated that clinicians should 
take into account external variables which may affect the participant’s 
performance (NICE, 2011). It is feasible that researchers and clinicians could 
ask participants to abstain from CCFS before being assessed or could simply 
note whether their participant has consumed caffeine.  Researchers can also 
easily check that participants are well rested and have not had a reduced 
amount of sleep the night before their assessment.  
If performance can be affected by subtle external factors present during a 
typical testing session, as demonstrated in this thesis, this has implications for 
all of the processes mentioned above. External factors should be considered 
and investigated further so that these can be controlled for when assessing 
participants on neuropsychological tests.  
The positive feedback received regarding VREAD has suggested that virtual 
assessments, particularly spatial route based tests, are suitable for application 
in elderly cohorts (Wan Shamsuddin et al., 2011a; Wan Shamsuddin et al., 
2011b). Whereas some previous research has highlighted concerns about the 
prior computer experience of the elderly and the possibility that there may be 
the potential for anxiety related to using computer based tools, this was not 
problematic in this thesis and even the elderly who did not possess any prior 
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experience of computers successfully completed the task.  Although it is clear 
that in its current form VREAD is not suitably challenging, the findings have 
implicated that with further work the test does have the potential to be used as a 
cognitive assessment in the future. 
 
9.7 Thesis conclusion 
This thesis has highlighted that subtle external factors that are prevalent during 
typical testing conditions can skew neuropsychological data with significant 
consequences. This signifies the need for researchers to consider such factors 
when using cognitive batteries as a part of their research, and to wherever 
possible control for these. Evaluation of a novel virtual neuropsychological test 
has shown that this may be a useful tool for the detection of cognitive 
impairment after further alterations to the tests design are made.  
Although the thesis has implications for the neuropsychological assessment of 
AD and cognitive impairments in the elderly, the findings are also applicable to 
the field of experimental psychology and cognitive research as a whole.  The 
consideration of these subtle every day external factors are important for any 
experimental paradigm in human brain research.  The thesis has investigated 
the effects of external factors on tests commonly used in elderly populations for 
the detection of cognitive impairment but these factors may also affect 
performance on other cognitive batteries used in the diagnosis of other medical 
conditions and or other age groups or cognitive processes.  
The accuracy and reliability of neuropsychological test scores is vital if 
researchers are to continue to interpret scores, and compare these with 
normative data sets, determine treatment, evaluate performance over time, 
select participants for research inclusion, predict cognitive decline or design 
new interventions. Future research investigating the factors mentioned in this 
thesis and the study of other external variables which may affect cognition will 
add valuable knowledge to the field of neuropsychology and cognitive 
neuroscience and further improve the accuracy of neuropsychological testing. 
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Appendix 1: Lifestyle and Dietary Questionnaire 
This questionnaire will assess lifestyle and dietary intake of certain foods and drinks.  
Please answer the following questions by placing a tick in the box or filling in the space 
provided.  If you are uncomfortable with any of the questions and do not wish to answer 
specific ones you are not obliged to do so.   Please complete the section below 
Age: 
  Height: 
  Gender: 
 
1. Please indicate which of the following applies to you and how many years this 
applies. 
Married 
Living with partner 
Widowed   
Single 
Divorced 
2. Please state your ethnic origin................................................... 
3. What type of diet do you eat? 
        Vegetarian  (Please state the number of years you have been a vegetarian........) 
      Vegan (no dairy or meat products)  
        Meat eater 
4. How many years approximately have you spent in the education system? 
.............................................................................................................................. 
5. Do you have a family history of any of the following conditions/ have you ever 
suffered from any of the following? 
 Family 
History? 
 Suffering 
from? 
 
 Yes No Yes No 
Depression     
Stroke     
Alzheimer’s Disease     
Epilepsy     
High Cholesterol     
Arthritis     
Diabetes     
Heart Disease     
Hypothyroidism     
Food Allergy  
Please state to what 
foods............................ 
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6. Have you ever suffered from a head injury and were you unconscious? If so 
please state when this occurred. 
...............................................................................................................................
...............................................................................................................................
................ 
7. Please state below if you are currently taking any prescribed medication and 
what medical condition this is 
for...........................................................................................................................
............................................................................................................................... 
8. Are you currently taking any vitamins, minerals or other natural supplements? 
Yes 
No  
Sometimes 
If so please list supplements including brand and dose.............................................. 
9. Are you currently taking any antibiotics? 
Yes 
No 
10. Are you currently physically active? 
Yes 
No 
Sometimes 
If yes please state the type of exercise you carry out and how many hours of this 
exercise you undertake per 
week..................................................................................................................................
.......................................................................................................................................... 
11. How much water, excluding tea and coffee, do you drink each day? 
1-2 glasses 
3-5 glasses 
6 or more glasses 
12. How many alcoholic beverages do you consume on a weekly basis? 
More than five 
3-4 
2 or fewer 
None 
13. How many cigarettes do you smoke per day? 
More than twenty 
Ten to twenty 
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Five to Nine 
Less than Five 
None 
14. Please indicate which of the following activites you carry out and state whether 
this is rarely, sometimes or often. 
 
 Rarely Sometimes Often 
Reading the newspaper    
Reading a book/novel    
Puzzles such as 
crosswords 
   
Sewing or Knitting    
Watch Television    
Play games such as 
cards or bingo 
   
 
15. How many portions of fresh, tinned or frozen fruit do you eat each day? One 
portion is the equivalent of handful of grapes or one apple etc. 
More than four 
One –three 
One or fewer 
16. How many portions of fresh or frozen vegetables do you eat each day?  One 
portion is equivalent to a handful of peas or three florettes of broccoli. 
More than six 
4-6 
2-4 
1 or less 
17. Please complete the table below stating how many of the following foods you 
eat per day, month and week. 
 
 
Per Day Per Week  Per Month 
Eggs 
 
   
Milk in Pints 
 
   
Cups of caffeinated coffee 
 
   
Cups of Caffeinated Tea 
 
   
Cups of caffeinated green tea 
 
   
Salmon 
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18. What type of cooking oil do you use? 
  Supermarket own brand 
  Vegetable Oil 
  Olive Oil 
  Extra virgin olive oil 
 Sun Flower Oil 
19. Please state in the space provided which cooking method you use when 
preparing fish 
.............................................................................................................. 
Thank you for taking the time to complete this questionnaire 
Sardines 
 
   
Mackeral 
 
   
Trout 
 
   
Herring     
Cod/ Haddock    
Tinned Tuna    
River Cobbler/ Basa    
Shell Fish  
 
   
Chocolate – including biscuits, 
cake and bars 
   
Chicken    
Red Meats – such as beef    
Take away foods/ Processed food    
Turmeric – an ingredient found in 
curry 
   
Walnuts    
Brazil Nuts    
Almonds    
Peanuts    
Hazelnuts    
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Appendix 2: Usability Questionnaire 
Personal Details. 
Age  : 
Gender : 
Previous Virtual Reality Experience :   
Please indicate with a number from 1 to 5 whether you agree with the following 
statements. 1 = Completely disagree, 5 = Completely agree 
1. I had quickly learned how to move through the virtual application. 
Completely 
disagree         
  1   2    3   4  5  Completely agree         
2. I found it easy to move myself through the virtual application. 
Completely 
disagree         
  1   2    3   4  5  Completely agree         
4.The Instructions for the tasks are clear. 
Completely 
disagree         
  1   2    3   4  5  Completely agree         
5. I liked using the arrow keys to move around the application. 
Completely 
disagree         
  1   2    3   4  5  Completely agree         
6. I often feel disoriented in using the application. 
Completely 
disagree         
  1   2    3   4  5  Completely agree         
7. It was easy for me to look around in the virtual application. 
Completely 
disagree         
  1   2    3   4  5  Completely agree        
8. I would have preferred to have more freedom of movement. 
Completely 
disagree      
  1   2    3   4  5  Completely agree   
9. The speed of movement was too fast. 
Completely 
disagree         
  1   2    3   4  5  Completely agree         
10. Overall, I feel comfortable using the application. 
Completely 
disagree         
  1   2    3   4  5  Completely agree         
11. Overall, I am satisfied with the experience of using the application. 
Completely 
disagree         
  1   2    3   4  5  Completely agree         
 
No Yes 
